Thank you to the 2013 ASHI Corporate Supporters Abbott Molecular Art Robbins Instruments Bio-Rad Laboratories DiaSorin, Inc. Elsevier GenDx Histogenetics Immucor Life Technologies Linkage Biosciences Inc. MLC Group, LLC mTilda HLA Software Specialists National Marrow Donor Program Olerup, Inc. Omixon Biocomputing One Lambda Inc., a part of Thermo Fisher Scientific Inc. STEMCELL Technologies Inc.

Final Program 3

Table of Contents

General Information...... 5 ASHI Program Planning Committee...... 9 Abstract Reviewers...... 10 Board of Directors...... 13 Corporate Supporters...... 14 Exhibitor Directory...... 15 Award Winners...... 27 Schedule at a Glance...... 34 Abstracts...... 42 Hotel and Exhibit Floor Plans...... 95

4 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 General Information Registration Registration is located on the Lobby Level to the left of the main entrance.

Sunday, November 17 Noon – 7:30 PM Monday, November 18 7:00 AM – 4:00 PM Tuesday, November 19 7:30 AM – 6:00 PM Wednesday, November 20 8:00 AM – 6:00 PM Thursday, November 21 8:00 AM – 10:30 AM

Speaker Ready Room The Speaker Ready Room is located in Parlor D on the Lobby Level, Level 3.

Sunday, November 17 5:00 PM – 7:00 PM Monday, November 18 7:00 AM – 4:00 PM Tuesday, November 19 7:00 AM – 4:30 PM Wednesday, November 20 7:00 AM – 4:30 PM Thursday, November 21 7:30 AM – 10:30 AM

Exhibits/Internet Café Exhibits and Internet Café are located in the River Exhibition Hall on the First Floor.

Exhibit and Poster Viewing Hours Monday, November 18 9:15 AM – 10:15 AM 1:00 PM – 2:15 PM 3:15 PM – 4:15 PM 5:30 PM – 7:00 PM

Tuesday, November 19 9:15 AM – 10:15 AM 1:00 PM – 2:15 PM 3:15 PM – 4:15 PM

Wednesday, November 20 9:45 AM - 10:45 AM

Poster Mounting Times Sunday, November 17 3:00 PM – 7:00 PM Monday, November 18 7:00 AM – 9:00 AM

Poster Dismounting Time Wednesday, November 20 Noon – 2:00 PM (Any poster still in place at 2:00 PM will be discarded.)

Final Program 5 General Information ADA Compliance ASHI fully complies with the legal requirements of the Americans with Disabilities Act rules and regulations. If any participant is in need of special accommodations, please notify the hotel and indicate the type of assistance needed. ASHI cannot ensure the availability of appropriate assistance without advance notice.

Cameras and Cell Phones No cameras of any kind are permitted inside educational session rooms. Any violation of this policy may result in the offender being removed from the meeting. As a courtesy to fellow attendees, please turn off cell phones during educational sessions.

Meeting Objectives The 39th ASHI Annual Meeting has been designed to provide participants with a comprehensive review of a variety of topics related to the fields of genomics, immunogenetics, immunology, histocompatibility, and transplantation. The keynote address will set the stage with a discussion of the next generation of transplantation – engineering autologous tissues from pleuripotent stem cells. Plenary and symposium sessions will examine the relationship between immunogenetics and human population history, our diseases and their treatments; new findings in the quest for tolerance in transplantation; current strategies for improving outcomes in stem cell transplantation in the US and Europe; and new roles for complement in clinical transplantation and in the laboratory.

Workshop sessions are designed to provide participants with practical information that can be utilized in their laboratories and transplant programs. Workshop topics will include a report of findings from the 2012 antibody consensus conference in Rome, an overview of next generation sequencing platforms, how to cope with information technology and results reporting, non-HLA antibodies, quality assurance for modification of assays, ethical dilemmas in transplantation, and statistical analysis for clinical research studies. Case studies in solid organ and stem cell transplantation provide attendees with informative presentations of challenges that laboratories face in providing testing for complex patients. Abstract and poster sessions provide attendees the opportunity to learn about clinical and basic research projects that could change future laboratory and clinical practice.

After attending this meeting, participants should be able to identify important roles for immunogenetics that reach beyond transplantation, new roles for complement within transplantation, new possibilities for achieving tolerance, and current best practices in hematopoietic stem cell transplantation. Participants will be able to critically assess various aspects of laboratory testing, from detection of clinically relevant anti-HLA and non-HLA antibodies, to the very latest methods in HLA typing, to managing, reporting and analyzing the results.

6 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Evaluation Participants must complete an evaluation in order to receive a certificate documenting credits earned for attending sessions. Sessions must be attended in their entirety. Partial credit is not available. Following the meeting, complete the evaluation and print your certificate by visiting http://2013.ashi-hla.org/ and clicking on the evaluation-specific icon. A username and password will be provided to you via e-mail upon the end of the meeting. Online meeting evaluations will be available from November 21 – December 21, 2013, after which time certificates will no longer be available.

Physicians This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Institute for the Advancement of Human Behavior (IAHB) and the American Society for Histocompatibility & Immunogenetics. The IAHB is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Statement The IAHB designates this live activity for a maximum of 31.5 PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CHT, CHS, ABHI Diplomates The American Board of Histocompatibility and Immunogenetics has approved the 39th Annual Meeting content for a maximum of 27.5 contact hours and 4.125 continuing education credits (CEC); and has approved the Inspectors’ Training Workshop content for a maximum of 7.5 contact hours and 1.125 CEC, applicable for Certified Histocompatibility Technologists (CHT), Certified Histocompatibility Specialists (CHS), and ABHI Diplomates.

Abstract Awards The following awards will be presented to the highest ranked abstracts accepted for oral presentations: ASHI Scholars, International Scholar, Best Solid Organ Case Study and Best Stem Cell Case Study. Three posters will be awarded the following: President’s Choice, Best Visual and Most Innovative.

Internet Café – Supported by Abbott Molecular Complimentary computer stations are provided enabling you to access the Internet. The Internet Café is located in the River Exhibition Hall. Use of these computers is limited to 15 minutes.

Final Program 7 Hotel Information Link @ Sheraton Cafe Located on Level 2 Free wireless, free workstations and online printing. Open daily from 6:00 AM until 5:00 PM

FedEx Office Business Center Located across the hall from meeting registration

Hours of Operations Monday – Friday 7:00 AM – 5:00 PM Saturday 8:00 AM – 3:00 PM Sunday 8:00 AM – 3:00 PM

Special Services Large-format color printing, signs and banners, pre-convention printing and file assistance. 24 Hour guest access.

Restaurants Shula’s Steak House Enjoy SHULA CUT steaks and fresh seafood at one of the top steak houses in America. Open daily from 5:30 pm to 10:30 pm Shula’s Bar is open daily 5:00 pm - 11:00 pm

Chi Bar Located in the center of the lobby, Chi Bar is the ideal place to network and gather. Offering bar bites and cocktails, Chi Bar is in the center of all the action. Open daily from 3:00 pm – 11:00 pm.

Link @ Sheraton Cafe Located just one level below the lobby, LINK @ Sheraton Cafe is the place to connect. Enjoy a variety of salads, sandwiches, paninis, soups, salads, breakfast pastries and coffee. Free wireless, free workstations and online printing. Open daily from 6:00 am - 5:00 pm.

LB’s Bistro & Patisserie LB’s Bistro & Pâtisserie is the first restaurant of World Champion Pastry Chef Laurent Branlard. Combine fresh ingredients and simple yet unique combinations of flavors to create your own breakfast or lunch. Open daily for breakfast from 6:30 am - 11:00 am and for lunch from 11:30 am - 2:00 pm.

8 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Program Planning Committee Program Planning Chair Workshops Chairs Amy Hahn, PhD, D(ABHI) Nebila Abdulwahab, MT(ASCP), CHT, CHS Albany Medical College Ohio State University Hospital

Plenary and Symposia Sessions David Partlow, MS, MT, CHS Thomas Ellis, PhD, D(ABHI) MD Anderson Cancer Center University of Wisconsin-Madison Abstract Chairs Luis Hidalgo, PhD, D(ABHI) Patricia Campbell, MBChB, FRCP(UK), FRCP(C) University of Alberta Hospitals University of Alberta Hospitals

Jill Hollenbach, PhD Annette Jackson, PhD, D(ABHI) Children’s Hospital Oakland Research Institute Johns Hopkins University School of Medicine

Lawrence Jennings, MD, PhD Shalini Pereira, PhD, D(ABHI) Ann & Robert H. Lurie Children’s Hospital of Fred Hutchinson Cancer Research Center Chicago Daniel Ramon, PhD, D(ABHI), HCLD(ABB) Donna Lucas, MS, CHS University of Michigan Johns Hopkins University

Joannis Mytilineos, MD, PhD IKT Ulm Special thanks to the following for additional programming suggestions: Marilyn Pollack, PhD, D(ABHI) Vicky Turner, PhD, D(ABHI) University of Texas Health Science Center Malek Kamoun, MD, PhD David Eckels, PhD, D(ABHI) Rajalingam Raja, PhD Uuniversity of California, San Francisco Continuing Medical Education Immunogenetics Center Accreditation Manager Jillian Davis, Amedco Corporation John Schmitz, PhD, D(ABMLI, ABHI) UNC Chapel Hill

Final Program 9 Abstract Reviewers Moheeb Al-Awwami, PhD, CHT, CHS Deborah Crowe, PhD, D(ABHI) King Faisal Hospital Specialist Hospital & DCI Laboratory Research Centre Steven DeGoey, BS, CHS Rabab Ali Abdullah Al-Atta, MD Mayo Clinic King Fahad Specialist Hospital-Dammam Julio Delgado, MD, MS, D(ABHI) Medhat Askar, MD, PhD, D(ABHI) University of Utah Allogen Laboratories Sara Dionne, PhD Fleur Aung, MD Labs, Inc. University of Texas Nicholas DiPaola, PhD Lee Ann Baxter-Lowe, PhD, D(ABHI) Ohio State University Medical Center University of California San Francisco Ronald Domen, MD Noureddine Berka, PhD, D(ABHI) Penn State Milton S. Hershey Medical Center Calgary Laboratory Services Illias Doxiadis, PhD Maria Bettinotti, BS, MT(ASCP), CHT Leiden University Medical Center Quest Diagnostics Nichols Institute Zeying Du, MD, PhD Rainer Blasczyk, MD, PhD University of Illinois At Chicago Hannover Medical School David Eckels, PhD, D(ABHI) Benita Book, CHT, CHS The University of Utah / University Health Indiana University Care

Bob Bray, PhD, D(ABHI) Gehad ElGhazali, MD Emory University Hospital Mafraq Hospital and Sheikh Khalifa Medical City Kevin Burns, MD BloodSource Thomas Ellis, PhD, D(ABHI) University of Wisconsin-Madison Patricia Campbell, MBChB, FRCP(UK), FRCP(C) Cindy Ellison, PhD, D(ABHI) University of Alberta Hospitals University of Manitoba

Michael J. Cecka, PhD, D(ABHI) Moe Elrefaei, MD, PhD University of California Los Angeles Puget Sound Blood Center

James Cicciarelli, PhD Hooi Sian Eng, PhD National Institute of Transplantation Johns Hopkins University

Frans Claas, PhD Sallyanne Fossey, PhD, D(ABHI) Leiden University Medical Center DCI Laboratory

Adriana Colovai, PhD Sujata Gaitonde, MD Montefiore-Einstein Transplant Center University of Illinois At Chicago

Daniel Cook, PhD, D(ABHI) Manish Gandhi, MD Clinic Care, Inc. d/b/a/ Allogen Laboratories Mayo Clinic

10 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstract Reviewers Howard Gebel, PhD, D(ABHI) Ronald Kerman, PhD Emory University Hospital Baylor College of Medicine

Ketevan Gendzekhadze, PhD Pamela Kimball, PhD, HCLD City of Hope Medical College of Virginia

Maria Gerbase-De Lima, MD, PhD William Klitz, PhD Federal University of San Paulo University of California, School of Public Health Alin Girnita, MD, D(ABHI) University of Pittsburgh Ellen Klohe, PhD, D(ABHI) Inland Northwest Blood Center David Gjertson, PhD University of California, Los Angeles Janette Kwok, PhD Queen Mary Hospital Clara Gorodezky, DSc, PhD InDRE, SSA Chantale Lacelle, PhD, D(ABHI) UT Southwest Medical Center Amy Hahn, PhD, D(ABHI), Albany Medical College Chih-Hung Lai, PhD Cedars-Sinai Medical Center Gregory Hale, MD All Children’s Hospital Mary Sue Leffel, PhD, AMBMLI, D(ABHI) Johns Hopkins University- Immunogenetics John Hart, MBA, CHS Johns Hopkins University Curt Lind, CHS Children’s Hospital of Philadelphia, William Hildebrand, PhD, D(ABHI) Immunogenetics Lab University of Oklahoma Health Science Center Robert Liwski, MD Chak-Sum Ho, PhD Dalhousie University Gift of Life Michigan Andrew Lobashevsky, MD, PhD, D(ABHI) Susan Hsu, D(ABHI) Indiana University School of Medicine American Red Cross Blood Services Penn- Jersey Region Mayra Lopez-Cepero, PhD, D(ABHI) LifeLink Foundation Charlene Hubbell, BS, MT(ASCP), SBB Health Science Center Steven Mack, BA, PhD Children’s Hospital Oakland Annette Jackson, PhD, D(ABHI) Johns Hopkins University School of Medicine Gabriel Maine, PhD William Beaumont Hospital Andres Jaramillo, PhD, HCLD(ABB) Gift of Hope Organ & Tissue Network Susana Marino, MD, PhD, D(ABHI) University of Chicago Hospital Medical Center Malek Kamoun, MD, PhD University of Pennsylvania Narinder Mehra, PhD All-India Institute of Medical Sciences Siva Kanangat, PhD Rush University Medical Center Derek Middleton, DSc, PhD, FRC Royal Liverpool University Hospital

Final Program 11 Abstract Reviewers Joshua Miller, MD Jerry Rosenberg, MD, PhD Northwest University Feinberg School of Gift of Life Michigan Medicine Jennifer Schiller, PhD Thalachallour Mohanakumar, PhD, D(ABHI) Blood Center of Wisconsin Washington University School of Medicine David Senitzer, PhD, D(ABHI), ABMLI Dimitri Monos, PhD City of Hope National Medical Center Children’s Hospital of Philadelphia Hiroko Shike, MD Gerald Morris, MD, PhD Penn State Hershey Medical Center University of California, San Diego

Omar Moussa, PhD Anajane Smith, MA Medical University of South Carolina Seattle Cancer Care Alliance Pathology & Laboratory Medicine Peter Stastny, MD Cathi Murphey, PhD University of Texas Southwest Immunodiagnostics, Inc. Brian Susskind, PhD, MS, BA, D(ABHI) Karen Nelson, PhD, D(ABHI) University of Cincinnati Puget Sound Blood Center Anat Tambur, DMD, PhD, D(ABHI) Allen Norin, PhD, D(ABHI) Northwestern University SUNY Downstate Medical Center Gary Teresi, MT, CHS Paul Norman, PhD Allogen Laboratories Stanford University Marcel G.J. Tilanus, PhD Carol Pancoska, PhD, D(ABHI) Maastricht University Medical Centre Community Blood Services

Shalini Pereira, PhD, D(ABHI) Kathryn Tinckam, MD Fred Hutchinson Cancer Research Center University Health Network

Donna Phelan, BA, CHS, MT(HEW) Margareth Torres, PhD Barnes-Jewish Hospital Hospital Israelita Albert Einstein

Michele Prod, BS, MT(ASCP), CHS Victoria Turner, PhD, D(ABHI) Rush University Medical Center St. Jude Hospital Histocompatibility Qingyong Xu, PhD Rajalingam Raja, PhD Saskatoon Health Region & University of UCLA Immunogenetics Center Saskacthewan

Daniel Ramon, PhD, D(ABHI), HCLD(ABB) Danny Youngs, BS, CHS University of Michigan Puget Sound Blood Center Sandra Resto-Ruiz, PhD, HCLD(ABB) Aiwen Zhang, MD, PhD LifeLink Foundation Allogen Lab, Cleveland Clinic Lucie Richard, PhD Hema-Quebec Yizhou Zou, MD, PhD Centre South University China

12 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 2013 Board of Directors

2013 Executive Committee 2013 Board of Directors President Maria Bettinotti, PhD, D(ABHI) (2013) Marilyn S. Pollack, PhD, D(ABHI) (2013) Quest Diagnostics Nichols Institute University of Texas Health Science Center Joannis Mytilineos, MD, PhD (2013) President Elect IKT Ulm John A. Gerlach, PhD, D(ABHI) (2013) Michigan State University Walter Herczyk, MT(ASCP), CHS (2014) University of Chicago Medical Center Past President Amy B. Hahn, PhD, D(ABHI) (2013) Malek Kamoun, MD, PhD (2014) Albany Medical College University of Pennsylvania

Vice President of Operations Lorita Rebellato-De Vente, PhD, MS, Judith E. Baker, CHS, I(ASCP) (2014) D(ABHI) (2014) East Carolina University Brody School Secretary of Medicine Dorothy M. Levis, MT(ASCP), CHS(ABHI) (2013) Dawn R. Wagenknecht, MS, CHS Gift of Life Michigan (2014) St. Francis Hospital Treasurer Elizabeth R. Trimble, MT(ASCP), Donna P. Lucas, MS, CHS(ABHI) (2014) CHS(ABHI) (2015) Johns Hopkins University Via Christi Regional Medical Center Michael D. Gautreaux, PhD, D(ABHI) (2013) Wake Forest University Health Sciences

Dean Sylvaria, BS, CHS(ABHI) (2015) Beth Israel Deaconess Medical Center

For additional contact information, please visit www.ashi-hla-org/about/governance/bod/

Final Program 13 Corporate Supporters Diamond Level Life Technologies (Lanyards)

One Lambda, Inc. a part of Thermo Fisher Scientific Inc. (Unrestricted Educational Grant) (Pocket Schedule At A Glance)

Platinum Level Abbott Molecular (Internet Café) Immucor (Final Program)

Gold Level Histogenetics (Registration Bags)

Silver Level DiaSorin, Inc. (Notepads and pens) GenDx (ASHI’s Run for a Life 5k Fun Run/Walk) Olerup, Inc. (Water Bottles)

Bronze Level Bio-Rad Laboratories mTilda HLA Software Specialists (Distinguished Scientist Award) (ASHI Scholar Award)

Elsevier National Marrow Donor Program (International Scholar Award) (Outstanding Technologist Award)

Linkage Biosciences, Inc. STEMCELL Technologies, Inc. (Distinguished Service Award) (Rose Payne Award)

Friends of ASHI Art Robbins Instruments MLC Group, LLC (OTA Dinner) Omixon Biocomputing

14 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Exhibit Information Exhibitor Booth Numbers

Abbott Molecular 90 American Foundation for National Marrow Donor Program, Donation & Transplantation 405 Bioinformatics Research 410 Biologic Tx 309 Olerup, Inc. 303 Bioplastics Cyclertest Inc. 406 Omixon Biocomputing 313 Bio-Rad Laboratories 116 One Lambda Inc., a part of Thermo CEDARLANE 404 Fisher Scientific Inc. 103 chemagen from PerkinElmer, Inc. 505 Path-Tec 502 DiaSorin, Inc. 219 Promega Corporation 94 Embi Tec 93 PROTRANS 120 GenDx 400 Qiagen, Inc. 311 GenTrak, Inc. 412 ROSE GenTec, Ltd. 221 Histogenetics 113 Solid Phase Immunoassays Website 401 Illumina 315 STEMCELL Technologies Inc. 110 Immucor, Inc. 211 SystemLink, Inc. 112 LabCorp 318 Texas BioGene 411 Life Technologies, Inc. 205 Trans-Type Diagnostics 509 Linkage Biosciences, Inc. 301 Viracor-IBT Laboratories 407 Miltenyi Biotec 92 World Transplant Congress 506 mTilda 30

Final Program 15 Exhibitor Company Descriptions

Abbott Molecular 90 1300 East Touhy Avenue Des Plaines, IL 60018 Phone: (800) 553-7042 www.abbottmolecular.com

Abbott Molecular is a leader in molecular diagnostics for the analysis of DNA, RNA, and proteins. Our instruments and reagents detect pathogens and subtle changes in patients’ genes and chromosomes, permitting earlier diagnosis, the selection of appropriate therapies and improved monitoring of disease progression.

American Foundation for Donation & Transplantation 405 8154 Forest Hill Avenue Suite 3 Richmond, VA 23235 Phone: (804) 323-9893 E-mail: [email protected] www.amfdt.org

The American Foundation for Donation & Transplantation, formerly SEOPF, is the continuation of the oldest transplantation and donation professional organization in the United States. Founded in 1969 in Richmond, Virginia by Drs. David Hume and Bernard Amos, SEOPF gave rise to UNOS and now has become the AFDT. www.amfdt.org (800)-KIDNEY9.

Biologic Tx 309 40-D Commerce Way Totowa, NJ 07512 Phone: (845) 774-5082 E-mail: [email protected] www.biologictx.com

BiologicTx® specializes in the administration of intravenous biologic therapies. After the patient has been successfully transplanted, BiologicTx® will provide comprehensive management of their oral immunosuppressive regime, ensure compliance, and provide necessary biologic interventions. Our philosophy is to lead, manage, and care with the highest level of respect, integrity, and dignity.

16 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Exhibitor Company Descriptions (continued)

Bioplastics Cyclertest, Inc 406 2933 South Miami Boulevard Suite 121 Durham, NC 27703 Phone: (919) 806-8811 E-mail: [email protected] www.cyclertest.com

BIOplastics/CYCLERtest Inc. is positioned to assist with two key variables in (q)PCR, thermal cyclers and plastic vessels. DRIFTCON dynamic multi-channel temperature calibration systems (calibrated to ISO 17025 Standards) meet most accreditation requirements for PCR temperature calibration, and together with our Extreme Uniformity plastic disposables help provide consistent and reproducible results.

Bio-Rad Laboratories 116 4000 Alfred Nobel Drive Hercules, CA 94547 Phone: (510) 724-7000 E-mail: [email protected] www.bio-rad.com/diagnostics

Bio-Rad offers a complete line of industry standard HLA Serology Typing Trays (Lymphotype); Serological (Lymphoscreen) and ELISA-based (AbScreen/Abldent*) Antibody Diagnostics Systems; Molecular Typing Systems (SSO and SSP) with full automation platforms; Immune Monitoring, Infectious Disease and Traditional Blood Group Serology Products to meet your laboratory needs. *Not available in US. CEDARLANE 404 1210 Torrentine Street Burlington, NC 27215 Phone: (336) 513-5135 E-mail: [email protected] www.cedarlanelabs.com

CEDARLANE is a leading supplier of high quality reagents to the global life science research and diagnostic communities. We specialize in producing COMPLEMENT for tissue typing and bacteriocidal assays. Other manufactured products include Cedarlane’s Lympholyte® cell separation media, cell purification Immunocolumns and Antibodies including our B/ T cell Positive Control Antisera and antibodies to complement components. Also, acting as a distributor and consolidator for many global institutions, Cedarlane’s customers can take advantage of access to over 2 million products from over 1000 top global suppliers.

Final Program 17 Exhibitor Company Descriptions (continued) chemagen from PerkinElmer, Inc 505 940 Winter Street Waltham, MA 02451 Phone: (800) 762-4000 E-mail: [email protected] www.chemagen.com chemagen a leading supplier of automation and reagents for fast and reliable magnetic bead based DNA, RNA extraction for sample volumes from 10 ul to 10 ml for blood, tissues, saliva, bacteria, food, PCR products. One instrument performs all functions with fast processing, unmatched sample volume range and robust chemistry.

DiaSorin, Inc. 219 1951 Northwestern Avenue Stillwater, MN 55082 Phone: (800) 328-1482 E-mail: [email protected] www.diasorin.com

The Arrow instrument from DiaSorin is a dual purpose platform, ideally suited to the Molecular Diagnostic and Cytogenetic laboratories where cost effective DNA preparation and cell separation can be automated. Using established paramagnetic bead chemistry, the Arrow instrument can extract nucleic acids from a wide variety of sample types and deplete or enrich a subset of lymphocytes. Visit booth #219 for a demonstration.

Embi Tec 93 7738 Arjons Drive San Diego, CA 92126 Phone: (858) 684-3190 E-mail: [email protected] www.embitec.com Embi Tec manufactures and distributes innovative, cost and space effective lab equipment such as the RunOne Electrophoresis System, MultiCaster Systems, ViewOne LabLite (miniature white light box), LightOne Illuminators for setting up and cherry-picking 96 or 384-well plates, PrepOne Sapphire (non-UV, blue light box), PrepOne ImageCatcher and AnyBlood Direct PCR Buffers.

GenDx 400 Yalelaan 48 Utrecht 3593CM, Netherlands Phone: +31 30 252 3799 E-mail: [email protected] www.gendx.com

GenDx develops and markets a comprehensive line of in vitro diagnostic (IVD) tests and services, analysis software and education. The company is a pioneer in the area of Sequencing- Based Typing (SBT) and Next Generation Sequencing (NGS) for transplantation procedures.

18 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Exhibitor Company Descriptions (continued)

GenTrak, Inc 412 P.O. Box 1290 Liberty, NC 27298 Phone: (336) 622-5266 E-mail: [email protected] www.GenTrakinc.com

GenTrak, Inc. manufactures a quality line of classical HLA serology trays and frozen cell trays. HLA serology testing provides quick, cost effective results. Come and see our Texas Biogene products that specialize in simple laboratory automation for pre- and post PCR processes. The innovative split well ABCDRDQ in one tray and SBT (Group Specific Primers) can provide unambiguous solutions for your laboratory needs.

Histogenetics 113 300 Executive Boulevard Ossining, NY 10562 Phone: (914) 762-0300 E-mail: [email protected] www.histogenetics.com

Histogenetics, based in New York, USA, is an international leader in DNA sequence-based (SBT) tissue (HLA) typing services and serves clients around the globe. Histogenetics has been developing sophisticated tools by integrating robotics and bio- informatics to provide the ultimate quality of HLA typing information to the community that could save lives.

GMSBiotech 508 1622 West Colonial Parkway Suite 1A Inverness, IL 60067 Phone: (512) 827-6945 E-mail: [email protected] www.gmsbiotech.com

GMSBiotech is an in vitro diagnostics company with a patented DNA microarray technology for HLA typing, transfusion medicine and virology. We have developed simple and inexpensive clinical tests that provide high resolution genotyping data, yet can be performed in any laboratory setting: hence our name, GMSBiotech, “Genetics Made Simple”.

Final Program 19 Exhibitor Company Descriptions (continued)

Illumina 315 5200 Illumina Way San Diego, CA 92122 Phone: (858) 202-4500 E-mail: [email protected] www.illumina.com

Illumina provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics; paving the way for molecular medicine and ultimately transforming healthcare.

Immucor, Inc 211 550 West Avenue Stamford, CT 06902 Phone: 1 (888) 329-0255 E-mail: [email protected] www.immucor.com

We are proud to announce that LIFECODES, a world-class leader in transplant and transfusion diagnostics, is now part of Immucor. Together, Immucor and LIFECODES provide a broad portfolio of automated assays and cutting edge technology to ensure a good match between donors and recipients of blood component and organs.

LabCorp 318 1440 York Court Extension Burlington, NC 27215 Phone: (800) 533-1037 E-mail: [email protected] www.labcorp.com

Laboratory Corporation of America® Holdings (LabCorp®) operates one of the nation’s most extensive clinical laboratory networks. LabCorp has one of the largest and most experienced HLA testing laboratories, providing comprehensive HLA analysis, KIR genotyping, anti-HLA antibody testing, cross match, ImmuKnow, and chimerism analysis. LabCorp maintains a dedicated doctoral staff, as well as a diverse group of skilled technologists, IT staff and account managers. LabCorp offers its specialty testing services globally through its expansive cooperative affiliations.

Life Technologies, Inc 205 5791 Van Allen Way Carlsbad, CA 92008 Phone: (760) 603-7200 www.lifetechnologies.com

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to moving science forward to improve life in meaningful ways for everyone. Our premier brands are the most cited, most trusted in the life sciences industry: Invitrogen™, Applied Biosystems®, Gibco®, Molecular Probes®, Novex®, TaqMan®, Ambion®, and Ion Torrent™.

20 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Exhibitor Company Descriptions (continued)

Linkage Biosciences, Inc 301 890 Dubuque Avenue South San Francisco, CA 94080 Phone: (866) 575-8915 E-mail: [email protected] www.linkagebio.com

Real-Time PCR HLA typing is transforming the workflow of HLA laboratories. Linkage Biosciences is a molecular diagnostics company developing products that dramatically improve complex genetic testing using Real-Time PCR. LinkSēq™, the company’s HLA testing product line, is used in solid organ and hematopoietic stem cell transplantation as well as pharmacogenomic and autoimmune disease testing and research.

Miltenyi Biotec 92 6125 Cornerstone Court E San Diego CA 92121 Phone: (800) 367-6227 E-mail: [email protected] www.miltenyibiotec.com

Miltenyi Biotec’s mission is to improve scientific understanding and medical progress. We provide products and services that advance biomedical research and cellular therapy. Honoring this mission drives our commitment to support the translation of basic research into therapy in the areas of immunology, cancer, neuroscience and stem cell biology. We innovate products that address sample preparation, separation of cells and their analysis, and that advance the concept of cellular therapy. “Researchers working for researchers” is our promise to provide pioneering products to our customers. mTilda 307 5292 Lost Creek Road Eagle Point, OR 97524 Phone: (541) 826-6581 E-mail: [email protected] www.mtilda.com

With over a decade of perfecting the user’s approach, this HLA management software offers unprecedented abilities for search, vendor integration, accuracy and ease of use. A remarkably robust and completely integrated approach that allows you to do more faster, better and more accurately. Stop by for a demo!

National Marrow Donor Program, Bioinformatics Research 410 3001 Broadway Street, NE Minneapolis, MN 55413 Phone: (612) 460-6230 E-mail: [email protected] bioinformatics.nmdp.org

NMDP: Bioinformatics Research We provide HLA expertise and services for international researchers, have the data and expertise you need, and are the scientists for the NMDP. Come along and see how we can help you.

Final Program 21 Exhibitor Company Descriptions (continued)

Olerup, Inc 303 901 S Bolmar Street Suite R West Chester, PA 19382 Phone: (877) 653-7871 E-mail: [email protected] www.olerup.com

Olerup is a life science company with a focus on transplantation that provides high quality products and services, in order to facilitate safe and effective bone marrow and solid organ transplants. Olerup is the global distributor of innovative molecular diagnostic products and services for transplantation: HLA typing (Olerup SSP® and SBT Resolver™) and for non-HLA antibody detection (XM-ONE®). Olerup’s product offerings are distributed through Olerup, Inc. (Americas) and Olerup GmbH (rest of world).

Omixon Biocomputing 313 56 Petzval Jozsef Street Budapest 1119, Hungary Phone: +36 30 830 7652 E-mail: [email protected] www.omixon.com

Omixon specializes in the analysis of targeted NGS data. We help to investigate challenging genomic regions such as BRCA, CFTR and HLA. Omixon Target offers the highest possible HLA typing precision using NGS data. It gives high resolution results with whole genome, exome, targeted DNA, or with RNA seq data.

One Lambda, Inc., a part of Thermo Fisher Scientific Inc 103 21001 Kittridge Street Canoga Park, CA 91303 Phone: (818) 702-0042 E-mail: [email protected] or [email protected] www.onelambda.com

One Lambda, Inc., the global leader in transplant diagnostics, is proud to introduce our new line of LABType® products employing the next generation Luminex System. Our LABScreen® Single Antigen assays for DSA monitoring continues to be the gold standard in antibody detection. Furthermore, the recent introduction of our biomarkers products, C1qScreen™ and AT1R are paving the way for better antibody profiling. We invite you to stop by our exhibit to learn more about our exciting product line.

22 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Exhibitor Company Descriptions (continued)

Path-Tec 502 1333-A Belfast Avenue Columbus, GA 31904 Phone: (706) 569-6368 E-mail : [email protected] www.path-tec.com

Path-Tec is a leading provider of specimen and client management solutions. We understand the challenges that laboratories encounter with their pre-analytical processes and we provide a complete offering that includes product development and management, inventory management, courier and carrier management, supply and specimen logistics and client management technology.

When partnering with Path-Tec, laboratories benefit from our specimen management expertise to reduce costs, improve client service levels and improve overall operational efficiencies. We are committed to helping laboratories grow and thrive in today’s health care environment.

Promega Corporation 94 2800 Woods Hollow Road Madison, WI 53711 Phone: (608) 274-4330 E-mail: [email protected] www.promega.com

Promega Corporation is a leader in providing innovative solutions to life science, forensic, clinical research and molecular diagnostics markets. Our products consist of kits, reagents and automated platforms. These solutions span the laboratory workflow from nucleic acid purification to amplification to final analysis. The new Maxwell® CSC Instrument, a cGMP compliant nucleic acid extraction system, enhances your laboratory workflow, providing the highest quality output possible and success in critical downstream applications. Stop by the Promega booth to learn more.

PROTRANS 120 Ketschau 2 Hockenhein, 68766, Germany Phone: +49 620 529 2990 E-mail: [email protected] www.protrans.info

PROTRANS is a company for research, development and production of diagnostic products for organ and bone marrow transplantation, located in Germany, near Frankfurt and next to the university city of Heidelberg.

Final Program 23 Exhibitor Company Descriptions (continued)

Qiagen, Inc 311 19300 Germantown Road Germantown, MD 20874 E-mail: [email protected] www.qiagen.com

QIAGEN is the leading global provider of sample and assay technologies that are used to transform biological materials into valuable molecular information. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to four customer classes: Molecular Diagnostics, Academia, Applied Testing, and Pharma.

ROSE GenTec, Ltd 221 G02a Unit, Kestrei Court, Harbour Road, Portishead Avon BS20 7AN, UK E-mail: [email protected] www.rose-europe.de

ROSE Europe is one of the leading biotech firms worldwide that dedicates itself to the research and development of high quality and cost-efficient in-vitro diagnostic products and services for HLA typing. Our pipelines include the newest NGS ROSE kit flexible for all platforms, SBT high resolution kits and the broadest combinations of SSP low resolution kits.

Scisco Genetics, Inc 504 307 Westlake Avenue North Suite 300 Seattle, WA 98109 E-mail: [email protected] www.sciscogenetics.com

Scisco Genetics is dedicated to providing high quality sequence-based typing solutions and services. Our complete approach includes protocols, reagents, and analysis software that provide a ready to go next generation genotyping system that is easy to use, yields high resolution data, and is price competitive with other HLA typing systems.

Solid Phase Immunoassays Website 401 2041 East Monument Street Baltimore, MD 21205 E-mail: [email protected] www.immunoassays.net Solid Phase Immunoassay Website We have created a website, www.immunoassays.net, to provide a single site (resource) where laboratorians can access the most current findings on solid phase immunoassays which can affect the use of these assays in the lab. Match Program Update We will be demonstrating the updated version of the match program for living donor transplants, now in worldwide use to help transplant centers manage their kidney exchange programs.

24 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Exhibitor Company Descriptions (continued)

STEMCELL Technologies Inc 110 570 West 7th Avenue Suite 400 Vancouver, BC V5Z 1B3 Canada Phone: 1 (800) 667-0322 E-mail: [email protected] www.stemcell.com

STEMCELL Technologies provides fast and easy cell isolation solutions for HLA and chimerism analysis, facilitating high-volume sample processing and reliable results. EasySep™ and RosetteSep™ are fast, gentle on cells, and stable at room temperature. SepMate™ isolates PBMCs in just 15 minutes, and RoboSep™ fully automates cell isolation, saving technician time and eliminating cross-contamination.

SystemLink, Inc 112 23475 Rock Haven Way Suite 140 Dulles, VA 20166 Phone: (703) 651-5706 E-mail: [email protected] www.histotrac.com

Visit the SystemLink booth to learn about building a complete, customizable HLA laboratory management system to meet the needs of your laboratory. HistoTrac is a seamless system with flexible design, providing functionality to make data entry and data access quick and easy. Of special interest: -Paired Kidney Exchange module -HistoTrac on the Web See the HistoTrac software for yourself - in the exhibit hall or in your office.

Texas BioGene 411 635 Presidential Drive Richardson, TX 75081 Phone: (972) 644-1888 E-mail: [email protected] www.texasbiogene.com

Texas BioGene Inc. (TBG) has been developing, manufacturing, and marketing HLA SSP and SBT Tying Kits. Our HLA SSP tray includes a unique divided well format that contains 5 loci (A, B, C, DRB, and DQB1) on a single tray. Our SBT product contains extended exon coverage of HLA loci in both Locus Specific and Group Specific amplification formats. We also offer small and simple automation for all your HLA laboratory needs.

Final Program 25 Exhibitor Company Descriptions (continued)

Trans-Type Diagnostics 509

3513 Urbana Pike Frederick, MD 21704 Phone: (301) 874-2231 E-mail: [email protected]

TRANS-TYPE DIAGNOSTICS provides HLA serological test kits for immunogenetics laboratories throughout the world. Our products are backed by a quarter of a century of experience and offer consistent results with comprehensive antigen coverage. Visit our booth, meet our staff and learn how we can be a valuable resource to your laboratory.

Viracor-IBT Laboratories 407 1001 NW Technology Drive Lee’s Summit, MO 64086 Phone: (800) 305-5198 E-mail: [email protected] www.viracorIBT.com

With nearly 30 years of expertise in infectious disease, immunology and allergy testing, Viracor- IBT is committed to helping medical professionals solve challenging problems. Viracor-IBT provides testing services to 50% of the current U.S. transplant programs. We’re passionate about providing timely, actionable information, never losing sight of the patients ultimately served.

World Transplant Congress 506 15000 Commerce Parkway Suite C Mt. Laurel, NJ 08054 Phone: (856) 439-0880 www.wtc2014.org

The World Transplant Congress (WTC) is a joint meeting of the American Society of Transplant Surgeons (ASTS), The Transplantation Society (TTS) and American Society of Transplantation (AST). The Congress is designed for physicians, surgeons, scientists, nurses, organ procurement personnel, and pharmacists from all over the world who wish to come together in a common forum to share in the cutting edge research in the field of solid organ and tissue transplantation. WTC will take place July 26-31, 2014 at the Moscone West Convention Center in San Francisco, California. We hope to see you there!

26 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Paul I. Terasaki Clinical Science Award The Paul I. Terasaki Clinical Science Award was established in 2003 to honor an individual, group, or institution in recognition of significant accomplishments and/or contributions to the fields of clinical transplantation, histocompatibility and immunogenetics. This award was made possible by a grant from the Paul I. Terasaki Foundation.

The winner of the 2013 Paul I. Terasaki Clinical Science Award is:

Thalachallour Mohanakumar, PhD, D(ABHI) Washington University School of Medicine Thalachallour Mohanakumar, PhD, the Jacqueline G. and William E. Maritz Professor of Surgery, is an internationally renowned organ transplantation scientist and an exceptional collaborator and mentor. His contributions have played a leading role in the success of the transplant programs at Washington University Medical Center. In the laboratory, Mohanakumar has made seminal contributions regarding the structure and function of peptides and their role in preventing organ rejection, particularly in kidney and lung transplants, and in defining the human immune responses to pig organs. Mohanakumar, also a professor of pathology and immunology, has been equally influential as a mentor to a wide number of scientists in transplantation immunology and histocompatibility. Among his former trainees are the heads of five abdominal transplant programs, five directors of histocompatibility laboratories, and three heads of research and development in the world of industry. His mentoring has led to abstract presentations at more than 400 national and international meetings. He also contributes as director of the clinical histocompatibility and immunogenetics laboratory at Washington University School of Medicine. He has received major national awards from the American Society of Transplantation, the American Society for Histocompatibility and Immunogenetics and the Juvenile Diabetes Research Foundation. He is acknowledged as one of the most prolific continuously funded grantees from the National Institutes of Health (NIH), publishing more than 415 papers. He also has served on several NIH study sections. Dr. Mohanakumar earned his doctorate of veterinary medicine in 1966 from Madres Veterinary College in India. He received his doctoral degree from Duke University in 1974 and then concluded his training with an immunology postdoctoral fellowship at the same institution. After serving on the faculty of the Medical College of Virginia, Virginia Commonwealth University for 11 years, he joined the Washington University faculty in 1987.

Final Program 27 The Rose Payne Award The Rose Payne Award was established in 1984 to honor a great scientist and to recognize her longstanding contributions to the field of immunogenetics. As a founding member, Dr. Rose Payne was always willing to share her knowledge and assist others in their endeavors. For more than 30 years, Dr. Payne made significant contributions in areas related to HLA. The Rose Payne Award was established as a tangible recognition of the high regard in which she was held.

The winner of the 2013 Rose Payne Award is:

Andrea A. Zachary, PhD, D(ABHI) Johns Hopkins University School of Medicine (Award supported by STEMCELL Technologies Inc.)

Andrea A. Zachary, PhD, D(ABHI) is a co-director of the Division of Immunogenetics and Transplantation Immunology at the Johns Hopkins University School of Medicine. She received her MS degree in immunology from The Ohio State University and her PhD in genetics from Case Western Reserve University. From 1971-1991 she served as laboratory supervisor, project scientist, and ultimately laboratory director of the Immunogenetics and Transplantation Immunology of the Cleveland Clinic Foundation. From 1991-1994 she was the Chief of Transplantation at NIAID, NIH after which she joined the faculty at Johns Hopkins. Dr. Zachary has published over 150 scientific articles, chapters, and books and has given more than 150 invited talks. She was a founder and served for 32 years on the program and faculty committees of the SEOPF Histocompatibility Specialist Course. She has participated in the International Histocompatibilty Workshops since 1976, working on the identification of HLA antigens, disease associations, and factors relevant to successful transplantation. She was instrumental in the development of the desensitization program pioneered by the Johns Hopkins Comprehensive Transplant Center and identified multiple factors affecting the application and effectiveness of desensitization. She wrote the algorithm that is used for the calculation of CPRA and participated in the determination of the antigen, phenotype, allele, and genotype frequencies of more than 15,000 donors in the UNOS registry. She conceived of and directed development of a method for the identification, quantification, and isolation of HLA-specific B cells. As president of ASHI, in 1991, she launched and participated in a project to further the identification of the HLA alleles in African-Americans, Native Americans, Alaska Natives, Cuban Americans, and Puerto Rican Americans. She has participated in the development and evaluation of new technologies for the characterization of HLA antibodies. Her current interests are in the mechanisms underlying desensitization and the role of non-HLA antibodies in transplantation. She has been a member of the UNOS Board of Directors, the Planning and Program Committees of the Surgeon General’s Workshop on Organ Donation, and currently serves on the International HLA Council and as an International Advisor to the Hong Kong Society for Histocompatibility and Immunogenetics. She has received several awards including the ASHI Distinguished Service Award (2000), the Ohio State University Alumni Association Professional Achievement Award (2001), and the ASHI Distinguished Scientist Award (2010).

28 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 ASHI Distinguished Scientist Award The ASHI Distinguished Scientist Award was established in 2001 to honor a distinguished scientist who is an ASHI member. This individual must have contributed significantly to the field of immunogenetics and/or transplant immunobiology.

The winner of the 2013 ASHI Distinguished Scientist Award is:

Derek Middleton, DSc, PhD, FRCPath Royal Liverpool University Hospital (Award Supported by Bio-Rad Laboratories) Professor Derek Middleton is Director of the Transplant Immunology Laboratory at the Royal Liverpool Hospital, since 2009, and Professor at University of Liverpool. His undergraduate training at Queen’s University, Belfast (QUB) was in Microbiology. His first role in H&I was at the N.Ireland Tissue Typing Service in Belfast, (He was the first full- time member of the laboratory.) where he worked for more than 30 years, becoming Director in 1984. During that time he completed his PhD (QUB,1981), gained Membership of Royal College of Pathologists, London (1987) followed by Fellowship (1997) and was awarded the DSc (QUB,2001) for his research. He is a Visiting Professor, School of Biomedical Science, University of Ulster, 2000- present and was awarded the UK National Health Service Award in 2012 for Excellence in Research

Derek was co-founder with Phil Dyer of the British Society of H&I (BSHI) and served as Chairman 1993-96. He was elected as an International Histocompatibility Councillor 2002 and was co- chairman, with Steve Marsh, of the 16th International HLA and Immunogenetics Workshop held in Liverpool in conjunction with the EFI and BSHI meeting in 2012 and is co-President of 17th International Histocompatibility Workshop.

He has been a member of ASHI since 1987. During that period he has been a member of the Scientific and Clinical Affairs Committee and is in his second session as Chair of the International Committee and been co-author on two best abstract awards at the annual meeting. The Belfast laboratory was the first UK lab to gain ASHI accreditation and subsequently Derek was an inspector for ASHI in Europe. He has also held administrative positions at EFI at Royal College of Pathologists, at UK Transplant Authority and British Transplantation Society.

He has published 330 papers in the HLA field and authored many chapters of books (including the ASHI Laboratory Manual) and was joint author of “Histocompatibility Testing: A Practical Approach.” He has mentored close to 50 PhD and MSc students and held more than 30 research grants. He serves on the editorial boards of Tissue Antigens, is a section editor in Human Immunology and reviews editor in International Journal of Immunogenetics and has refereed manuscripts for many journals, in addition to refereeing grants and examining Ph.Ds.

Derek was the innovator and organiser of N.Ireland Stem Cell Registry, whose molecular typed donors are incorporated into British Bone Marrow Donor Registry. He initiated, planned and administers the website www.allelefrequencies.net which has data on over 1000 normal populations on HLA and KIR frequencies, including rarity of HLA alleles, and has recently introduced two new sections on KIR disease associations and HLA epitope frequencies. He has given plenary lectures in more than 30 countries including annual meetings of ASHI, EFI, BSHI and the International Summer Schools.

Derek spent the early parts of his career characterizing reagents for HLA typing and subsequently exchanging these reagents with many other HLA laboratories, and in performing diverse disease association studies. His PhD examined various immune factors to ascertain their relevance in

Final Program 29 solid organ transplantation. He was then heavily involved in the development of DNA techniques both in the Belfast laboratory and in helping to implement these techniques in many world-wide laboratories. RFLP was followed by SSOP, initially at the 2-digit level and subsequently at higher levels. These techniques were used in Belfast to study many populations and effect of matching in solid organ transplantation. This was followed by the development of a SSOP system for KIR genes and subsequent allele determination for some of these genes. Much of his career has involved collaborative projects with other centres, notably the CTS study run by G.Opelz.

In Liverpool his main interest is now the relevance of antibodies determined by Luminex techniques, in solid organ transplantation. Recently, along with his transplant colleagues from Liverpool, he has been part of the team to perform the first transplants in Gaza and to initiate training there in order that the hospital can be self-sufficient. He firmly believes that a big role of an H&I laboratory is to maintain, along with the transplant surgeon, constant management and monitoring of the patients in an attempt to ensure that the difficult-to-transplant patients have the opportunity of transplant.

ASHI Distinguished Service Award The ASHI Distinguished Service Award was established in 1999 to honor colleagues who have contributed significantly to serving ASHI.

The winner of the 2013 ASHI Distinguished Service Award is:

Robert E. Lewis, Jr., PhD University of Mississippi Medical Center (Award Supported by Linkage Biosciences, Inc.)

Dr Robert E. Lewis, Professor of Pathology and Co-Director of the Division of Immunopathology and Transplantation Immunology at the University of Mississippi Medical Center (UMMC), has served the American Society for Histocompatibility and Immunogenetics during the past quarter century as a Member of the Board of Directors, Chair of Publications and as Executive Liaison with Elsevier for publications, with special emphasis on negotiations with the Publisher to enhance the organization’s flagship journal, HUMAN IMMUNOLOGY. His considerable experience and expertise as Senior Editor of the scientific journals, IMMUNOLOGIC RESEARCH, EXPERIMENTAL AND MOLECULAR PATHOLOGY, and TRANSGENICS, have proven invaluable in overseeing the Society’s publications. Robert is co-author of a spate of books on immunology, including Atlas of Immunology, Illustrated Dictionary of Immunology, and Immunology Guidebook, among others and co-author of approximately 200 scientific article publications. His current research interests include: molecular mechanisms of graft rejection and Toll-like receptor expression and function in metastatic breast, colorectal, and prostate cancer patients. He is a Fellow of the Royal Society of Medicine (London) and holds professional membership in the American Association of Immunologists, the American Society for Investigative Pathology, and the Society for Experimental Biology and Medicine, among a host of others. A native Mississippian, Robert completed undergraduate and M.S. degrees at Ole Miss in Oxford and his PhD in Immunopathology at the University of Mississippi Medical Center, Jackson. After completing postdoctoral training he received a faculty appointment at UMMC, where he has served for almost 40 years.

30 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 ASHI Outstanding Technologist Award The Outstanding Technologist Award has honored some of the most active and creative technologists in the field of HLA. Candidates must have made significant and sustained contributions to ASHI. The Outstanding Technologist Award is dedicated to all ASHI technologists past, present and future for the fine work they do every day in creating better patient outcomes and saving lives.

The winner of the 2013 Outstanding Technologist Award is:

Maurine Davidson, BS, CHS University of Minnesota Medical Center (Award Supported by National Marrow Donor Program)

Armed with an Associate Degree as a Clinical Laboratory Technician and a BS in biology, I accepted a job in the Clinical Chemistry Lab at the University of Minnesota Hospital in the late 70’s. Within a couple months, it became clear that this was not the career I for which I had prepared. Desperate to find something different, I interviewed for a position as a “Junior Scientist” in the Immunology Lab. Cool! What lab rat wouldn’t want to be known as a Junior Scientist, even if it was in something as dull and boring as immunology? Little did I know that I had, in fact, found my career home. I knew I had made the right choice almost immediately. This wasn’t a lab that performed the traditional immunology tests I had learned about in training; this was a lab that performed HLA testing (whatever that was) for transplantation. So not only did I have the coolest job title in the world, but I was involved with the fairly new and sexy field of organ transplantation. An added bonus was the opportunity to work with a group of other young Junior Scientists who had also found their career home. We were a young and close-knit group doing serological HLA typing, crossmatching, and antibody testing. We needed electricity for our centrifuges and microscopes, but computers? Not so much. We were also busy getting married and having babies. I married Jeff Tordoff in June of 1979. Our lab had recently come under the directorship of Dr. Fritz Bach, and it was an exciting time in HLA. Our lab manager, Harriet Noreen, worked closed with Dr. Bach as they brought DNA-based methods into the clinical setting. Harriet asked for volunteers to learn and develop these molecular methods; I didn’t waste any time getting my name on that list. Harriet, Mary Stewart, and I worked for several years doing HLA typing by RFLP and by SSO. Harriet even performed (successful) PCR without a thermal cycler! Working with P32 was not much fun, as Annette Jackson and I learned in our participation in the 11th International HLA Workshop. As molecular methods became more mainstream, we trained additional staff and developed QC and QA procedures. Our work became more clinical than developmental, and our patients were better served because of these new methods. We migrated from P32 to digoxigenin, and eventually to fluorescence on the Luminex platform. My job title changed from Junior Scientist to Lead Tech to Senior Tech to Technical Supervisor. Supervision of the DNA lab became my job as we continued to support several transplant programs. We also performed NMDP registry typing from 1993 until 2013. The one thing that didn’t change was my love of HLA. This love for HLA (and Harriet’s encouragement) led to my becoming an inspector for ASHI. This has proven to be a great opportunity to meet other HLA folks, learn other ways of doing things, and help make our labs even better. I’ve been honored to serve on the Accreditation Review Board since 2005.

And those other young Junior Scientists? Prior to Harriet’s retirement last year, nine of us were still coming to the lab every day to perform HLA testing on our patients. We need more than electricity now; if the computer network is down, we might as well just go to the home. The methods have changed, but the need for skilled and passionate HLA scientists and techs has not diminished. Words cannot express how grateful I am for the fabulous career I’ve had as an HLA technologist.

Final Program 31 The ASHI Rising Star Award The ASHI Rising Star Award (formerly ASHI/SEOPF J. Marilyn MacQueen) recognizes an outstanding HLA technologist who has worked in the field for less than three years and desires to pursue a career in HLA.

The winner of the 2013 Rising Star Award is:

Katarzyna Brooks, B.S., CHT (ABHI) Gift of Hope Organ & Tissue Donor Network

Katarzyna (Kasia) Brooks was born and raised in Chicago by parents who emigrated from Poland in the early 1980s. In 2006, she earned a Bachelor of Science degree in Biological Sciences from the University of Illinois at Chicago and became the first member of her family to graduate from college. Shortly after graduation, Kasia accepted a position in an independent microbiology laboratory where she worked for 4.5 years. During her tenure there, she gained valuable experience in molecular biology and microbial genetics and co-authored three meeting abstracts.

In January 2011, Kasia joined the Histocompatibility & Immunogenetics Laboratory at Gift of Hope Organ & Tissue Donor Network in Itasca, Illinois, as a Medical Technologist. Gift of Hope is one of the nation’s largest organ procurement organizations and is entrusted by the federal government with coordinating organ and tissue donation in northern Illinois and northwest Indiana. At Gift of Hope, Kasia has become an expert in several techniques, including molecular HLA typing, crossmatching, antibody screening and identification, post-transplant monitoring, and infectious diseases screening. She also participates in a rotating on-call schedule on weekends and holidays and is key member of the laboratory’s research and development team. In that role, Kasia has co-authored seven meeting abstracts and two journal articles. Her current research interest is to further define the nature of non- HLA auto-antibodies that cause positive T-cell flow cytometry crossmatches in HIV-infected patients.

In March 2012, Kasia was accredited as a Certified Histocompatibility Technologist by the American Board of Histocompatibility & Immunogenetics and joined the ASHI community. Kasia enjoys being part of an advancing field that welcomes and embraces change and is excited to be part of its continuous growth. She is very grateful to be led by a laboratory director whose excitement and passion for this field has inspired her to be an even better scientist, and she enjoys working with a team that is open to sharing their ideas in working together toward improvements that can enhance the ability of the organization to make more organs available to people in need of lifesaving transplants. Kasia’s immediate goals are to become an active member of ASHI by volunteering in committees and to train as an ASHI laboratory inspector. Outside of the laboratory, Kasia enjoys an active lifestyle that includes cross-fit training, obstacle mud races and traveling with her husband.

32 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 ASHI Scholars and International Scholar Awards The best abstracts submitted for the 2013 Annual Meeting will be recognized during the Awards Symposium and the submitters will give an oral presentation during the Special Abstract Scholar Session. These abstracts received the highest rating by the reviewers, and the awards are provided to recognize individuals who made a significant advance in either clinical or basic research areas. The authors were selected from more than 255 submitted abstracts. Recipients receive a monetary award and award plaque for their research.

Special Abstract Session: Scholar Awards Wednesday, November 20 • 2:00 PM – 3:30 PM

Sebastiaan Heidt, PhD - ASHI International Scholar Leiden University Medical Center Leiden, Netherlands

Abstract #59-OR: EVIDENCE FOR A POSSIBLE ROLE OF MEMORY B CELLS IN ACUTE KIDNEY GRAFT REJECTION. (Award Supported by Elsevier)

Fang Li, PhD - ASHI Scholar University of California Los Angeles, CA

Abstract # 56-OR: ACTIVATION AND CYTOSKELETAL REMODELING OF HUMAN ENDOTHELIAL CELLS BY HLA CLASS II ANTIBODIES.

Yi-Ping Jin, MD - ASHI Scholar University of California Los Angeles, David Geffen School of Medicine Los Angeles, CA (Award Supported by mTilda HLA Software Specialists)

Abstract #58-OR: SIGNALING NETWORKS REGULATING HLA CLASS II ANTIBODY-MEDIATED ACTIVATION AND MIGRATION OF ENDOTHELIAL CELLS.

Tenisha West, MS - ASHI Scholar Rush University Medical Center Chicago, IL

Abstract #57-OR: VALIDATION OF A MULTIPLEX LUMINEX ASSAYS TO DETECT POTENTIAL BIOMARKERS ASSOCIATED WITH RENAL ALLOGRAFT REJECTION.

Final Program 33 Schedule at a Glance Sunday, November 17

7:00 AM – 9:00 AM ASHI’s 1st Run for a Life 5K Fun Run/Walk

8:00 AM – 5:00 PM Accreditation Inspector’s Training Workshop Sheraton Ballroom II

Noon – 7:30 PM Registration Open Convention Registration

5:30 PM – 7:00 PM Accreditation & Proficiency Testing Update Sheraton Ballroom IV & V

7:00 PM – 8:00 PM Keynote Address : Next Generation Transplantation: iPS Cells for Engineering Autologous Tissues Sheraton Ballroom IV & V

Darrell N. Kotton, MD Boston University School of Medicine

8:00 PM – 9:00 PM Welcome Reception Sheraton Promenade

Monday, November 18 7:00 AM – 4:00 PM Registration Open Convention Registration

8:00 AM – 9:30 AM Plenary I: Genomics: From Population to Personal Sheraton Ballroom IV & V

Moderators Jill M. Hollenbach, PhD Rajalingam Raja, PhD

Variable NK Cell Receptors and their MHC Class I Ligands in Immunity, Reproduction and Human Evolution Peter Parham, PhD Stanford School of Medicine

The Impact of Recent Demography and Purifying Selection on Rare Single Nucleotide Variants John Novembre, PhD The University of Chicago 9:30 AM – 10:00 AM AM Refreshment Break 10:00 AM – Noon Symposium I: Individualized Medicine and the MHC Sheraton Ballroom IV & V

34 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Schedule at a Glance (continued) Moderators Marilyn S. Pollack, PhD, D(ABHI) Amy B. Hahn, PhD, D(ABHI)

The Common Genetic Basis for Autoimmune Disease David A. Hafler, MD, MSc Yale School of Medicine

Genetics of Spondyloarthritis – HLA-B27 and Beyond John D. Reveille, MD The University of Texas Medical School

A Molecular Mechanism for HLA-Linked Drug Reactions-Lessons from Abacavir Hypersensitivity Syndrome James McCluskey, FAA The University of Melbourne

Noon – 2:00 PM User Group Luncheons:

Illumina Presentation: Overview of Illumina Technology & Applications Mayfair

Linkage Biosciences, Inc.: Real-Time PCR HLA Workshop Michigan A & B

Olerup, Inc.: Lunch Symposium Superior A & B

One Lambda, Inc., part of Thermo Fisher Scientific: Symposium Sheraton Ballroom IV

STEMCELL Technologies, Inc.: Standardize sample preparation for cleaner, more consistent flow cytometry crossmatch assays Erie

2:00 PM – 3:30 PM Workshop 1: Case Studies in Stem Cell Transplantation Sheraton Ballroom II

Moderator Carrera Kostur

Workshop 2: Summary of the 2012 Rome Antibody Consensus Meeting Sheraton Ballroom V

Final Program 35 Schedule at a Glance (continued)

Patricia M. Campbell, MBChB, FRCP(UK), FRCP(C) University of Alberta Hospitals Andrea A. Zachary, PhD, D(ABHI) Johns Hopkins University School of Medicine Peter Nickerson, MD, FRCPC Canadian Blood Services

Abstract Session 1: New Assays (Genomics/Proteomics) Sheraton Ballroom III

Moderator Thalachallour M. Mohanakumar, PhD, D(ABHI)

Abstract Session 2: Clinical Transplantation Testing Sheraton Ballroom I

Moderator Kathryn Tinckam, MD, MMSc, FRCPC

3:30 PM – 4:00 PM PM Refreshment Break

4:00 PM – 5:30 PM Workshop 3: Next-Gen Sequencing of HLA: The Fullfillment of a Great Promise Sheraton Ballroom IV

Kenneth Beckman, PhD University of Minnesota Genomics Center Dimitri S. Monos, PhD University of Pennsylvania

5:30 PM – 7:00 PM Poster Session & Reception River Exhibit Hall

7:00 PM – 9:00 PM ASHI/ARB Inspectors’ & International Reception Mayfair

7:00 PM – Midnight User Group Dinner: Abbott Molecular Scientific Meeting Michigan A

Tuesday, November 19 7:30 AM – 6:00 PM Registration Open Convention Registration

8:00 AM – 9:30 AM Plenary II: Tolerance: Organ and Stem Cell Transplantation Sheraton Ballroom IV & V

36 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Schedule at a Glance (continued)

Moderators Mary S. Leffell, PhD, ABMLI, D(ABHI) Anat Tambur, DMD, PhD, D(ABHI)

Tolerance in Stem Cell Transplantation Megan Sykes, MD Columbia University College of Physicians and Surgeons

Tregitopes- an Immunomodulation Powerhouse: Alternative to IVIG? Anne S. De Groot, MD EpiVax, Inc.

9:30 AM -10:00 AM AM Refreshment Break

10:00 AM – Noon Symposium II: Current Trends in Hematopoietic Stem Cell Transplantation Sheraton Ballroom IV & V

Moderators Victoria Turner, PhD, D(ABHI) David Senitzer, PhD, D(ABHI, ABMLI)

Donor Selection Guidelines for Allogeneic Hematopoietic Stem Cell Transplantation Stephen R. Spellman, MBS Center for International Blood and Marrow Transplant Research

Strategies to Enhance Engraftment after Cord Blood Transplant Colleen Delaney, MD Fred Hutchinson Cancer Research Center

Hematopoietic Stem Cell Transplantation in Europe Joannis M. Mytilineos, MD, PhD IKT Ulm

Noon – 2:00 PM User Group Luncheons:

Life Technologies Workshop Sheraton Ballroom II

2:00 PM – 3:30 PM Workshop 4: Case Studies in Solid Organ Transplantation Sheraton Ballroom III

Moderator Jessica Jackstadt, MT(ASCP), CHT

Final Program 37 Schedule at a Glance (continued)

Workshop 5: Practicalities of Interfacing with Laboratory Information Systems Sheraton Ballroom V Pedro Cano, MD, MBA University of Texas Martin Maiers National Marrow Donor Program John Hart, MBA, CHS Johns Hopkins University

Abstract Session 3: Genetic Polymorphism (MHC/MIC/KIR/Cytokines) Sheraton Ballroom I

Moderator Marcelo A. Fernandez-Viña, PhD, D(ABHI)

Abstract Session 4: Basic Science Transplantation Sheraton Ballroom II

Moderator Frans H.J. Claas, PhD

3:30 PM – 4:00 PM PM Refreshment Break

4:00 PM – 5:30 PM Workshop 6: HLA DSA Subclasses, Isotypes and non-HLA Antibodies: What‘s Important for Transplant Screening? Sheraton Ballroom V

Alin Girnita, MD University of Cincinnati James C. Cicciarelli, PhD Mendez Institute of Transplantation

Abstract Session 5: HLA Typing/Anthropology/ Disease Association Sheraton Ballroom II

Moderator Elizabeth A. Trachtenberg, MS, PhD, D(ABHI)

Abstract Session 6: Best of the Rest Sheraton Ballroom III

Moderator William H. Hildebrand, PhD, D(ABHI)

38 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Schedule at a Glance (continued)

5:30 PM – 7:00 PM Directors’ Forum Sheraton Ballroom II

Technologists’ Forum Sheraton Ballroom III

Wednesday, November 20

7:30 AM – 8:15 AM Women in Transplant Breakfast Michigan A & B

8:00 AM – 6:00 PM Registration Open Convention Registration

8:30 AM – 10:00 AM Plenary III: Scientific Award Lectures Sheraton Ballroom IV & V

Rose Payne Award My IgGnoble Career Andrea Zachary, PhD, D(ABHI) Paul Terasaki Award Immune responses to tissue restricted self-antigens in the pathogenesis of chronic rejection: Cross talk between Allo and Autoimmunity Thalachallour Mohanakumar, PhD, D(ABHI) Distinguished Scientist Award Life-Time Long Time in H&I Collaboration Derek Middleton, DSc, PhD, FRCPath

10:00 AM – 10:30 AM AM Refreshment Break

10:30 AM – Noon Symposium III: Awards & Business Meeting Sheraton Ballroom IV & V

1:00 PM – 2:00 PM UNOS Histocompatibility Update Sheraton Ballroom V

2:00 PM – 3:30 PM Workshop 7: Laboratory Developed Testing: Validating Test Modifications Sheraton Ballroom IV

Donna Lucas, MS, CHS Johns Hopkins University Robert Bray, PhD, D(ABHI), HCLD/CC(ABB) Emory University Hospital Robert Liwski, MD Dalhousie University Special Abstract Session: Scholar Awards Sheraton Ballroom V

Final Program 39 Schedule at a Glance (continued)

Moderators Peter Stastny, PhD Jeffrey A. Borgia, PhD Malek Kamoun, MD, PhD

3:30 PM – 4:00 PM PM Refreshment Break

4:00 PM – 5:30 PM Workshop 8: Ethical Dilemmas in Transplantation Sheraton Ballroom V Meaghann Weaver, MD St. Jude Children’s Research Hospital William Parker, MD University of Chicago

Workshop 9: Understanding Common Statistical Methodologies for Histocompatibility and Immunogenetics Research Sheraton Ballroom IV

David Gjertson, PhD University of California Los Angeles Immunogenetics Center Brent Logan, PhD Medical College of Wisconsin

8:00 PM – Close ASHI Night Out: The Second City’s 101st Mainstage Revue Ticketed Event

Thursday, November 21

8:00 AM – 10:30 AM Registration Open Convention Registration 8:00 AM – 9:30 AM Plenary IV: New Horizons in Complement Sheraton Ballroom IV & V Moderators Donna Lucas, MS, CHS Dolly Tyan, PhD, D(ABHI) The Complement Cascade: A Series of Anti- and Pro-Inflammatory Tipping Points William M. Baldwin, III, MD, PhD Cleveland Clinic New Pathways of Complement Mediated Injury in Transplantation Steven H. Sacks, PhD King’s College London

9:30 AM – 10:00 AM AM Refreshment Break

40 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Schedule at a Glance (continued)

10:00 AM – Noon Hot Topic: The C1q Assay – Is It Ready for Prime Time? Sheraton Ballroom IV & V

Moderators Tom Ellis, PhD, D(ABHI) Robert Liwski, MD

Is It Clinically Relevant to Test for C1q-binding HLA Specific Antibodies in Solid Organ Transplantation? Adriana Zeevi, PhD University of Pittsburgh, Thomas E. Starzl Transplantation Institute

C1q Testing: Results from an Inter-Laboratory Comparison Paul R. Warner, PhD, D(ABHI) Puget Sound Blood Center Selected C1q Abstracts

Final Program 41 Abstracts Monday, November 18, 2013 2:00 PM - 3:30 PM Workshop 1: Case Studies in Stem Cell Transplantation 1-OR HLA TYPING OF DNA FROM BUCCAL SWAB AND DRIED BLOOD SAMPLES FOLLOWING PROLONGED STORAGE AT ROOM TEMPERATURE. Gail H. Flickinger1, Susan Hsu3, Neng Yu2, Tatiana Lebedeva2, Wei Dong3, Jonathan Barone3, Craig L. Malmberg1, Michelle Setterholm1. 1Scientific Services, National Marrow Donor Program, Minneapolis, MN, USA; 2New England HLA Laboratory, American Red Cross - Northeast Division, Dedham, MA, USA; 3Histocompatibility/Molecular Genetics, American Red Cross Penn-Jersey Region, Philadelphia, PA, USA.

2-OR A CASE OF MIXED UMBILICAL CORD/ RECIPIENT CHIMERISM IN BUCCAL CELLS, FOLLOWED BY COMPETITION BETWEEN CORD AND A SECOND HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT. Paula Y. Arnold, Christy C. Embrey, Susana Raimondi, Sheila Shurtleff, E. Victoria Turner. Pathology, St. Jude Children’s Research Hospital, Memphis, TN, USA.

3-OR DONOR SELECTION FOR HUMAN CELL TRANSPLANTATION AND THE ROLE PLAYED BY ANTI-DP ANTIBODIES. Shalini Pereira1,2,3, Olga Menninger2, Dana McLendon2, Debra Cordell2, Sandra Warnock2, Sue McKinney4. 1Clinical Research Division, Fred Hutchinson Cancer Resaerch Center, Seattle, WA, USA; 2Clinical Immunogenetics Laboratory, Seattle Cancer Care Alliance, Seattle, WA, USA; 3Department of Laboratory Medicine, University of Washington, Seattle, Seattle, WA, USA; 4Children’s Hospital & Research Center, Oakland, CA, USA. Pereira: Linkage Biosciences: Consultant; Science Med Advisor; Stockholder; Scisco Genetics: Consultant; Science Med Advisor. 4-OR CASE STUDY: SALIVA DNA NOT EQUIVALENT TO BUCCAL SWAB DNA AS A SURROGATE FOR A GERMLINE SAMPLE. Lois E. Regen1, Sandra L. Warnock1, Scott McElhone5, Maggie Sprague1, Min Fang2,4,5, Shalini E. Pereira1,2,3. 1Clinical Immunogenetics Lab, Seattle Cancer Care Alliance, Seattle, WA, USA; 2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 3Department of Laboratory Medicine, University of Washington, Seattle, WA, USA; 4Department of Pathology, University of Washington, Seattle, WA, USA; 5Cytogenetics Laboratory, Seattle Cancer Care Alliance, Seattle, WA, USA.

42 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 5-OR SUCCESSFUL BONE MARROW TRANSPLANT IN THE PRESENCE OF DONOR SPECIFIC ANTI-HLA ANTIBODIES. Manish J. Gandhi1, Steven De Goey1, Cynthia Kroning1, Mike Chen2, Jar-How Lee2, Laurie Voit1, Mrinal S. Patnaik3. 1Division of Transfusion Medicine, Mayo Clinic, Rochester, MN, USA; 2Transplant Diagnostics, Thermo Fisher Scientific, Canoga Park, CA, USA;3 Division of Hematology, Mayo Clinic, Rochester, MN, USA. Chen: Thermo Fisher Scientific: Employee. Lee: Thermo Fisher Scientific: Employee. 6-OR CASE STUDY: CHROMOSOME GENOMIC ARRAY TESTING (“VIRTUAL KARYOTYPE”) CONFIRMS LOSS OF HETEROZYGOSITY ORIGINALLY DETECTED BY HLA TYPING. Lois E. Regen1, Sandra L. Warnock1, Scott W. McElhone5, Randy P. Williams1, Rita C. Witherspoon1, Min Fang2,3,5, Shalini Pereira1,2,4. 1Clinical Immunogenetics Laboratory, Seattle Cancer Care Alliance, Seattle, WA, USA; 2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 3Department of Pathology, University of Washington, Seattle, WA, USA; 4Department of Laboratory Medicine, University of Washington, Seattle, WA, USA; 5Cytogenetics Laboratory, Seattle Cancer Care Alliance, Seattle, WA, USA.

Monday, November 18, 2013 2:00 PM - 3:30 PM Abstract Session 1: New Assays (Genomics/ Proteomics) 7-OR A NEW COMBO-FLOW CROSSMATCH (CFXM) FOR SIMULTANEOUS DETECTION OF IgG AND COMPLEMENT FIXING ANTIBODIES (CFAbs). Ge Chen, Flavia Sequeira, Dolly Tyan. Pathology, Stanford University, Palo Alto, CA, USA.

8-OR PRIMER DESIGN FOR SHORT AMPLICON-BASED NGS. Kathrin Lang1, Irina Böhme1, Vinzenz Lange1, Bianca Schöne1, Johanna M. Andreas1, Daniel M. Baier2, Jan Hofmann2, Jürgen Sauter2, Julia Pingel2, Gerhard Ehninger3, Alexander H. Schmidt2. 1Research and Development, DKMS Life Science Lab, Dresden, Germany; 2DKMS German Bone Marrow Donor Center, Tübingen, Germany; 3Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany. 9-OR A NOVEL HLA-DSA FLOW CROSSMATCH (DSA-FXM). Ge Chen, Lingling Lin, Flavia Sequeira, Dolly Tyan. Pathology, Stanford University, Palo Alto, CA, USA.

Final Program 43 Abstracts 10-OR NEW APPROACHES TO DEFINE BINDING MOTIFS AND SUPERTYPES IN PEPTIDE BINDING ANALYSIS. Rico Buchli1, Rebecca McAdams1, Aaron D. Rennels1, Rodney S. VanGundy1, William H. Hildebrand1,2. 1R&D, Pure Protein LLC, Oklahoma City, OK, USA; 2Microbiology and Immunology, Oklahoma University Health Sciences Center, Oklahoma City, OK, USA.

11-OR ACCURATE TYPING OF HUMAN LEUKOCYTE ANTIGEN (HLA) BY NEXT-GENERATION EXOME SEQUENCING. Chang Liu1, Xiao Yang2, Brian Duffy3, T. Mohanakumar4, Robi D. Mitra5, Michael C. Zody2, John D. Pfeifer1. 1Department of Pathology & Immunology, Washington University School of Medicine, St Louis, MO, USA; 2Genome Sequencing and Analysis Program, Broad Institute of MIT & Harvard, Cambridge, MA, USA; 3HLA Laboratory, Barnes-Jewish Hospital, St Louis, MO, USA; 4Department of Surgery, Pathology & Immunology, Washington University School of Medicine, St Louis, MO, USA; 5Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St Louis, MO, USA.

12-OR A NEXT GENERATION HLA SEQUENCING METHOD PROVIDES ROBUST RELIABLE CLASS II TYPING OF AN HSCT COHORT. Anajane G. Smith1,2, Shalini E. Pereira1,2, Dan E. Geraghty1,2, John A. Hansen2. 1HLA, Scisco Genetics, Seattle, USA; 2Human Immunogenetics, Fred Hutchinson Cancer Research Center, Seattle, USA. Smith: Scisco Genetics: Consultant. Pereira: Scisco Genetics: Science Med Advisor. Geraghty: Scisco Genetics: Science Med Advisor. 13-OR HLA MISMATCHES THAT ARE IDENTICAL FOR THE ANTIGEN RECOGNITION SITE: AN INVENTORY OF THE FUNCTIONAL CONSEQUENCES. Dave Roelen1, Yvonne de Vaal1, Cynthia Vierra-Green2, Stephanie Waldvogel2, Stephen Spellman2, Frans Claas1, Machteld Oudshoorn1. 1Immunohaematology and Blood Transfusion, LUMC, Leiden, Netherlands; 2Immunobiology and Observational Research, Center for International Blood and Marrow Transplant Research, Minneapolis, USA.

44 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts Monday, November 18, 2013 2:00 PM - 3:30 PM Abstract Session 2: Clinical Transplantation Testing 14-OR CLINICAL RELEVANCE OF DONOR SPECIFIC HLA ANTIBODIES IN PATIENTS WITH FUNCTIONING RENAL ALLOGRAFTS AFTER MORE THAN TEN YEARS POST TRANSPLANTATION. Peter Masiakos, Grace Pan, Rosanne Scandaliato, Kwaku Marfo, Liise Kayler, Stuart Greenstein, Enver Akalin, Adriana Colovai. Transplant Surgery, Montefiore Medical Center, Bronx, NY, USA.

15-OR VIRTUAL CROSSMATCH VERSUS FINAL FLOW CYTOMETRIC CROSSMATCH – REVIEW OF 2000 CROSSMATCHES PERFORMED IN THE PAST THREE YEARS. Yu Sun, Yonghong Song, Liang Wan, Wendy E. Wegner, Dong-Feng Chen. Clinical Transplantation Immunology Laboratory, Duke University Medical Center, Durham, NC, USA.

16-OR ANALYSIS OF ANTI-HLA ANTIBODIES IN SENSITIZED KIDNEY TRANSPLANT CANDIDATES SUBJECTED TO DESENSITIZATION WITH INTRAVENOUS IMMUNOGLOBULIN AND RITUXIMAB. Andrew L. Lobashevsky1,2, Nancy G. Higgins2, Kevin M. Rosner2, Muhammad A. Mujtaba1, William C. Goggins3, Tim E. Taber1. 1Department of Medicine, Indiana University, Indianapolis, IN, USA; 2Indiana University Health Transplant Center, Transplant Immunology Laboratory, Indianapolis, IN, USA; 3Department of Surgery, Indiana University, Indianapolis, IN, USA.

17-OR IS RACE A RISK FACTOR FOR POOR KIDNEY TRANSPLANT SURVIVAL? Allen J. Norin1,2, David J. Hochman1,4, Amarpali J. Brar2, Nabil J. Sumrani,3, Dale J. Distant3, Devon J. John3, Mary J. Mondragon-Escorpizo1,4, Moro J. Salifu2. 1Transplant Immunology & Immunogenetics, SUNY Downstate Medical Center, Brooklyn, NY, USA; 2Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA; 3Surgery, SUNY Downstate Medical Center, Brooklyn, NY, USA; 4Pathology, SUNY Downstate Medical Center, Brooklyn, NY, USA. Norin: Immucor - Lifecodes: Speakers Bureau. 18-OR INCIDENCE OF HLA ANTIBODIES AFTER ISLET CELL TRANSPLANTATION: INITIAL RESULTS OF THE CLINICAL ISLET TRANSPLANTATION (CIT) CONSORTIUM TRIAL. Malek Kamoun1, Jane Kearns1, Eline Luning Prak1, William R. Clarke2, Dixie J. Ecklund3, Thomas Eggerman4, Nancy Bridges6, Ali Naji5, on behalf of the CIT Investigators. 1Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA; 2Biostatistics, University of Iowa, Iowa City, IA, USA; 3Clinical Trials Statistical & Data Management Center, University of Iowa, Iowa City, IA, USA; 4NIDDK, NIH, Bethesda, MD, USA; 5Surgery, University of Pennsylvania, Philadelphia, PA, USA; 6NIAID, NIH, Bethesda, MD, USA.

Final Program 45 Abstracts 19-OR A COMPARISON OF MFIS WITH FLOW CYTOMETRIC CROSSMATCH OUTCOMES AS A MEANS TO CORRELATE ANTIBODY TESTING WITH VIRTUAL CROSSMATCH PREDICTION. Arlene Locke, Kevin Moua, Maria Cabarong, Ping Rao, Qiuheng Zhang, Elaine F. Reed, David Gjertson. UCLA Immunogenetics Center/ Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, USA.

20-OR FAVORABLE OUTCOME OF RENAL ALLOGRAFT RECIPIENTS WITH DONOR SPECIFIC HLA ANTIBODIES. Kwaku Marfo, Maria Ajaimi, Michelle Lubetzky, Adriana Colovai, Peter Masiakos, Graciela deBoccardo, Enver Akalin. Transplant Surgery, Montefiore Medical Center, Bronx, NY, USA.

Tuesday, November 19, 2013 2:00 PM - 3:30 PM Workshop 4: Case Studies in Solid Organ Transplantation 21-OR QUANTITATIVE ANALYSIS OF MIXTURES BY DEEP SEQUENCING OF HLA GENE AMPLICONS USING NEXT GENERATION SYSTEMS. Cherie L. Holcomb1, Melinda Rastrou1, Bryan Hoglund1, Damian Goodridge2, Daniel R. Salomon3, Henry A. Erlich1. 1Human Genetics, Roche Molecular Systems, Inc., Pleasanton, CA, USA; 2Software Development, Conexio Genomics, Perth, Australia; 3Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA. Holcomb: Roche: Employee. Rastrou: Roche: Employee. Hoglund: Roche: Employee. Goodridge: Conexio Genomics: Employee. Erlich: Roche: Employee. 22-OR FALSE-NEGATIVE VIRTUAL CROSSMATCH DUE TO UNOS’ UNACCEPTABLE ANTIGEN DATABASE LIMITATIONS: THE SAGA CONTINUES. Zeying Du1, Kristin Dastych1, Natasia Kowalkowski1, Wuhua Sun1, Bozena Labuda2, Andres Jaramillo1,2, Sujata Gaitonde1. 1Pathology, Univesity of Illinois Hospital and Health Sciences System, Chicago, IL, USA; 2Histocompatibility Laboratory, Gift of Hope Organ & Tissue Donor Network, Itasca, IL, USA.

23-OR DSA SCORING METHOD FOR ENHANCED VITUAL CROSS MATCH PREDICTABILITY: CASE STUDIES. Allen J. Norin1,2, David Hochman1,3, Ballabh Das1,3. 1Transplant Immunology & Immunogenetics, SUNY Downstate Medical Center, Brooklyn, NY, USA; 2Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA; 3Pathology, SUNY Downstate Medical Center, Brooklyn, NY, USA. Norin: Immucor - Lifescodes: Speakers Bureau.

46 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 24-OR HOW A ROUTINE DECEASED DONOR CROSSMATCH PREVENTED TRANSMISSION OF UNDIAGNOSED LYMPHOMA – A CASE REPORT. Kyle R. Putnam, Christine R. Peiter, Dorothy Levis, Jerry C. Rosenberg, Sam Ho. Histocompatibility Laboratory, Gift of Life Michigan, Ann Arbor, MI, USA.

25-OR SEQUENTIAL ANALYSIS OF HLA-C1q FOLLOWING AN HLA INCOMPATIBLE RENAL TRANSPLANTATION. Alyson A. Morris1, Carly J. Callender2, Renato M. Vega1, Annette M. Jackson1. 1Medicine, Johns Hopkins University, Baltimore, MD, USA; 2Pathology and Laboratory Medicine, University of California at Los Angeles, Los Angeles, CA, USA.

26-OR FATAL GRAFT VERSUS HOST DISEASE (GVHD) AFTER ZERO MISMATCH KIDNEY/ PANCREAS TRANSPLANTATION. Gizem Tumer, Tiffany K. Roberts-Wilson, Robert A. Bray, Howard M. Gebel. Pathology, Emory University School of Medicine, Atlanta, GA, USA.

27-OR AGGRESSIVE ACUTE ANTIBODY-MEDIATED REJECTION OF NEGATIVE FLOW CROSSMATCH 3rd KIDNEY TRANSPLANT WITH EXCLUSIVE DISPARITY AT HLA-DP. Beata Mierzejewska1, Caitlin Baum2, Paul Schroder2, Annette Blair3, Connie Smith3, Rene Duquesnoy4, Marilyn Marrari4, Michael Rees1, Stanislaw Stepkowski2. 1Urology, University of Toledo, Toledo, OH, USA; 2Microbiology&Immunology, University of Toledo, Toledo, OH, USA; 3Pathology, University of Toledo, Toledo, OH, USA; 4Pathology, University of Pittsburgh, Pittsburgh, PA, USA. Tuesday, November 19, 2013 2:00 PM - 3:30 PM Abstract Session 3: Genetic Polymorphism (MHC/ MIC/KIR/Cytokines) 28-OR KILLER IMMUNOGLOBULIN-LIKE RECEPTORS AND UNIQUE TARGET-INDUCED IMMUNE RESPONSES OF NATURAL KILLER (NK) CELL SUBSETS. Rehan M. Faridi1, Taylor J. Kemp1, Abdelhamid Liacini1, Poonam Dharmani-Khan1, Victor Lewis2, Jan Storek3, Noureddine Berka1,4, Faisal M. Khan1,2,4. 1Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada; 2Pediatrics, University of Calgary, Calgary, Canada; 3Medicine, University of Calgary, Calgary, Canada; 4Tissue Typing Laboratory, Calgary Laboratory Services, Calgary, Canada.

Final Program 47 Abstracts 29-OR THE PRESENTATION OF HIV PEPTIDE LIGANDS BY HLA-A*11:01. Jane C. Yaciuk, Matthew Skaley, Curtis P. McMurtrey, Daryl Cox, Wilfried Bardet, Fredda Schafer, Danijela Mojsilovic, Christopher J. Stewart, Steven Cate, Stephen Vernon, Ken Jackson, William H. Hildebrand. Department of Microbiology and Immunology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

30-OR NMR SPECTROSCOPY REVEALS UNEXPECTED STRUCTURAL VARIATION AT THE PROTEIN- PROTEIN INTERFACE IN MHC CLASS I MOLECULES. Andreas Ziegler1, Monika Beerbaum2, Martin Ballaschk2, Natalja Erdmann2, Christina Schnick1, Anne Diehl2, Barbara Uchanska-Ziegler1, Peter Schmieder2. 1Institut für Immungenetik, Charité- Universitätsmedizin Berlin, Berlin, Germany; 2Biomolecular NMR, Leibniz-Insitut für Molekulare Pharmakologie, Berlin, Germany.

31-OR FLUCTUATING AND GEOGRAPHICALLY SPECIFIC SELECTION CHARACTERIZE RAPID EVOLUTION OF THE HUMAN KIR LOCUS. Jill A. Hollenbach1,Arnav Moudgil2, Peter Parham2 and Paul J. Norman2. 1Center for Genetics, Children’s Hospital Oakland Research Institute, Oakland, CA USA; 2Departments of Structural Biology and Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA USA.

32-OR VALIDATION OF A NEW METHOD FOR KIR GENOTYPING: REAL-TIME PCR LinkSeq™ KIR. Ketevan Gendzekhadze1, Lan-Feng Cao1, Zachary Antovich2, Ngoc Ly2, David Senitzer1. 1HLA Laboratory, City of Hope, Duarte, CA, USA; 2Immunogenetics, Linkage Biosciences, South San Francisco, CA, USA.

33-OR DIVERSIFY HLA-LIGANDS (HLA-L) FOR KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) GENES IN UMBILICAL CORD BLOOD UNITS (UCBU) COULD BENEFIT PATIENTS (PTS) IN NEED OF HEMATOPHOIETIC STEM CELLS (HSC) TRANSPLANT (Tx). Kai Cao1, Edward Guerrero1, Yudith Carmazzi1, Ttus Barnes1, Pedro Cano1, Katy Rezvani2, Elizabeth Shpall2, Marcelo A. Fernández-Viña3. 1Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Stem Cell Transplanttion and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Pathology, Stanford University School of Medicine, Palo Alto, CA, USA.

34-OR COMPLETE NUCLEOTIDE SEQUENCES FOR MORE THAN ONE HUNDRED KIR HAPLOTYPES. Paul J. Norman1, Steve Norberg2, Neda Nemat-Gorgani1, Melissa Won2, Arnav Moudgil1, Thomas Royce2, Lisbeth A. Guethlein1, Laurent Abi-Rached1, Kevin L. Gunderson2, Mostafa Ronaghi2, Peter Parham1. 1Department of Structural Biology, Stanford University School of Medicine, Stanford, USA; 2Advanced Research, Illumina Inc, San Diego, USA.

48 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts Tuesday, November 19, 2013 2:00 PM - 3:30 PM Abstract Session 4: Basic Science Transplantation 35-OR FACILITATING CELLS DERIVED FROM DECEASED DONOR BONE MARROW AND MOBILIZED PERIPHERAL BLOOD HAVE SIMILAR PHENOTYPIC AND FUNCTION PROPERTIES. Iwona M. Konieczna1, Jie He1, James M. Mathew1, William M. Miller2, Joseph R. Leventhal1. 1Comprehensive Transplant Center, Northwestern University, Chicago, IL, USA; 2Chemical and Biological Engineering Department, Northwestern University, Evanston, IL, USA.

36-OR ENDOTHELIAL CELL GENE EXPRESSION PROFILE IN RESPONSE TO EXPOSURE WITH ENDOTHELIAL CELL ANTIBODIES. Viktorija Makarovaite, Maribeth Flaws, Lindsay Murdoch, Maria Oppermann, Michele Prod, Sylvia Piggott, Ina Kurbegovic-Skaljic, Siva Kanangat. Pathology, Rush University Medical Center, Chicago, IL, USA.

37-OR FcgRIIa ALLELES INFLUENCE MONOCYTE RECRUITMENT BY HLA I ANTIBODY-ACTIVATED ENDOTHELIAL CELLS. Nicole M. Valenzuela1,2, Elaine F. Reed1,2. 1Pathology and Laboratory Medicine, UCLA, Los Angeles, CA, USA; 2UCLA Immunogenetics Center, UCLA, Los Angeles.

38-OR IDENTIFICATION OF URINARY microRNAs THAT ARE DISCRIMINATIVE OF ACUTE REJECTION IN KIDNEY TRANSPLANTATION. Michael Eikmans1, Jacqueline D.H. Anholts1, Sebastiaan Heidt1, Johan W. de Fijter2, Frans H.J. Claas1. 1Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands; 2Nephrology, Leiden University Medical Center, Leiden, Netherlands.

39-OR ALLOGENICITY OF HUMAN CARDIAC STEM/PROGENITOR CELLS. Laura Lauden1, Wahid Boukouaci1, Noémie Dam1, Ryad Tamouza1,2, Dominique Charron1,2, Reem Al-Daccak1,2. 1UMRS940 “Hematology, Immunology, and Therapeutic Targets” Hopital Saint Louis, INSERM, Paris, France; 2Laboratoire d’Immunologie et d’Histocompatibilité, Hôpital Saint Louis, AP-HP, Paris, France.

Final Program 49 Abstracts 40-OR RENAL ALLOGRAFT RECIPIENTS CARRYING HIGH INTERLEUKIN-10 PRODUCING GENOTYPES HAVE BETTER ALLOGRAFT SURVIVAL. Faisal M. Khan1,2,3, Gaurav Tripathi1, Abdulnaser Alabadi4, Pietro Ravani4, Serdar Yilmaz4, Noureddine Berka1,3. 1Pathology & Laboratory Medicine, University of Calgary, Calgary, Canada; 2Pediatrics, University of Calgary, Calgary, Canada; 3Tissue Typing Laboratory, Calgary Laboratory Services, Calgary, Canada; 4Medicine, University of Calgary, Calgary, Canada.

41-OR RELEVANCE OF PRO- AND ANTI-INFLAMMATORY CYTOKINE GENOTYPES ON THE DEVELOPMENT OF ACUTE REJECTION EPISODES AND CHRONIC ALLOGRAFT NEPHROPATHY FOLLOWING LIVE DONOR RENAL TRANSPLANTATION. Jamshaid A. Siddiqui1, Gurvinder Kaur1, Dipankar Bhowmik2, Narinder K. Mehra1. 1Transplant Immunology and Immunogentics, All India Institution of Medical Sciences, New Delhi, Delhi, India; 2Nephrology, All India Institute of Medical Sciences, New Delhi, Delhi, India. Tuesday, November 19, 2013 4:00 PM - 5:30 PM Abstract Session 5: HLA Typing/Anthropology/ Disease Association 42-OR DEVELOPMENT OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLD) AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IS INFLUENCED BY THE DONOR’S KILLER IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) - CENTROMERIC B/X LINKAGE GROUP. Rehan M. Faridi1, Taylor J. Kemp1, Poonam Dharmani-Khan1, Gaurav Tripathi1, Abdelhamid Liacini1, Victor Lewis2, Noureddine Berka1,4, Jan Storek3, Faisal M. Khan1,2,4. 1Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada; 2Pediatrics, University of Calgary, Calgary, Canada; 3Medicine, University of Calgary, Calgary, Canada; 4Tissue Typing Laboratory, Calgary Laboratory Services, Calgary, Canada.

43-OR DIFFERENTIAL BINDING OF CITRULLINATED VERSUS NATIVE VIMENTIN PEPTIDES TO HLA MOLECULES CONTAINING RESISTANT AND SUSCEPTIBLE RA EPITOPES. Kirsten M. Anderson1, Mary A. Portas2, Michael T. Aubrey2, Brian M. Freed2. 1Immunology, University of Colorado Graduate School, Aurora, CO, USA; 2ClinImmune Labs, University of Colorado School of Medicine, Aurora, CO, USA.

50 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 44-OR EVALUATION OF IMPACT OF UPDATES TO THE COMMON AND WELL DOCUMENTED ALLELE LIST (CWD2) ON HLA TYPING OF US POPULATIONS. Loren Gragert1, Martin Maiers1, Vicky Turner2, Michelle Setterholm6, Craig Malmberg6, Jane Kempenich6, David Senitzer3, Ketevan Gendzekhadze3, Neng Yu4, Marcelo Fernandez-Vina5. 1Bioinformatics Research, National Marrow Donor Program, Minneapolis, USA; 2HLA Laboratory, St Jude Children’s Hospital, Memphis, USA; 3Histocompatability Laboratory, City Of Hope, Los Angeles, USA; 4HLA Laboratory, American Red Cross, Dedham, USA; 5School Of Medicine, Stanford University, Palo Alto, USA; 6Scientific Services, National Marrow Donor Program, Minneapolis, USA.

45-OR ANALYSIS OF HLA REGION POLYMORPHISMS ASSOCIATED WITH CANCER. Amy E. Kennedy3, Sandeep K. Singh1, Karina Villalba2, M. Tevfik Dorak3. 1Environmental and Occupational Health, Robert Stempel College of Public Health and Social Work, Miami, FL, USA; 2Health Promotion and Disease Prevention, Robert Stempel College of Public Health and Social Work, Miami, FL, USA; 3Epidemiology, Robert Stempel College of Public Health and Social Work, Miami, FL, USA.

46-OR KIR AND HLA PLAY DISTINCT ROLES IN HIV INFECTION AND AIDS PROGRESSION. Elizabeth A. Trachtenberg1, Irina M. Berry2, Robert J. Nichols1, Koy Saeteurn1, Martha B. Ladner1, Henry A. Erlich1,3, Steven Wolinsky2. 1Center for Genetics, Children’s Hosptial Oakland Research Institute, Oakland, CA, USA; 2Division of Infectious Disease, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 3Dept Human Genetics, Roche Molecular Systems, Pleasanton, CA, USA.

47-OR IDENTIFICATION OF CLASS I AND CLASS II HLA EPITOPES IN TYPE 1 DIABETES. Christina L. Roark1, Kirsten M. Anderson2, Lucas J. Simon1, Ronald P. Schuyler3, Michael T. Aubrey1, Brian M. Freed1. 1ClinImmune Labs and Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA; 2Department of Immunology, University of Colorado School of Medicine, Aurora, CO, USA; 3Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA.

48-OR DERIVING HLA TYPING FROM WHOLE MHC NEXT-GENERATION SEQUENCING DATA. Jamie L. Duke1, Ariella Sasson2, Kate Mackiewicz1, Curt Lind1, Endre Major3, Tim Hague3, Attila Berces3, Dimitri Monos1,4. 1Department of Pathology and Laboratory Medicine, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA; 2Center for Biomedical Informatics, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA; 3Omixon, Inc., Budapest, Hungary; 4Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA. Major: Omixon, Inc.: Other: Contractor. Hague: Omixon, Inc.: Other: Contractor. Berces: Omixon, Inc.: Employee; Stockholder.

Final Program 51 Abstracts Tuesday, November 19, 2013 4:00 PM - 5:30 PM Abstract Session 6: Best of the Rest 49-OR ASSESSMENT OF MULTI-DONOR CHIMERISM (MDC) AFTER A SECOND ALLOGENEIC PROGENITOR CELL TRANSPLANT (HPCT) FROM A DIFFERENT DONOR USING qPCR IN A STEPWISE APPROACH IN PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA: POTENTIAL USE TO DETERMINE THE RISK OF RELAPSE. Morris Kletzel1,2, Sana Khan2, Marie Olszewski2. 1Pediatrics, Northwestern University Feinbery School of Medicine, Chicago, IL, USA; 2Hematology, Oncology, Transplant, Lurie Children’s Hospital of Chicago, Chicago, IL, USA.

50-OR PREDICTED INDIRECTLY RECOGNIZABLE HLA EPITOPES CORRELATE WITH CHRONIC GRAFT-VERSUS-HOST-DISEASE AND RELAPSE-RELATED MORTALITY IN PEDIATRIC PATIENTS AFTER CORD BLOOD TRANSPLANTATION. Kirsten A. Thus1, Can Kesmir2, Eric Borst1, Roel A. de Weger3, Jaap Jan Boelens4, Eric Spierings1. 1Immunology, University Medical Center Utrecht, Utrecht, Netherlands; 2Theoretical Biology, University Utrecht, Utrecht, Netherlands; 3Pathology, University Medical Center Utrecht, Utrecht, Netherlands; 4Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands.

51-OR INTERLEUKIN-10 LOW PRODUCING GENOTYPES CONFER STRONG RISK OF GRAFT VERSUS HOST DISEASE. Gaurav Tripathi1, Victor Lewis2, Jan Storek3, Noureddine Berka1,4, Faisal M. Khan1,2,4. 1Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada; 2Pediatrics, University of Calgary, Calgary, Canada; 3Medicine, University of Calgary, Calgary, Canada; 4Tissue Typing Laboratory, Calgary Laboratory Services, Calgary, Canada.

52-OR HLA EXPRESSION LEVELS AND EFFECT ON FLOW CROSSMATCH RESULTS. Danny Youngs, Karen Nelson, Paul Warner. Immunogenetics Laboratory, Puget Sound Blood Center, Seattle, WA, USA.

53-OR DONOR SPECIFIC ANTIBODY IS A PREDICTOR OF DE-NOVO AUTOIMMUNE HEPATITIS FOLLOWING PEDIATRIC LIVER TRANSPLANTATION. Michelle J. Hickey1, Laura J. Wozniak2, Tiffany Smith1, Gertrudes Aguas1, Giovanni Lopez1, Yael Korin1, Robert S. Venick2, Sue V. McDiarmid2, Elaine F. Reed1. 1Department of Pathology and Laboratory Medicine, Immunogenetics Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 2Pediatric Gastroenterology, Hepatology, and Nutrition, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

52 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 54-OR EVALUATION OF HLA ANTIBODIES IN DECEASED DONOR SIMULTANEOUS LIVER-KIDNEY TRANSPLANT RECIPIENTS. R. Carlin Walsh, Joshua Levitsky, Jennifer R. Zitzner, Anat R. Tambur. Comprehensive Transplant Center, Northwestern University, Chicago, IL, USA.

55-OR HLA IMMUNE RESPONSE MONITORING – SOLUBLE HLA IMMUNOGENICITY EVALUATION IN A MOUSE MODEL. Rico Buchli1, Shannon L. Caseltine2, Rebecca D. McAdams1, Rodney S. VanGundy1, Timea Wichner3, Aaron D. Rennels1, Jane C. Yaciuk5, Rene J. Duquesnoy4, Jon Weidanz3, William H. Hildebrand1,5. 1R&D, Pure Protein LLC, Oklahoma City, OK, USA; 2R&D, Abilene Laboratories, Abilene, TX, USA; 3Immunotherapeutics and Biotechnology, Texas Tech University HSC, School of Pharmacy, Abilene, TX, USA; 4Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 5Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Wednesday, November 20, 2013 2:00 PM - 3:30 PM Special Abstract Session: Scholar Awards 56-OR ACTIVATION AND CYTOSKELETAL REMODELING OF HUMAN ENDOTHELIAL CELLS BY HLA CLASS II ANTIBODIES. Fang Li, Sahar Salehi, Xiaohai Zhang, Elaine F. Reed. Immunogenetics Center, Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, USA.

57-OR VALIDATION OF A MULTIPLEX LUMINEX ASSAYS TO DETECT POTENTIAL BIOMARKERS ASSOCIATED WITH RENAL ALLOGRAFT REJECTION. Tenisha West, Cristina Fhied, Maribeth Flaws, Siva Kanangat, Jeffrey Borgia. Pathology, Biochemistry, Rush University Medical Center, Chicago, IL, USA.

58-OR SIGNALING NETWORKS REGULATING HLA CLASS II ANTIBODY-MEDIATED ACTIVATION AND MIGRATION OF ENDOTHELIAL CELLS. Yi-Ping Jin, Elaine F. Reed. Pathology and Laboratory Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA.

Final Program 53 Abstracts 59-OR EVIDENCE FOR A POSSIBLE ROLE OF MEMORY B CELLS IN ACUTE KIDNEY GRAFT REJECTION. Sebastiaan Heidt1, Manon Vergunst1, Jacqueline D.H. Anholts1, Michael Eikmans1, Hans W. de Fijter2, Frans H.J. Claas1. 1Dept. of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands; 2Dept. of Nephrology, Leiden University Medical Center, Leiden, Netherlands. Thursday, November 21, 2013 10:30 AM - 12:00 PM Special Abstract Session: The C1q Assay - Is It Ready for Prime Time? 60-OR THE ANTI-HUMAN GLOBULIN ENHANCED C1QSCREEN™ ASSAY IMPROVES THE DETECTION OF COMPLEMENT BINDING DONOR SPECIFIC HLA ANTIBODIES. Robert Liwski1, Sandra Lee1, Roxanne Sperry1, Peter Nickerson2, Robert Bray3, Howard Gebel3. 1Pathology, Dalhousie University, Halifax, NS, Canada; 2Medicine, University of Manitoba, Winnipeg, MB, Canada; 3Pathology, Emory University, Atlanta, GA, USA.

61-OR ANTI-HUMAN GLOBULIN ENHANCED C1qSCREENTM ASSAY POSITIVITY CORRELATES WITH THE CDC-AHG CROSSMATCH RESULTS. Robert Liwski1, Sandra Lee1, Roxanne Sperry1, Anne Halpin2, Luis Hidalgo2, Patricia Campbell3. 1Pathology, Dalhousie University, Halifax, NS, Canada; 2Lab Medicine and Pathology, University of Alberta Hospitals, Edmonton, AB, Canada; 3Medicine, University of Alberta, Edmonton, AB, Canada.

62-OR POSITIVITY IN THE C1q ASSAY DEPENDS ON THE HLA ANTIBODY STRENGTH. Xiaohai Zhang, Elaine F. Reed, Michael Cecka, Raja Rajalingam, Qiuheng Zhang. UCLA Immunogenetics Center, University of California, Los Angeles, CA, USA.

Poster Session 1-P TOWARD A SAUDI CALCULATED PRA: SIMILARITIES AND DIFFERENCES WITH UNOS CALCULATOR. Saber Al Zahrani1, Adel Shawhatti1, Abdelhamid Liacini1, Minal Borkar3, Gaurav Tripathi3, Mohammad I. Awaji1, Mohammed I. Al Saghier2, Abdulrahman Housawi2, Khaled Hamawi2, Rabab AlAttas2, Ahmed AlOtaibi1, Faisal M. Khan3,4,5, Noureddine Berka3,5. 1Histocompatibility and Immunogenetics Laboratory, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia; 2MOTC Program, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia; 3Pathology & Laboratory Medicine, University of Calgary, Calgary, Canada; 4Pediatrics, University of Calgary, Calgary, Canada; 5Tissue Typing Laboratory, Calgary Laboratory Services, Calgary, Canada.

54 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 2-P IMPACT OF LISTING UNACCEPTABLE ANTIGNES BASED ON C1q POSITIVE IN PAIRED KIDNEY EXCHANGE PROGRAM. Moheeb Al-Awwami1, Khalid Almeshari2, Hassan Aleid2, Pall Abeed2, Amal Algharably1, Fadi Alzayer1. 1Histocompatibility and Immunogenetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; 2Department of Kidney and Pancreas Transplantation, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

3-P COMPARISON OF LUMINEX SINGLE ANTIGEN MFI VERSUS FLOW CYTOMETRY MEDIAN CHANNEL SHIFT IN PREDICTION OF A POSITIVE T CELL CDC CROSSMATCH. Fadi S. AlZayer, Amal N. AlGharably, Maha A. AlHarbi, Sahar M. Sandooqah, Moheeb A. AlAwwami. Pathology & Laboratory Medicine, King Faisal Specialist Hospital & RC, Riyadh, Saudi Arabia.

4-P COMPLEMENT FIXING DONOR-SPECIFIC ANTIBODIES IDENTIFIED BY THE C1q ASSAY IN COMBINED LIVER-KIDNEY TRANSPLANTS WITH AMR. Medhat Askar2, Jane Kearns1, Valerie McCarro1, Shahper Khan2, Lynne Klingman2, Stuart Flechner4, John Fung3, Malek Kamoun1. 1Pathology and Laboratory Medicine, University of Penn., Philadelphia, PA, USA; 2Allogen Laboratories, Cleveland Clinic, Cleveland, OH, USA; 3Digestive Disease Institute, Cleveland Clinic, Cleveland, OH, USA; 4Surgery, Cleveland Clinic, Cleveland, OH, USA.

5-P LUMINEX SAB FAILS TO PREDICT FCXM AND CDC-XM RESULTS BY PRESENTING A DONOR SPECIFIC ANTIBODY WITH LOWER MFI. Mohammad I. Awaji1, Ricardo Lopez1, Dalal Abduladheem1, Rodney Scott1, Abdelhamid Liacini1, Rabab Alattas1, Faisal M. Khan2,3,4, Noureddine Berka2,4. 1Histocompatibility and Immunogenetics Laboratory, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia; 2Pathology & Laboratory Medicine, University of Calgary, Calgary, Canada; 3Pediatrics, University of Calgary, Calgary, Canada; 4Tissue Typing Laboratory, Calgary Laboratory Services, Calgary, Canada.

6-P FACTORS THAT AFFECT HLA EXPRESSION AND CROSSMATCH OUTCOME. Jessica L. Badders, Karl P. Schillinger, Andrea A. Zachary, Mary S. Leffell, Annette M. Jackson. Medicine, Johns Hopkins University, Baltimore, MD, USA.

7-P EVALUATION OF THE HUMORAL IMMUNE RESPONSE TO HUMAN LEUKOCYTE ANTIGENS (HLA) IN BRAZILIAN RENAL TRANSPLANT CANDIDATES. Patricia K. Saito1, Roger H. Yamakawa1, Erica A. Pereira2, Waldir V. da Silva Junior3, Sueli D. Borelli1. 1Department of Basic Science of Healthy, State University of Maringa, Maringa, Parana, Brazil; 2HLA Typing Laboratory, Histogene Histocompatibility and Genetic Laboratory, Maringa, Parana, Brazil; 3Department of Statistics, State University of Maringa, Maringa, Parana, Brazil.

Final Program 55 Abstracts 8-P PRETREATMENT OF PATIENT SERUM WITH FETAL BOVINE SERUM (FBS) REDUCES NON- SPECIFIC BACKGROUND AND ENHANCES HLA ANTIBODY DETECTION IN BEAD AND CELL BASED ASSAYS. Charlene Breitenbach1, Laesha Kaelin1, Pamela Chapman2, Howard M. Gebel2, Robert A. Bray2. 1Transplant Immunoloigy, Henrico Doctor;s Hospital, Richmond, VA, USA; 2Pathology, Emory University, Atlanta, GA, USA.

9-P OLERUP US & EU XM-ONE AND XM-ONE (3:1) PROFICIENCY TESTING (PT) PROGRAM UPDATE. Manuel R. Carreno1, Annette Jackson2, Bruno Vanherberghen3, Håkan Hall3. 1Professional Training & Coaching, Olerup, Inc, West Chester, PA, USA; 2Immunogenetics, Johns Hopkins University, Baltimore, MD, USA; 3Research & Development, AbSorber AB, Stockholm, Sweden. Carreno: OLERUP, Inc: Consultant. Vanherberghen: AbSorber AB: Employee. Hall: AbSorber AB: Employee. 10-P SELECTION OF APPROPRIATE HUMAN SERA FOR NEGATIVE CONTROLS IN FLOW CROSSMATCHING TO DETERMINE RENAL TRANSPLANTATION COMPATIBILITY. Robert Cirocco, Jennifer Mendiolina, Lindsey Biondi, Michael Moritz. HLA Laboratory, Lehigh Valley Health Network, allentown, PA, USA.

11-P BUILDING A BETTER ALLO- HLA ANTIBODY POSITIVE CONTROL. Don M. Constantino, Kari M. Roberts, Peter T. Jindra, Amy B. Hahn. Transplantation Immunology Laboratoy, Albany Medical College, Albany, NY, USA.

12-P VERIFICATION HLA TYPING: ARE YOU SURE YOU USED THE RIGHT CELLS IN THAT FLOW CROSSMATCH? Maurine L. Davidson, Mary B. Stewart, Toni J. Lyrenmann, Carolynn Scalf, David H. Maurer. HLA/ Immunology Laboratory, University of Minnesota Medical Center, Fairview, Minneapolis, MN, USA.

13-P EpHLA-CONVERTER: A TOOL FOR AUTOMATIC INFERENCE OF HIGH-RESOLUTION HLA FOR SOLID ORGAN TRANSPLANTATION. José Renato Barroso1, Semiramis do Monte2, Adalberto da Silva3, Herton Sales Filho2, Anaregina Araújo2, Antonio Vanildo Lima2, Deylane Oliveira3, Rubens Santana2, Marayza Carvalho2, Luiz Claudio Sousa1. 1Departamento de Computação, Universidade Federal do Piauí, Teresina, Brazil; 2Departamento de Clínica Médica, Universidade Federal do Piauí, Teresina, Brazil; 3Departamento de Biologia, Universidade Federal do Piauií, Teresina, Brazil.

56 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 14-P IS THERE A ROLE FOR THE ELISA TEST IN HLA ANTIBODY SCREENING? Marilyn P. Downs, Jerry L. Morrisey, Sandra L. Smith. HLA Lab/Pathology, Scott & White Healthcare, Temple, TX, USA.

15-P THE CONUNDRUM OF SOLID PHASE SINGLE ANTIGEN IMMUNO ASSAYS (SPI-SA): RESULTS OF A COMPARATIVE ANALYSIS WITH TWO PROVIDERS. Yvonne M. Zoet1, Marry E.I. Franke2, Marian D. Witvliet1, Geert W. Haasnoot1, Arend Mulder2, Frans H.J. Claas1, Ilias I.N. Doxiadis1. 1Eurotransplant Reference Laboratory, Leiden University Medical Center, Leiden, Netherlands; 2Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands.

16-P THE NONSENSE OF REFRAINING HLA MATCHING IN POST MORTAL KIDNEY TRANSPLANTATION RESULTS IN INCREASE SENSITIZATION. Ilias I.N. Doxiadis, Frans H.J. Claas. Eurotransplant Reference Laboratory, Leiden University Medical Center, Leiden, Netherlands.

17-P EDTA-TREATMENT TO REMOVE INHIBITORY EFFECT OF SERUM SUBSTANCES WITHOUT INCREASING NEGATIVE CONTROL BEAD MFI IN MICRO-BEAD ASSAYS. Justine Gaspari, Jean Hess, Lorie Kumer, Lori Malec, Dennis Habig, Carolyn Fisher, Heather Casey, Kimberly Goss, Scott Frenchek, Ronald E. Domen, Hiroko Shike. Histocompatibility Laboratory, Penn State Hershey Medical Center, Hershey, PA, USA.

18-P CHARACTERIZATION OF A NON-EXPRESSED HLA B62 VARIANT AND ITS IMPACT IN RENAL TRANSPLANT. Jessica Gatulis1, Neng Yu1, Jennifer Brissette1, Maria Stavropoulos2. 1Histocompatibility, UMASS Memorial Health Care, Worcester, MA, USA; 2Histocompatiblity, Yale University School of Medicine, New Haven, CT, USA.

19-P A SAFE AND EFFECTIVE WAY TO PERFORM WASH STEPS IN THE TRAY BASED FCXM ASSAY. Anne Halpin1, Danny Chau1, Deanna Manna1, Luis Hidalgo1, Robert Liwski2, Patricia Campbell1. 1Histocompatibility Laboratory, University of Alberta Hospital, Edmonton, AB, Canada; 2Pathology, Dalhousie University, Halifax, NS, Canada.

20-P THE AMOUNT OF ANTIBODY DETECTED IN Bw4 REACTIVE SERA MAY BE UNDERESTIMATED USING SINGLE ANTIGEN BEADS PANELS. Jill Kolkman, Anne Halpin, Patricia Campbell, Luis Hidalgo. Histocompatibility Laboratory, University of Alberta Hospital, Edmonton, AB, Canada.

Final Program 57 Abstracts 21-P DETECTION OF DSA BY SPA AND ITS RELEVANCE TO CDC CROSS-MATCHING. Eric K. Ho1, Rodica Vasilescu1, Lloyd E. Ratner2, Nicole Suciu-Foca1, Raphael A. Clynes1. 1Pathology and Cell Biology, Columbia University, New York, NY, USA; 2Surgery, Columbia University, New York, NY, USA.

22-P DO ANTIBODIES AGAINST DENATURED ANTIGENS STILL EXIST WITH THE iBeads ASSAY? Mary Jackowski, Padma Kuchipudi, Dorothy Levis, Sam Ho. Histocompatibility Laboratory, Gift of Life Michigan, Ann Arbor, MI, USA.

23-P CASE STUDY: IgG ANTIBODY TO A SELF HLA ANTIGEN- REAL OR NOT? Jessica L. Jackstadt1, Donald M. Constantino1, Maryanne Mackey1, Laurel Gokee1, Jennifer Nielsen1, Kari Roberts1, Robert Jordan1, Peter Jindra1, David J. Conti2, Amy B. Hahn1. 1Transplantation Immunology Laboratory, Albany Medical College, Albany, NY, USA; 2Section of Transplantation, Division of General Surgery, Department of Surgery, Albany Medical College, Albany, NY, USA.

24-P ANALYSIS OF HLA CLASS I & II IgG SUBTYPES IN TRANSPLANT PATIENTS AND TRANSPLANT CANDIDATES USING THE SINGLE ANTIGEN BEAD-BASED LUMINEX METHOD. Sarah Mandley, Maria Oppermann, Maribeth Flaws, Michele Prod, Siva Kanangat. Pathology, Rush University Medical Center, Chicago, IL, USA.

25-P HLA ALLELE-SPECIFIC ANTIBODIES AND THEIR POTENTIAL SIGNIFICANCE IN TRANSPLANTATION. Priya Bhatia, Maria Oppermann, Ina Kurbegovic-Skaljic, Michele Prod, Sylvia Piggott, Siva Kanangat. Pathology, Rush University Medical Center, Chicago, IL, USA.

26-P PERSISTENT C1q BINDING DSA PATTERNS ASSOCIATED WITH INCREASED LONG-TERM POSTTRANSPLANT AMR, CMR, AND CAV IN HEART TRANSPLANT RECIPIENTS. Chih-Hung Lai1, Geraldine Ong1, Mehrnoush Naim1, Qi Wang1, Jignesh Patel2, Jon Kobashigawa2, Nancy L. Reinsmoen1. 1HLA Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA; 2Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

58 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 27-P IMPACT OF VARYING MFI THRESHOLDS ON CPRA VALUES AND ACCESS TO DECEASED DONOR ORGANS. Jennifer Lai1, Eddie Mui1, David Eckels3, Howard Gebel2, William Bry1, Steven Katznelson1, Parul Patel1, Robert Bray2. 1Barry S. Levin Department of Transplantation, California Pacific Medical Center, San Francisco, CA, USA; 2Pathology, Emory University, Altanta, GA, USA; 3Pathology, University of Utah, Salt Lake City, UT, USA.

28-P C1q ASSAY: MAKING SENSE OF SENSITIVITY. Mayra Lopez-Cepero1, Mark Weston2, John P. Leone2, Lori Wright1, Sandra Resto-Ruiz1. 1Transplant Inmmunology Lab, LifeLink Foundation, Tampa, FL, USA; 2TGMG, Tampa General Hospital, Tampa, FL, USA.

29-P IN VITRO INHIBITION OF COMPLEMENT ACTIVATING HLA ANTIBODY BY C1 ESTERASE INHIBITOR (Berinert®). John Lunz1, Guilherme Costa2, Jeffrey Teuteberg2, Brian Feingold5, George Mazariegos3, Jon Lomago1, Larry Jelinek1, Diane Ritter1, Judith Vensak4, Mel Berger4, Adriana Zeevi1. 1Pathology, University of Pittsburgh, Pittsburgh, PA, USA; 2Surgery, University of Pittsburgh, Pittsburgh, PA, USA; 3Surgery, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA; 4CSL Behring, Cleveland, OH, USA; 5Cardiology, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA. Lunz: CSL Behring: Grant Research. Vensak: CSL Behring: Employee. Berger: CSL Behring: Employee. Zeevi: CSL Behring: Grant Research. 30-P IMPACT OF COLD/WARM ISCHEMIA REPERFUSION TIME ON DELAYED GRAFT FUNCTION AND EXPRESSION OF ALLOGRAFT INFLAMMATORY FACTOR-1 IN KIDNEY TRANSPLANTATION. D. Olga McDaniel, Andrea Barker, Hurtis R. Tullos, Fauzia Butt. Surgery, University of Mississippi Medical Center, Jackson, MS, USA.

31-P IMPLEMENTING IN-HOUSE INFECTIOUS DISEASE TESTING TO OPTIMIZE ORGAN ALLOCATION. Scott McDonald, Kristy Crissler, Kristen Coulter. Laboratory Services, Midwest Transplant Network, Westwood, KS, USA.

32-P INTERFERING FACTORS INTERFERE WITH VIRTUAL CROSSMATCH (vXM) INTERPRETATION. Tracy T. McRacken1, Katherine Keatley1, Monica Stephens1, Kevin Hogan1, Cynthia Spraggins1, Alyssa Zannini1, Weenafreda Fortes1, Elaine Phelps1, Robert A. Bray2, Howard M. Gebel2. 1Transplantation, Sentara Norfolk General Hospital, Norfolk, VA, USA; 2Pathology, Emory University Hospital, Atlanta, GA, USA.

Final Program 59 Abstracts 33-P A NEW WAY TO QC DTT. Jennifer Mendiolina, Angela Kessler, Robert Cirocco. HLA Lab, Lehigh Valley Health Network, Allentown, PA, USA.

34-P DONOR SPECIFIC ANTIBODIES AND PANEL REACTIVE ANTIBODY SCREEN VALIDATION & TESTING: - OUR EXPERIENCE FROM A STANDALONE LABORATORY IN INDIA. Mahendra N. Mishra, Vandana Lal. Transplant Immunology, Dr Lal Path Labs Pvt. Ltd. National Reference Laboratory, New Delhi, India.

35-P POSTIVE FLOW CYTOMETRY CROSMMATCH DUE TO LOW LEVELS OF NON-SELF PAN A LOCUS ANTIBODY: CHARACTERIZED BY BIOLOGICAL AND BIOINFORMATICAL APPROACHES. Sheree H. Waslaske, Cherryl Nasse, Thomas Thompson, Cindi G. Marchman, Elise M. McPherson, Omar Moussa. Pathology & Lab Medicine, Medical University of South Carolina, Charleston, SC, USA.

36-P LUMINEX SINGLE ANTIGEN C1Q NEGATIVE,CDC POSITIVE HLA SPECIFIC ANTIBODIES. Mehrnoush R. Naim, Chih-Hung Lai, Geraldine Ong, Qi Wang, Masukawa Robin, Maria R. Manalo, Alfredo Santiago, Dianne Paredes, Nancy L. Reinsmoen. Comprehensive Transplant-HLA Laboratory, Cedars Sinai Medical Center, Los Angeles, CA, USA.

37-P HLA ANTIBODY TESTING BY CLASSICAL AND MODIFIED LUMINEX-SINGLE ANTIGEN BEADS ASSAYS. Antonina Piazza1,2, Elvira Poggi1,2, Giuseppina Ozzella1,2, Domenico Adorno2. 1National Council of Researches, IFT, UOS di Roma S. Camillo, Rome, Italy; 2Tor Vergata University of Rome, Regional Transplant Center - Lazio, Rome, Italy.

38-P INCIDENCE OF A NOVEL INFECTIOUS AGENT IN PATIENTS WITH ADVANCED CARDIOVASCULAR DISEASE IN AWAITING HEART TRANSPLANTATION. Antonietta Picascia1, Linda Sommese1, Chiara Pagliuca2, Vincenza Grisolia3, Amelia Casamassimi4, Roberta Colicchio2, Maria Rosaria Catania3, Ernesto Mezza4, Francesco Paolo D’Armiento4, Paola Salvatore2, Claudio Napoli1,3. 1U.O.C. Division of Immunohematology, Transfusion Medicine and Transplant Immunology, Regional Reference Laboratory of Transplant Immunology, Second University of Naples, Naples, Italy; 2Department of Molecular Medicine and Medical Biotechnology, “Federico II” University of Naples, Naples, Italy; 3Functional Area of Microbiology, “Federico II” University of Naples, Naples; 4Department of General Pathology, Chair of Clinical Pathology, and Excellence Research Centre on Cardiovascular Diseases, Second University of Naples, Naples; 5Department of Pathology and Cytopathology, “Federico II” University of Naples, Naples, Italy.

60 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 39-P ANTI-B*44:02 DETECTED ON SINGLE-ANTIGEN (SA) BEADS SHOULD BE CONFIRMED THROUGH THE USE OF ADDITIONAL DETECTION TECHNIQUES. Bobbie Rhodes-Clark, Soumya Pandey, Marsha L. Rood, Catherine M. Lee, Dawnelle C. Crowley, Terry O. Harville. Pathology and Laboratory Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

40-P OPTIMIZATION OF LIVING DONATION IN ANTI-HLA ANTIBODY SENSITIZED PATIENTS UTILIZING KIDNEY PAIRED DONATION AND HLAMATCHMAKER. Bobbie Rhodes-Clark, Soumya Pandey, Marsha L. Rood, Dawnelle C. Crowley, Catherine M. Lee, Terry O. Harville. Pathology and Laboratory Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

41-P SINGLE CENTER EXPERIENCE WITH COMBINED ROUTINE AND FOR-CAUSE PANEL REACTIVE ANTIBODIES AND DONOR SPECIFIC ANTIBODIES SCREENING STRATEGY. Chee Loong Saw1, Dana Baran2, Istvan Mucsi2, Jean Tchervenkov3, Steven Paraskevas3, Cathy McIntyre1, Marcelo Cantarovich2. 1HLA Laboratory, Division of Hematology, McGill University Health Centre, Montreal, QC, Canada; 2Division of Nephrology and Multi-Organ Transplant Program, McGill University Health Centre, Montreal, QC, Canada; 3Department of Surgery and Multi-Organ Transplant Program, McGill University Health Centre, Montreal, QC, Canada.

42-P IMMUNE-RELATED PATTERN IN PEDIATRIC RENAL (PR) PATIENTS IS ASSOCIATED WITH FALSE POSITIVES (FP) IN SOLID PHASE FLOW PANEL REACTIVE ANTIBODY ASSAY (SPA). Chee Loong Saw1, David Blank2, Rose Djiana2, Allan Tulli2, Cathy McIntyre1, Barbara Iozzo3, Lorraine Bell3. 1HLA Lab Division of Hematology, McGill University Health Centre, Montreal, QC, Canada; 2Division of Biochemistry, McGill University Health Centre, Montreal, QC, Canada; 3Division of Nephrology, Montreal Children Hospital, Montreal, QC, Canada.

43-P OUTCOME OF KIDNEY TRANSPLANTATIONS PERFORMED WITH PREFORMED “NATURAL” DONOR SPECIFIC ANTIBODIES. Caroline Suberbielle1, Antoine Sicard2, Lucile Amrouche2, Maryvonnick Carmagnat1, Eric Thervet3, Michel Delahousse4, Christophe Legendre2, Dominique Charron1, Renaud Snanoudj2. 1Laboratoire Regional d’Histocompatibilite “Jean Dausset”, Hopital Saint Louis, Paris, France; 2Service de Nephrologie, Hopital Necker, Paris, France; 3Service de Nephrologie, Hopital Georges Pompidou, Paris, France; 4Service de Nephrologie, Hopital Foch, Suresnes, France.

44-P ANTIBODIES AGAINST DENATURED C-LOCUS ANTIGENS IN TWO PATIENTS WITH VENTRICULAR ASSIST DEVICES (VAD). Gizem Tumer, Tiffany K. Roberts-Wilson, Robert A. Bray, Howard M. Gebel. Pathology, Emory University School of Medicine, Atlanta, GA, USA.

Final Program 61 Abstracts 45-P DETECTION OF MICA ANTIBODIES - IN HLA ALLOSENSITIZED KIDNEY TRANSPLANT CANDIDATES ON THE DECEASED DONOR WAITING LIST IN PANAMA. Alejandro A. Vernaza1, Yina Gutierrez1, Carlos Viggiano2, Jose Manzanares2, Cesar Cuero3. 1Transplant Laboratory, Social Security Hospital, Panama; 2Nephrology Service, Social Security Hospital, Panama; 3Panamanian Transplant Organization, M.I.N.S.A., Panama.

46-P CLEARING THE FOG: A PROACTIVE APPROACH TO SAVE $$. Laurie L. Voit, Lisa M. Hallaway, Manish J. Gandhi. Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN, USA.

47-P HEART RECIPIENT PRA PRE VERSUS POST MECHANICAL DEVICE IMPLANTATION. Laurie L. Voit, Hope Stortz, Manish J. Gandhi. Division of Transfusion Medicine, Mayo Clinic, Rochester, MN, USA.

48-P VALIDATION OF VIRTUAL CROSSMATCH USING DONOR SPECIFIC ANTIBODY. Gina Wedermyer, Christina Roark, Brian Freed. ClinImmune Labs, University of Colorado, Aurora, CO, USA.

49-P MULTI-SUBSET DONOR LYMPHOID CHIMERISM PATTERNS DURING ACUTE GRAFT VERSUS HOST DISEASE AFTER LIVER TRANSPLANT. Aiwen Zhang1, Bijan Eghtesad2, Charles Miller2, Jeffrey Allen1, Raymond Jurcago1, Heather Eilrich1, Nizar Zein3, Andreas Tzakis4, Kareem Abu-Elmagd2, John Fung2, Medhat Askar1. 1Allogen Laboratories, Cleveland Clinic, Cleveland, OH, USA; 2Liver Transplant & Hepatobiliary Surgery, Cleveland Clinic, Cleveland, OH, USA; 3Gastroentrology and Hepatology, Cleveland Clinic, Cleveland, OH, USA; 4Transplant Center, Cleveland Clinic Florida, Weston, FL, USA.

50-P THE FREQUENCY OF DE NOVO DONOR HLA SPECIFIC ANTIBODIES (DSA) AND THEIR ASSOCIATION WITH HISTOLOGICAL FINDINGS AND C4d IMMUNOREACTIVITY IN TRANSPLANT LIVER BIOPSIES. Medhat Askar1, Lisa Yerian2, Lynne Klingman1, Aiwen Zhang1, Xiuli Liu2. 1Allogen Laboratories, Cleveland Clinic, Cleveland, OH, USA; 2Anatomic Pathology, Cleveland Clinic, Cleveland, OH, USA.

51-P C4d STAINING AND HISTOLOGICAL FEATURES OF PROTOCOL LUNG BIOPSIES IN PATIENTS WHO DEVELOP DE NOVO DONOR HLA SPECIFIC ANTIBODIES. Medhat Askar1, Marie Budev2, Lynne Klingman1, Aiwen Zhang1, Kenneth McCurry3, Carol Farver4. 1Allogen Laboratories, Cleveland Clinic, Cleveland, OH, USA; 2Allergy and Critical Care Medicine, Cleveland Clinic, Cleveland, OH, USA; 3Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, USA; 4Anatomic Pathology, Cleveland Clinic, Cleveland, OH, USA.

62 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 52-P DE NOVO DEVELOPMENT OF DONOR SPECIFIC HLA ANTIBODIES IS STRONGLY ASSOCIATED WITH ANTIBODY MEDIATED REJECTION FOLLOWING LIVE DONOR RENAL TRANSPLANTATION. Ajay K. Baranwal, Jamshaid A. Siddiqui, Sanjeev Goswami, Deepali K. Bhat, Narinder K. Mehra. Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi, Delhi, India.

53-P REAL TIME PCR DONOR HLA TYPING VIA RENAL ALLOGRAFT BIOPSY. Paul A. Brailey1, Jennifer Wendel1, Brittany Johnson1, Michael Cardi2, Steve Woodle3, Alin Girnita1. 1Hoxworth/Transplantation Immunology, University of Cincinnati Academic Health Center, Cincinnati, OH, USA; 2Renal Transplant, The Christ Hospital, Cincinnati, OH, USA; 3Department of Surgery, University of Cincinnati Academic Health Center, Cincinnati, OH, USA.

54-P NO ASSOCIATION BETWEEN THE NUMBER OF ACTIVATING KIR GENES AND THE INCIDENCE OF CMV DISEASE IN LIVER TRANSPLANT RECIPIENTS. Mohamed Elrefaei1, Paul Warner1, Rhonda Loken1, Karen Nelson1, Ajit Limaye2. 1Immunogenetics/HLA, Puget Sound Blood Center, Seattle, WA, USA; 2Medicine, University of Washington, Seattle, WA, USA.

55-P INCREASED SOLUBLE CD30 SERUM LEVELS ARE ASSOCIATED WITH FIBROSIS AND INFLAMMATORY INFILTRATE IN TWO-YEAR POST-TRANSPLANT PROTOCOL GRAFT BIOPSIES IN SIROLIMUS-TREATED KIDNEY RECIPIENTS. Patricia C. Grenzi1,2, Érika F. Campos1,2, Hélio Tedesco-Silva3, Claudia R. Felipe3, Marcello Franco2, Maria F. Soares4, José O. Medina-Pestana2,3, Maria Gerbase-DeLima1,2. 1Immunogenetics, Associação Fundo de Incentivo à Pesquisa-AFIP, São Paulo, SP, Brazil; 2Universidade Federal de São Paulo, São Paulo, SP, Brazil; 3Hospital do Rim e Hipertensão, São Paulo, SP, Brazil; 4Universidade Federal do Paraná, Curitiba, PR, Brazil.

56-P HUMORAL REJECTION AFTER SECOND LIVER TRANSPLANT. Idoia Gimferrer1, Sanam Husain2, Jeffrey McCormack2. 1HLA Laboratory, OUMS, Oklahoma City, OK, USA; 2Pathology Department, OUHSC, Oklahoma City, OK, USA.

57-P HYPERTENSION AND HLA-A MISMATCHING ARE ASSOCIATED WITH RESTARTING DIALYSIS IN KIDNEY TRANSPLANTATION. Vincenzo Grimaldi1, Stefano Federico2, Antonietta Picascia1, Francesco Cacciatore3, Francesco Cavalca1, Paolo Giannattasio1, Andrea Renda4, Claudio Napoli1. 1U.O.C. Immunohematology, Transfusion Medicine and Transplant Immunology (SIMT), Regional Reference Laboratory of Transplant Immunology (LIT), Azienda Universitaria Policlinico (AOU), 1st School of Medicine, Second University of Naples, Naples,; 2Department of Public Health, “Federico II” University of Naples, Naples, Italy; 3Cardiovascular Rehabilitation, Salvatore Maugeri Foundation, IRCCS, Telese Terme (BN), Italy; 4General, Thoracic and Vascular Surgery Department, General Surgery and Organ Transplantation, “Federico II” University of Naples, Naples, Italy.

Final Program 63 Abstracts 58-P CORRELATION OF CIRCULATING COMPLEMENT-FIXING DONOR SPECIFIC ANTIBODIES IDENTIFIED BT THE C1q ASSAY AND PRESENCE OF C4d in ENDOMYOCARDIAL BIOPSY: A SINGLE-CENTER RETROSPECTIVE STUDY. Malek Kamoun1, Jane Kearns1, Renee Frank1, Valerie R. McCarro1, Maria R. Molina3, Joyce W. Wald2, Lee R. Goldberg2, Priti Lal1. 1Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA; 2Medicine, University of Pennsylvania, Philadelphia, PA, USA; 3Heart Failure/ Transplant, Penn Transplant Center, Philadelphia, PA, USA.

59-P RELEASE OF DONOR SPECIFIC SOLUBLE HLA FOLLOWING KIDNEY TRANSPLANTATION. Sunil Daga1, Curtis McMurtrey2, David Lowe1, Daniel Mitchell1, David Briggs3, William Hildebrand2, Robert Higgins4, Daniel Zehnder1. 1Warwick Medical School, University of Warwick, Coventry, United Kingdom; 2Microbiology and Immunology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; 3Histocomaptibility & Immunogenetics, NHSBT, Birmingham, United Kingdom; 4Nephrology & Transplantation, Hospitals of Coventry & Warwickshire NHS Trust, Coventry, United Kingdom.

60-P RESULTS OF PROTOCOLIZED POST-TRANSPLANT DONOR SPECIFIC ANTIBODY (DSA) MONITORING IN KIDNEY TRANSPLANT RECIPIENTS: THE EXPERIENCE AT THE MAYO CLINIC IN ARIZONA. Marcelo Pando Rigal1, Yvonne Desmarteau1, Ala Nijim2, Kunam Reddy3, Raymond Heilman2, Riccardo Valdez1. 1Laboratory Medicine and Pathology, Mayo Clinic in Arizona, Phoenix, USA; 2Internal Medicine, Mayo Clinic in Arizona, USA; 3Surgery, Mayo Clinic in Arizona, Phoenix, USA.

61-P CLINICAL FLOW CYTOMETRY CROSSMATCH: DETECTION OF DONOR-T CELL, -B CELL, AND -ENDOTHELIAL PROGENITOR CELL SPECIFIC (EPC) IgG AND IgM ANTIBODIES IN TRANSPLANT RECIPIENT SERUM. Prabhakar Putheti1,2, Jeannette Knight1, Chaquetta Grace1, Arvind Menon1, Rex Friedlander1, Darshana Dadhania1,2, Vijay Sharma1,2. 1Immunogenetics and Transplantation Center, The Rogosin Institute, New York, NY, USA; 2Department of Medicine, Weill Cornell Medical Center, New York, NY, USA.

62-P C1Q BINDING ASSAY CAN PREDICT OUTCOMES IN AMR. Daniel S. Ramon1, TrisAnn Rendulic2, Jeong Park2, Kamal Abuarquob1, Yihung Huang3, Milagros Samaniego3. 1Histocompatibility Laboratory. Pathology, University of Michigan Health System, Ann Arbor, MI, USA; 2Pharmacy, UMHS, Ann Arbor, USA; 3Internal Medicine, UMHS, Ann Arbor, USA.

63-P QUALITY CONTROL IN THE HLA LABORATORY: THE EFFECT OF INTER-ASSAY VARIABILITY ON SINGLE ANTIGEN BEAD ASSAYS (SABs). Tiffany K. Roberts-Wilson, Gizem Tumer, Robert A. Bray, Howard M. Gebel. Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.

64 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 64-P HEPATITIS B VACCINATION MAY CAUSE HLA SENSITIZATION. Chee Loong Saw1, Valerie Ross2, Andrey Cybulsky3, Marie Mouchbahani3, Paul Barre3, Dana Baran4. 1HLA Lab Division of Hematology, McGill University Health Centre, Montreal, QC, Canada; 2Renal Transplant Clinic, Centre Hopitalier Universitaire Sherbrooke, Sherbrooke, QC, Canada; 3Division of Nephrology, McGill University Health Centre, Montreal, QC, Canada; 4Division of Nephrology and Multi-Organ Transplant Program, McGill University Health Centre, Montreal, QC, Canada.

65-P MODIFIED C1Q ASSAY DETECTS C1Q-BINDING ANTIBODY WITH HIGHER SENSITIVITY. Olga A. Timofeeva, Dong Li, Vinna P. San Juan, An T. Thai, Richard R. Sochacki, Jing Guan, Mariam K. Awwad, Sandra Rosen-Bronson. Clinical Laboratory, Histocompatibility, Georgetown University Hospital, Washington, DC, USA.

66-P NO DIRECT CORRELATION BETWEEN DONOR SPECIFIC ANTIBODY (DSA) MEAN FLUORESCENCE INTENSITY (MFI) AND C4d POSITIVITY IN ANTIBODY MEDIATED REJECTION (AMR). Gizem Tumer, Tiffany K. Roberts-Wilson, Farris B. Alton, Stuart N. Lauren, Howard M. Gebel, Robert A. Bray. Pathology, Emory University Hospital, Atlanta, GA, USA.

67-P ROUTINE HLA ANTIBODY MONITORING OF RENAL ALLOGRAFT RECIPIENTS FOR DEVELOPMENT OF DONOR SPECIFIC ANTIBODIES. Eric T. Weimer1, Randal Detwiler2, Tomasz Kozlowski3, John L. Schmitz1. 1Pathology & Laboratory Medicine, UNC-Chapel Hill, Chapel Hill, NC, USA; 2Nephrology, UNC-Chapel Hill, Chapel Hill, NC, USA; 3Surgery, UNC-Chapel Hill, Chapel Hill, NC, USA.

68-P DONOR-SPECIFIC CLASS II HLA-DQ COMPLEMENT BINDING ANTIBODY IS ASSOCIATED WITH SEVERE REJECTION IN LUNG TRANSPLANTATION. Adriana Zeevi, Marilyn Marrari, John Lunz, Matthew Morrell, Cynthia Gries, John McDyer, Joseph Pilewski, Christopher Ensor, Rene Duquesnoy, Christian Bermudez. Medical School, University of Pittsburgh, Pittsburgh, PA, USA.

69-P IMMUNE FUNCTION ASSAY (IMMUKNOW) AS A PREDICTOR OF ALLOGRAFT REJECTION AND INFECTION IN KIDNEY TRANSPLANTATION. Jun He1, Yang Li1, Xudong Wei2, Chao Xu1, Xiaojing Bao1, Xiaoni Yuan1, Jianquan Hou2. 1Department of HLA Laboratory, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China; 2Department of Urinary Surgery, First Affiliated Hospital of Soochow University, Suzhou, China.

Final Program 65 Abstracts 71-P IMPACT OF T-CELL DEPLETING STRATEGIES ON THE DEVELOPMENT OF DONOR SPECIFIC ANTIBODIES. Chee Loong Saw1, Dana Baran2, Istvan Mucsi2, Jean Tchervenkov3, Steven Paraskevas3, Marcelo Cantarovich2. 1HLA Lab Division of Hematology, McGill University Health Centre, Montreal, QC, Canada; 2Division of Nephrology and Multi-Organ Transplant Program, McGill University Health Centre, Montreal, QC, Canada; 3Department of Surgery and Multi-Organ Transplant Program, McGill University Health Centre, Montreal, QC, Canada.

72-P IFNG+874 AA GENOTYPE IS AN IMPORTANT RISK FACTOR FOR THE DEVELOPMENT OF INVASIVE CERVICAL CANCER (CC) IN MEXICAN WOMEN. Carmen Alaez1, David Garcia1, Hilario Florea-A1, Andrea Munguia1, Jaime Berumen2, Clara Gorodezky1. 1Dept. of Immunology and Immunogenetics, InDRE, Secretary of Health. & Fundación Comparte Vida, A.C., Mexico City, DF, Mexico; 2Unit of Genomic Medicine, Hospital General de México, Secretary of Health and Faculty of Medicine, Universidad Nacional Autónoma de México, México City, DF, Mexico.

73-P STRONG ASSOCIATION BETWEEN THE IL2(-330G/T) GENOTYPE AND CLASSIC PARS PLANITIS (CPP) IN MEXICANS. Carmen Alaez1, Hilario Flores-A1, David Garcia1, Lourdes Arellanes2, Luz Elena Concha2, Clara Gorodezky1. 1Dept. of Immunology and Immunogenetics, Instituto de Diagnóstico y Referencia Epidemiológicas. Secretary of Health. & Fundación Comparte Vida, A.C., Mexico City, DF, Mexico; 2Inflammatory Eye Disease Clinic, Hospital Dr. Luis Sanchez Bulmes Asociacion Para Evitar la Ceguera en Mexico, Mexico City, DF, Mexico.

74-P RACIAL DIVERSITY IN MICA129 GENOTYPES AND LINKAGE DISEQUILIBRIUM WITH HLA-B. Aiwen Zhang1, Patrick Reville1, Amy Nowacki2, Dawn Thomas1, Paul Kawczak1, John McMichael1, Ronald Sobecks3, Medhat Askar1. 1Allogen Laboratories, Cleveland Clinic, Cleveland, OH, USA; 2Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA; 3Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

75-P CHARACTERIZATION OF KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) GENOTYPES AND GROUP B HAPLOTYPES IN SOUTHERN CHINESE HAN POPULATION. Xiaojing Bao1, Miao Wang2, Huifen Zhou2, Xiaojin Wu2, Li Yang1, Chao Xu1, Xiaoni Yuan1, Jing Zhang2, Lingjie Li1, Depei Wu2, Jun He1. 1Department of HLA Laboratory, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China; 2Department of Hematology, Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China.

66 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 76-P ASSIGNING KIR TYPES FROM NGS SHORT READ DATA. Endre Major, Krisztina Rigo, Attila Berces, Tim Hague, Szilveszter Juhos. Omixon, Omixon Biocomputing, Budapest, Hungary.

77-P THE POLYMORPHISM OF LEUKOCYTE AND ERYTHROCYTE ANTIGENS IN NEPHROPATHIC PATIENTS FROM SOUTHERN BRAZIL. Roger H. Yamakawa1, Patricia K. Saito1, Waldir V. da Silva Junior2, Cesar A. Serra5, Arlete J. Marquezone4, José M.V. Obregon5, Adaelson A. da Silva3, Sergio S. Yamada6, Luiz C. de Mattos7, Sueli D. Borelli1. 1Department of Basic Science of Healthy, State University of Maringa, Maringa, Parana, Brazil; 2Department of Statistics, State University of Maringa, Maringa, Parana, Brazil; 3Nephrology, Clínica do Rim de Maringá, Maringa, Parana, Brazil; 4Nephrology, Hospital Santa Casa de Misericórdia de Maringá, Maringa, Parana, Brazil; 5Nephrology, Ethos Clin, Maringa, Parana, Brazil; 6Department of Medicine, State University of Maringa, Maringa, Parana, Brazil; 7Departament of Molecular Biology, College of Medicine of Rio Preto, Sao Jose do Rio Preto, Sao Paulo, Brazil.

78-P DIFFERENTIAL TRANSCRIPTION PROFILES FOR MHC CLASS I GENES IN ORANGUTANS: NEGLIGIBLE TRANSCRIPTION OF C AND PARTICULAR B LOCUS/LINEAGE IN PERIPHERAL BLOOD DERIVED CELL-LINES. Natasja G. de Groot1, Corrine M.C. Heijmans1, Marit K. van der Wiel1, Jeroen H. Blokhuis1,2, Arend Mulder3, Lisbeth A. Guethlein2, Gaby G.M. Doxiadis1, Frans H. Claas3, Peter Parham2, Ronald E. Bontrop1,4. 1Comparative Genetics and Refinement, Biomedical Primate Research Centre, Rijswijk, Netherlands; 2Structural Biology and Microbiology and Immunology, Stanford University, Stanford, USA; 3Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands; 4Theoretical Biology and Bioinformatics, Utrecht University, Utrecht, Netherlands.

79-P FURTHER EXPLORATION OF HLA REGION ASSOCIATIONS WITH LUNG CANCER RISK. Sandeep K. Singh1, Ziyad Ben Taleb1, Amy E. Kennedy3, Karina Villalba2, M. Tevfik Dorak3. 1Environmental and Occupational Health, Robert Stempel College of Public Health and Social Work, Miami, FL, USA; 2Health Promotion and Disease Prevention, Robert Stempel College of Public Health and Social Work, Miami, FL, USA; 3Epidemiology, Robert Stempel College of Public Health and Social Work, Miami, FL, USA.

80-P DETECTION OF A NOVEL HLA-C*04 ALLELE CONTAINING SEQUENCES FROM THE C*07:02 ALLELE GROUP IN EXON 3. Jean F. Garcia-Gomez, Ketevan Gendzekhadze, David Sentizer. Histocompatibility Laboratory, City of Hope National Medical Center, Duarte, CA, USA.

Final Program 67 Abstracts 81-P POLYMORPHIC FREE HLA CLASS I HEAVY CHAINS ARE EXPRESSED BY MALE GAMETOGENIC CELLS IN THE HUMAN TESTIS. Heinz Hutter1, Astrid Blaschitz1, Andreas Ziegler2, Barbara Uchanska-Ziegler2, Gottfried Dohr1. 1Institut für Zellbiologie, Histologie und Embryologie, Medizinische Universität Graz, Graz, Austria; 2Institut für Immungenetik, Charite-Universitätsmedizin Berlin, Freie Universität Berlin, Berlin, Germany.

82-P THE PREVALENCE OF CCR5 DELTA 32 MUTATION IN SAUDI ARABIA. Dunia Jawdat1,3, Muhannad Alarifi3, Abdulrahman Al-Turki3, Abdulaziz Alalwan3, Faisal Al-Amro3, Noura Atallah1, Meshal Al Muallimi1, Mohammed Al-Balwi3, Ali Hajeer2,3. 1Cord Blood Bank, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; 2College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; 3Pathology and Lboratory Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia.

83-P AN ASSOCIATION OF ACTIVATING KIR RECEPTORS ON HIGHER CREATININE LEVELS IN RENAL ACUTE CELLULAR REJECTION. Angela Kessler, Robert Cirocco. HLA Lab, Lehigh Valley Health Netowrk, Allentown, PA, USA.

84-P HEAT SHOCK PROTEIN-70 Hom M493T GENOTYPING INCREASES THE PREDICTIVE POTENTIAL OF HLA-B*5701 AS A PHARMACOGENETIC TEST FOR ABACAVIR HYPERSENSITIVITY. Faisal M. Khan1,2,3, Taylor J. Kemp1, Rehan M. Faridi1, Poonam Dharmani-Khan1, John Gill4, Noureddine Berka1,3. 1Pathology & Laboratory Medicine, University of Calgary, Calgary, Canada; 2Pediatrics, University of Calgary, Calgary, Canada; 3Tissue Typing Laboratory, Calgary Laboratory Services, Calgary, Canada; 4Medicine, University of Calgary, Calgary, Canada.

85-P ALLELE LEVEL KIR TYPING BY NEXT GENERATION SEQUENCING. Martha B. Ladner1, William Pickle1, Damian Goodridge3, Henry A. Erlich2, Elizabeth A. Trachtenberg1. 1Center for Genetics, Children’s Hospital & Research Center, Oakland, CA, USA; 2Department of Human Genetics, Roche Molecular Systems, Inc, Pleasanton, CA, USA; 3Conexio Genomics, Australia.

86-P CAN LABTYPE SSO MEDIUM RESOLUTION RESOLVE DNA SEQUENCING BASED TYPING AMBIGUITIES? Abdelhamid Liacini1, Adel A. Shawhatti1, Saber AlZahrani1, Mohammad I. Awaji1, Rabab Alattas1, Faisal M. Khan2,3,4, Noureddine Berka2,4. 1Histocompatibility&Immunogenetics Laboratory, King Fahd Specialist Hospital-Dammam, Dammam, Saudi Arabia; 2Pathology & Laboratory Medicine, University of Calgary, Calgary, Canada; 3Pediatrics, University of Calgary, Calgary, Canada; 4Tissue Typing Laboratory, Calgary Laboratory Services, Calgary, Canada.

68 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 87-P HAPLOTYPE ASSOCIATION OF HLA-DQB1*03:19 AND HLA-DR11 IN SAUDI ARABIAN POPULATION. Abdelhamid Liacini1, Adel A. Shawhatti1, Mohammad I. Awaji1, Saber AlZahrani1, Rabab Alattas1, Faisal M. Khan2,3,4, Noureddine Berka2,4. 1Histocompatibility&Immunogenetics Laboratory, King Fahd Specialist Hospital-Dammam, Dammam, Saudi Arabia; 2Pathology & Laboratory Medicine, University of Calgary, Calgary, Canada; 3Pediatrics, University of Calgary, Calgary, Canada; 4Tissue Typing Laboratory, Calgary Laboratory Services, Calgary, Canada.

88-P HIGH FREQUENCY OF THE +3010 G AND +3142 C ALLELES OF THE 3’ UNTRANSLATED REGION OF THE HLA-G GENE AND VARIABLE LEVELS OF SOLUBLE sHLA-G IN CHILDHOOD ACUTE MYELOID LEUKEMIA. Norma Lucena-Silva1,2,3, Rossana Santos1,2, Renan Garcia1, Alessandra Monteiro2, Ester Vinhas1,2, Teresa Fonseca2, Francisco Pedrosa2, Eduardo Donadi3. 1Immunology, Aggeu Magalhães Research Center, Oswaldo Cruz Foundation, Recife, Pernambuco, Brazil; 2Pediatric Oncology, IMIP Hospital, Recife, Pernambuco, Brazil; 3Medicine, Faculty of Medicine of the University of São Paulo,, Ribeirão Preto, São Paulo, Brazil.

89-P KIR GENOTYPE DISTRIBUTION AMONG SYMPTOMATIC PATIENTS WITH AND WITHOUT HELICOBACTER PYLORI INFECTION: IS THERE ANY ROLE OF THE B HAPLOTYPE? Rouba Hoteit, Dina Shammaa, Rabab Abdel Khalek, Rami Mahfouz. Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

90-P KIR GENOTYPE DISTRIBUTION AMONG PATIENTS WITH MULTIPLE MYELOMA: HIGHER PREVALENCE OF KIR 2DS4 AND KIR 2DS5 GENES. Rouba Hoteit, Dina Shammaa, Rami Mahfouz. Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

91-P KIR GENOTYPE DISTRIBUTION AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: IS THERE A ROLE FOR KIR 2DS4 AND KIR 2DS5 GENES? Rouba Hoteit, Dina Shammaa, Rami Mahfouz. Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

92-P UNUSUAL HLA-DRB1-DQA1-DQB1 ASSOCIATION FOUND IN AN EXTENDED HAPLOTYPE IN SEVEN BRAZILIAN INDIVIDUALS. Maria E. Moraes1, Matilde Romero1, Maria I. Hue1, Gerlandia Pontes2, Margareth A. Torres2. 1Immunogenetic, JRM - Investigacoes Imunologicas, Rio De Janeiro, RJ, Brazil; 2Immunogenetic, LIG -Laboratorio De Imunogenetica, Sao Paulo, SP, Brazil.

Final Program 69 Abstracts 93-P MIC AND NKG2D GENES POLYMORPHISM IN MEXICAN POPULATION. Miriam E. Nieves-Ramirez, Eyerahi Bravo-Flores, Oswaldo Partida-Rodriguez, Martha E. Perez- Rodriguez. HLA Laboratory, Medical Research Unit in Immunology, Mexican Institute of Social Security, Mexico City, Mexico.

94-P SYSTEMATIC CLONAL SEQUENCING OF HUMAN LEUKOCYTE ANTIGEN (HLA). Kazutoyo Osoegawa, Martha Ladner, Elizabeth Trachtenberg. Children’s Hospital Oakland Research Institute, Children’s Hospital & Research Center Oakland, Oakland, CA, USA.

95-P IL-4 GENE CLUSTER POLYMORPHISMS:IL-4 (-1098 G/T), IL-4 (-590 C/T), IL-4 (-33 C/T), IL-4Ra (+1902 G/A) IN THE HEALTHY POPULATION FROM THE NORTH-WEST REGION OF RUSSIA. Anastasia Pavlova, Iulia Sokolova, Irina Pavlova. Immunohematology, Russian Institute of Haematology and Transfusiology, Saint-Petersburg, Russian Federation.

96-P KIR GENOTYPES IN HEMATOPOIETIC STEM CELL TRANSPLANTATION. Martha Perez-Rodriguez1, Eyarahi Bravo-Flores1, Elizabeth Sanchez-Valle2, Margarita Contreras- Serratos2, Julio Martinez-Alvarez3, Araceli Arrazola-Garcia3. 1Immunology Research Department, Pediatric Hospital, CMN S-XXI, IMSS, Mexico, DF, Mexico; 2Hematopoietic Cell Transplantation, Specialty Hospital, CMN S-XXI, IMSS, Mexico, DF, Mexico; 3Blood Bank, Specialty Hospital, CMN S-XXI, IMSS, Mexico, DF, Mexico.

97-P KIR HAPLOTYPE AND GENOTYPE DISTRIBUTION IN HEMATOPOIETIC STEM CELL TRANSPLANT DONORS IN PANAMA. Alejandro A. Vernaza1, Juan C. Moscoso1, Medhat Askar2, Ernesto Fanilla3, Ricardo Aguilar1. 1Transplant Laboratory, Social Security Hospital, Panama; 2Allogen Laboratory, Cleveland Clinic, OH, USA; 3Hematology, ION, Panama.

98-P KIR mRNA EXPRESSION IN PBMC AND ENRICHED NK CELLS ASSAYED BY QUANTITATIVE REAL-TIME PCR. Yao Yuan1, Sharon D. Adams1, David M. Dinauer2, Christopher M. Rosenau2, Marcela R. Uribe1, Willy A. Flegel1. 1Department of Transfusion Medicine, NIH Clinical Center, Bethesda, USA; 2Medical Sciences Research and Development, Life Technologies, Brown Deer, USA.

70 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 99-P HLA ALLOIMMUNIZATION FROM RED CELL TRANSFUSIONS IN NEWLY DIAGNOSED TREATED ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION. Fleur M. Aung1, Benjamin Lichtiger1, Hagop Kantarjian2. 1Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

100-P ROLE OF ANTI-HLA ANTIBODY DETECTED BY A BEAD-BASED SOLID PHASE ASSAY IN HEMATOPOIETIC STEM CELL TRANSPLANTATION. Myra Coppage, Angela Busacco, Danielle Meehan. Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.

101-P BENEFICIAL EFFECTS OF AUTOLOGOUS BONE MARROW CELL INFUSION IN PATIENTS WITH CHRONIC CRITICAL LIMB ISCHEMIA: LONG TERM FOLLOW-UP. Angelo Matarazzo1, Vincenzo Grimaldi2, Anna Florio1, Linda Sommese2, Claudio Napoli2. 1Vascular Surgery, 1st School of Medicine, Second University of Naples, Naples, Italy; 2U.O.C. Immunohematology, Transfusion Medicine and Transplant Immunology (SIMT), Regional Reference Laboratory of Transplant Immunology (LIT), Azienda Universitaria Policlinico (AOU), 1st School of Medicine, Second University of Naples, Naples,.

102-P LOSS OF DONOR CHIMERISM IN PATIENT UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FOR MDS. Zahra Kashi1, Parisa Pourani1, Russ Martin1, Margi Bryant2. 1HLA, Kashi Clinical Laboratories, Portland, OR, USA; 2Blood & Marrow Transplant Center, The Jewish Hospital, Cincinnati, OH, USA.

103-P THE VALUE OF CBC IN DETERMINATION OF ACCURATE PATIENT HLA TYPING. Zahra Kashi1, Russ Martin1, Allison Franco2, Meagan Barner1, Parisa Pourani1, Christopher Cheng1, Brian Whitt1. 1Histocompatibility and Immunogenetics, Kashi Clinical Laboratories, Portland, OR, USA; 2Pediatric Hematology Oncology, Oregon Health Sciences University, Portland, OR, USA.

104-P IMPACT OF MATCHING OF HLA CLASS I AND CLASS II ALLELES IN THE DONOR AND RECIPIENT ON THE RISK GRAFT-VERSUS-HOST DISEASE AFTER UNRELATED ALLOGENIC HSCT: A SINGLE CENTER EXPERIENCE. Elena Kuzmich, Olga Makarenko, Nina Timofeeva, Natalia Ivanova, Boris Afanasyev, Alla Choroshailova. R. Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantology, Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation.

Final Program 71 Abstracts 105-P APPARENT LOSS OF CD33 MARKER EPITOPE IN A RELAPSED AML PATIENT THAT AFFECTED RESULTS OF LINEAGE SPECIFIC ENGRAFTMENT MONITORING. Tatiana Lebedeva1, Mary Chau1, Charlotte Cronin1, Sydara Vil1, Jason Law2, Marina Ohashi1, Sharon Alosco1, Neng Yu1. 1HLA Laboratory, American Red Cross, Dedham, MA, USA; 2Pediatric Hematology/ Oncology, Tufts Medical Center, Boston, MA, USA.

106-P HLA ALLELE AND HAPLOTYPE FREQUENCIES FOR CHRISTIAN AND MUSLIM ARAB DONORS IN HADASSAH REGISTRY. Amal Bishara1, Chiam Brautbar1, Shoshana Israel1, Michael Halagan2, Abeer Madbouly2, Marcelo Fernandez Vina3, Martin Maiers2. 1Bone Marrow Donor Registry, Hadassah Medical Center, Jerusalem, Israel; 2Bioinformatics Research, National Marrow Donor Program, MN, USA; 3Department of Pathology, School of Medicine, Standford University, Standford, CA, USA.

107-P THE SUCCESS STORY OF A LIS IMPLEMENTATION. Lucie Richard. Reference and Stem Cell Laboratory, Hema-Quebec, Saint-Laurent, QC, Canada.

108-P DIVERSITY OF HLA HAPLOTYPES IN CLINICAL PRACTICE. Pedro Cano1, Michael Seul2. 1HLA Typing Laboratory, Laboratory Medicine, MD Anderson Cancer Center, Houston, TX, USA; 2BioMolecular Analytics, LLC, Warren, NJ, USA.

109-P RARE ALLELES IN THE SOUTHERN BRAZILIAN PARANA STATE POPULATION. Joandrei Dos Santos Silva, Alessandro Pirri, Jose Samuel Da Silva, Maria Da Graça Bicalho. Genetics, Universidade Federal Do Parana, Curitiba, Parana, Brazil.

110-P A RETROSPECTIVE OVERVIEW: CHALLENGES IN FINDING A MATCH FOR BONE MARROW UNRELATED TRANSPLANTS (MUD) IN CALGARY, ALBERTA, CANADA. Luz Stamm1, Naree Ager2, Charlene Ott1, Noureddine Berka1, Laura Karlsson2, Diana Quinlan2. 1Tissue Typing, Calgary Laboratory Services, Calgary, AB, Canada; 2Bone Marrow Program, Tom Baker Cancer Centre, Calgary, AB, Canada.

111-P PREDICTING UNRELATED DONOR SEARCH PRODUCTIVITY USING GENOTYPE FREQUENCY. Kimberly Wadsworth, Janelle Olson, Katie Howe, Jason Dehn. Scientific Services, National Marrow Donor Program, Minneapolis, MN, USA.

72 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 112-P EXPLORATION OF THE POTENTIAL TO ENCOUNTER SINGLE CLASS I HLA ANTIGEN RECOGNITION SITE (ARS) MISMATCHES WITHIN AN UNRELATED DONOR TRANSPLANT SETTING. Stephanie L. Waldvogel1, Cynthia Vierra-Green1, Elizabeth Beduhn2, Jane Kempenich2, Frans H.J. Class3, Machteld Oudshoorn3,4, Stephen R. Spellman1. 1Immunobiology Research, Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA; 2Scientific Services, National Marrow Donor Program, Minneapolis, MN, USA; 3Dept. of Immunohaematology and Blood Transfusion, LUMC, Leiden, Netherlands; 4Europdonor Foundation, Leiden, Netherlands.

113-P TCR REPERTOIRE AS A BIOMARKER FOR CHIMERIC KIDNEY RECIPIENTS BENEFITING FROM FACILITATING CELL-ENRICHED STEM CELL TRANSPLANTATION. Iwona M. Konieczna1, James M. Mathew1, Suzanne T. Ildstad2, Joshua Miller1, Joseph R. Leventhal1. 1Comprehensive Transplant Center, Northwestern University, Chicago, IL, USA; 2Institute for Cellular Therapeutics, University of Louisville, Louisville, KY, USA.

114-P REGULATORY T AND B CELL CIRUITS IN TOLERANT HLA-IDENTICAL KIDNEY TRANSPLANT RECIPIENTS AND NORMAL VOLUNTEERS. James M. Mathew, Joseph R. Leventhal, Xuemei Huang, Li Chen, Anat R. Tambur, John J. Friedewald, Michael M. Abecassis, Joshua Miller. Surgery; Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

115-P AUTOMATED HIGH THROUGHPUT ISOLATION OF LYMPHOID AND MYELOID CELLS DIRECTLY FROM WHOLE BLOOD USING RoboSep-HT. Karina L. McQueen, Drew W. Kellerman, Zack Frehlick, Jo A.L. Gromadzki, Steven S.S. Poon, Steven M. Woodside, Terry E. Thomas. Research and Development, STEMCELL Technologies Inc., Vancouver, BC, Canada.

116-P EVALUATION OF ENGRAFTMENT MONITORING FOR ALLOGENEIC AND DOUBLE CORD BLOOD HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS USING REAL-TIME qPCR. Jennifer R. Zitzner, Emira Hadziahmetovic, Mary J. Haywood, R. Carlin Walsh, Anat R. Tambur. Transplant Immunology Laboratory, Department of Surgery, Northwestern University, Chicago, IL, USA.

117-P KIR TYPING WITH LINKSEQ™, A REAL-TIME PCR DETECTION SYSTEM. Roland Russnak, Elizabeth King, Ngoc Ly, Kai Quinto, Zachary Antovich. Department of Immunogenetics, Linkage Biosciences, South San Francisco, CA, USA. Russnak: Linkage Biosciences: Consultant. King: Linkage Biosciences: Employee; Stockholder. Ly: Linkage Biosciences: Employee; Stockholder. Quinto: Linkage Biosciences: Employee. Antovich: Linkage Biosciences: Employee; Stockholder.

Final Program 73 Abstracts 118-P THE POWER OF DECONVOLUTION – INHIBITION OF ANTI-HLA ANTIBODY REACTIVITIES USING SPECIFIC SOLUBLE HLA MOLECULES AS NEUTRALIZING AGENTS. Rico Buchli1, Arend Mulder2, Rene J. Duquesnoy3, Rebecca D. McAdams1, Rodney S. VanGundy1, Curtis P. McMurtrey4, Steven J. Cate4, Daniel Zehnder5,6, David P. Lowe5,7, David Briggs7, Robert Higgins6, Frans H.J. Claas2, William H. Hildebrand1,4. 1R&D, Pure Protein LLC, Oklahoma City, OK, USA; 2Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands; 3Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 4Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; 5Clinical Sciences Research Institute, The University of Warwick - Warwick Medical School, Coventry, United Kingdom; 6University Hospitals of Coventry & Warwickshire NHS Trust, Coventry, United Kingdom; 7NHSBT Birmingham, Birmingham, United Kingdom.

119-P HLA ANTIBODY TITRATION ANALYSIS – THE FIRST STEP IN QUANTITATIVE SIGNAL PATTERN INTERPRETATION. Rico Buchli1, Arend Mulder2, Rene J. Duquesnoy3, Rebecca D. McAdams1, Rodney S. VanGundy1, Curtis P. McMurtrey5, Steven J. Cate5, Daniel Zehnder4,6, David P. Lowe4,7, David Briggs7, Robert Higgins6, Frans H.J. Claas2, William H. Hildebrand1,5. 1R&D, Pure Protein LLC, Oklahoma City, OK, USA; 2Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands; 3Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 4Clinical Sciences Research Institute, The University of Warwick - Warwick Medical School, Coventry, United Kingdom; 5Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; 6University Hospitals of Coventry & Warwickshire NHS Trust, Coventry, United Kingdom; 7NHSBT Birmingham, Birmingham, United Kingdom.

120-P DESIGN OF A SPECIFIC, SENSITIVE ASSAY FOR THE DETECTION OF ANTI-VIMENTIN ANTIBODY USING Luminex® BEAD-BASED TECHNOLOGY. Bethany L. Dale, Donna P. Lucas, Mary S. Leffell, Andrea A. Zachary. Immunogenetics Laboratory, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

121-P INFORMATIVE PARALLEL SEQUENCING: HAPLOTYPE CLASSIFICATION BY MACHINE LEARNING. Ghazala Hashmi1, Dipika Patel1, Fleur Aung2, Pedro Cano2, Michael Seul1. 1BioMolecular Analytics, LLC, Warren, NJ, USA; 2MD Anderson Cancer Center, Houston, TX, USA. Hashmi: BioMolecular Analytics, LLC: Employee. Patel: BioMolecular Analytics, LLC: Employee. Seul: BioMolecular Analytics, LLC: Employee. 122-P A NOVEL ALLELE: HLA-B*13:01:06, IDENTIFIED BY SEQUENCE- BASED TYPING IN A CHINESE INDIVIDUAL. Yingfeng Huang1, Yin Tan2, Xin Ye3. 1Guangzhou First Municipal People’s Hospital Affiliated to Guangzhou Medical College, Department of Surgery, Guangzhou, China; 2Guangzhou Medical University, Biotechnology Experiment Center, Guangzhou, China; 3Guangzhou Blood Center, Institute of Blood Transfusion, Guangzhou, China.

74 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 124-P THE FUTURE HAS ARRIVED – ROUTINE HIGH THROUGHPUT HLA TYPING BY NGS. Vinzenz Lange1, Irina Boehme1, Patrick Paul1, Johanna M. Andreas1, Bianca Schoene1, Kathrin Lang1, Daniel M. Baier2, Jan A. Hofmann2, Jürgen Sauter2, Julia Pingel2, Alexander H. Schmidt2, Gerhard Ehninger3. 1DKMS Life Science Lab, Dresden, Germany; 2DKMS German Bone Marrow Donor Center, Tübingen, Germany; 3Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.

125-P NEXT GENERATION HLA SEQUENCING ON THE Illumina MiSeq. Curt Lind1, Jamie Duke1, Deborah Ferriola1, Katarzyna Mackiewicz1, Anna Papazoglou1, Steven Heron1, Dimitri Monos1,2. 1Immunogenetics Laboratory, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA; 2Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.

126-P ASSESSMENT OF iBEADS EFFICACY TO RULE OUT SAB NON-SPECIFIC REACTIONS. Mia Kost, Paraskevi Vogiatzi, Timothy Williams, Bradley Christensen, Nell Field, Judith Knakiewicz, Toan Ngo, Andrea Parkinson, Gregory Simmons, Thomas Franks, Debra Schauss, Judy Wysocki, Daniel S. Ramon. Histocompatibility Laboratory. Pathology, Universtity of Michigan Health System, Ann Arbor, MI, USA.

127-P HLA-A*33:44: A NEW ALLELE IDENTIFIED BY SEQUENCE-BASE TYPING IN A CHINESE BLOOD DONOR. Xin Ye1, Haoqian Ding1, Yingfeng Huang2, Yin Tan3. 1Guangzhou Blood Center, Institute of Blood Transfusion, Guangzhou, China; 2Guangzhou First Municipal People’s Hospital Affiliated to Guangzhou Medical College, Department of Surgery, Guangzhou, China; 3Guangzhou Medical University, Biotechnology Experiment Center, Guangzhou, China.

128-P EVALUATION OF LONG READ SEQUENCING CHEMISTRY FOR NEXT GENERATION SEQUENCING ON THE PGM PLATFORM. Bin Zhao, Carolyn Bialozynski, Joel Shi, Marie Radick, Scott Conradson, David Dinauer. Transplant Diagnostics, Life Technologies, Brown Deer, WI, USA. Zhao: Life Technologies: Employee. Bialozynski: Life Technologies: Employee. Shi: Life Technologies: Employee. Radick: Life Technologies: Employee. Conradson: Life Technologies: Employee. Dinauer: Life Technologies: Employee.

Final Program 75 Abstracts 129-P DEVELOPMENT OF THE FIRST FDA 510(K) CLEARED DNA SEQUENCING SYSTEM. Tina Agostini1, Joel Shi1, Zahra Kashi2, Harriet Noreen3, Maurine Davidson3, Anat Tambur4, Thomas Williams5, Jin Wu5, David Dinauer1. 1Transplant Diagnostics, Life Technologies, WI, USA; 2 Kashi Clinical Laboratories, Inc., Portland, USA; 3Immunology, University of Minnesota Medical Center, Fairview, Minneapolis, USA; 4Transplant Immunology, Northwestern University, Chicago, USA; 5University of New Mexico and TriCore Reference Laboratories, Albuquerque, USA. Agostini: Life Technologies: Employee. Shi: Life Technologies: Employee. Kashi: Life Technologies: Other: Study Site Participant. Noreen: Life Technologies: Other: Study Site Participant. Davidson: Life Technologies: Other: Study Site Participant. Tambur: Life Technologies: Other: Study Site Participant. Williams: Life Technologies: Other: Study Site Participant. Wu: Life Technologies: Other: Study Site Participant. Dinauer: Life Technologies: Employee.

130-P COMPLETE BI-DIRECTIONAL SEQUENCING OF HLA-DRB1 EXONS 2 AND 3. Tina Agostini, Joel Shi, Scott Conradson, David Dinauer. Transplant Diagnostics, Life Technologies, Brown Deer, WI, USA. Agostini: Life Technologies: Employee. Shi: Life Technologies: Employee. Conradson: Life Technologies: Employee. Dinauer: Life Technologies: Employee.

131-P THOUSAND GENOMES AND HLA TYPING BY NGS: HIDDEN TREASURES IN PUBLIC SHORT READ DATA Endre Major1, Krisztina Rigo1, Attila Berces1, Szilveszter Juhos1, Pierre-Antoine Gourraud2, Timothy James Hague1. 1Bioinformatics, Omixon Biocomputing, Budapest, Hungary; 2Neurology, UCSF School of Medicine, San Francisco, CA, USA.

132-P DEVELOPMENT OF AN HLA TYPING METHOD FOR THE ION TORRENT PGM NEXT GENERATION SEQUENCING PLATFORM. Carolyn Bialozynski, David Dinauer, Benjamin Gifford, Bin Zhao, Joel Shi, Marie Radick, Scott Conradson. R&D, Life Technologies, Brown Deer, WI, USA. Bialozynski: Life Technologies: Employee. Dinauer: Life Technologies: Employee. Gifford: Life Technologies: Employee. Zhao: Life Technologies: Employee. Shi: Life Technologies: Employee. Radick: Life Technologies: Employee. Conradson: Life Technologies: Employee. 133-P IDENTIFICATION OF NOVEL HLA ALLELES BY SEQUENCE BASED TYPING (SBT): A*01:114, A*02:397, A*11:129, A*32:46, B*44:160 AND C*07:307. Weicheng Zhao, Edward Guerrero, Dana Willis, Titus Barnes, Yudith Carmazzi, David Partlow, Pedro Cano, Kai Cao. Pathology & Laboratory Medicine, University of Texas MD Anderson Cancer Center, Hstonou, TX, USA.

76 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 134-P EXTENSION OF RELATIVE PREDISPOSITIONAL EFFECTS (RPE) METHOD TO HANDLE MULTIPLE IMPUTATION AND MULTIVARIATE REGRESSION. Stephanie DiPrima1, Loren Gragert1, Mark Albrecht1, Mei-Jie Zhang2, Xiabao Zhong2, Parameswaran Hari3, Meral Beksac4, Martin Maiers1. 1Bioinformatics Research, National Marrow Donor Program, Minneapolis, USA; 2Biostatistics, Medical College of Wisconsin, Center for International Blood and Marrow Transplant Research, Milwaukee, USA; 3Hematology and Oncology, Medical College of Wisconsin, Center for International Blood and Marrow Transplant Research, Milwaukee, USA; 4Department of Hematology, Ankara University, Ankara, Turkey. 135-P GENETIC STRUCTURE OF CODING REGION OF THE HFE GENE: SNPs, HAPLOTYPES AND SUGGESTED ALLELE NOMENCLATURE. Wagner N. Campos1, Juliana D. Massaro1, Ana L.C. Martinelli2, Celso T. Mendes-Junior3, Eduardo A. Donadi1. 1Division of Clinical Immunology, Department of Medicine, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Sao Paulo, Brazil; 2Division of Gastroenterology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Sao Paulo, Brazil; 3Departamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Sao Paulo, Brazil. 136-P THE RELEVANCE OF ALLELE LEVEL A-B-DRB1 HAPLOTYPES IN THE POPULATION STRUCTURE AND THE CLINICAL SETTING IN MEXICAN MESTIZOS. Hilario Flores-A, Carmen Alaez, Andrea Munguia, Clara Gorodezky. Dept. of Immunology and Immunogenetics, Instituto de Diagnóstico y Referencia Epidemiológicas. Secretary of Health. & Fundación Comparte Vida, A.C., Mexico City, DF, Mexico. 137-P HLA GENOTYPES IN PATIENTS REFERRED FOR CELIAC DISEASE TESTING: A REFERENCE LABORATORY EXPERIENCE. Manish J. Gandhi, Lisa Hallaway, Laurie Voit. Division of Transfusion Medicine, Mayo Clinic, Rochester, MN, USA. 138-P HLA TYPING AMBIGUITY OF SEQUENCE-SPECIFIC OLIGONUCLEOTIDE TYPING PROTOCOLS. Loren Gragert, Vanja Paunic, Joel Schneider, Martin Maiers. Bioinformatics Research, National Marrow Donor Program, Minneapolis, MN, USA.

139-P HLA-A, -B, -C, -DRB1, -DQA1, -DQB1 AND -DPB1 ALLELE FREQUENCIES IN A SAUDI POPULATION USING NEXT GENERATION SEQUENCING TECHNIQUE. Ali H. Hajeer1, Mohammed A. Al Balwi1,2, Aytül F. Uyar2, Mohammed A. Al Jumah3. 1Department of Pathology & Laboratory Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia; 2King Abdullah International Medical Research Centre, King Abdulaziz Medical City, Riyadh, Saudi Arabia; 3Istanbul Medical Faculty, Istanbul University, Instanbul, Turkey.

Final Program 77 Abstracts 140-P THE OPO EXPERIENCE WITH (ALMOST) REAL TIME HLA TYPING BY REAL-TIME PCR. Padma Kuchipudi, Lynden Gault, Dorothy Levis, Jerry C. Rosenberg, Sam Ho. Histocompatibility Laboratory, Gift of Life Michigan, Ann Arbor, MI, USA.

141-P IMPACT OF HLA-G EXON 8- INDEL POLYMORPHISM AND SOLUBLE LEVELS ON TYPE 1 DIABETES. Uma Kanga1, Manish Mourya1, Nikhil Tandon2, Abhishweta Saxena1, Poonam Coshic3, Narinder Kumar Mehra1. 1Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi, India; 2Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India; 3Transfusion Medicine, All India Institute of Medical Sciences, New Delhi, India.

142-P ALLELES PROBLEMATIC THROUGH THE AGES. Jane H. Kempenich, Elizabeth Beduhn, Gail Flickinger, Jason Dehn, John Hermanson. Scientific Services, National Marrow Donor Program, Minneapolis, MN, USA.

143-P ENHANCED HLA TYPING RESOLUTION WITH CELERA MOTIF-SPECIFIC SEQUENCING PRIMERS. Jana Kobrle, Robert Bruce, Birgit Drews, Douglas A. Bost. Product Development, Celera, Alameda, CA, USA. Kobrle: Celera: Employee; Stockholder. Bruce: Celera: Employee. Drews: Celera: Employee. Bost: Celera: Employee. 144-P COLLEGE OF AMERICAN PATHOLOGISTS HLA-B 27 PROFICIENCY TESTING DATA REVEALS INCREASED FALSE POSITIVE RATES FOR FLOW CYTOMETRY METHODS. Patricia M. Kopko, Arthur B. Eisenbrey, George C. Maha. Histocompatibility/Identity Committee, College of American Pathologists, Northfield, IL, USA.

145-P USE OF THE AUTOMATED NORDIAG ARROW SYSTEM FOR DNA EXTRACTION FROM BUCCAL SWABS. Massimo Mangiola, Sese Doreen, Chatenay-Lapointe Fronçois, Young Te Carolyn. Special Services, Rhode Island Blood Services, Providence, RI, USA.

146-P A COMPARISON OF LOW RESOLUTION TYPING BY LUMINEX AND SEQUENCE SPECIFIC PRIMERS. Mahendra N. Mishra, Vandana Lal. Transplant Immunology, Dr Lal Path Labs Pvt. Ltd. National Reference Laboratory, New Delhi, Delhi, India.

78 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 147-P A MULTI-CENTER CASE STUDY TO EVALUATE HLA TYPING RESOLUTION USING NOVEL SBTessenz ASSAYS SUITABLE FOR DONOR REGISTRIES. Jeroen Adema1, Nienke Westerink1, Jessica Gatulis2, Neng Yu2, Wang Dan3, Xiangjun Liu3, Dave Roelen4, Frans Claas4, Wietse Mulder1, Erik Rozemuller1. 1R&D, GenDx, Utrecht, Netherlands; 2Histocompatibility, UMASS Memorial Health care, Worcester, USA; 3BFR Biotech, BFR Gene Diagnostics, Beijing, China; 4Immunohematology and Blood Transfusion, Leiden University Medical Centre, Leiden, Netherlands. Adema: GenDx: Employee. Westerink: GenDx: Employee. Mulder: GenDx: Stockholder. Rozemuller: GenDx: Stockholder.

148-P THE NEXT GENERATION FOR GENETIC STUDIES AND DIAGNOSTICS OF HLA. Paul J. Norman1, Steve Norberg2, Thomas Royce2, Melissa Won2, Tobias Mann2, Neda Nemat- Gorgani1, Lisbeth A. Guethlein1, Laurent Abi-Rached1, Kevin L. Gunderson2, Mostafa Ronaghi2, Peter Parham1. 1Department of Structural Biology, Stanford University School of Medicine, Stanford, USA; 2Advanced Research, Illumina Inc, San Diego, USA. 149-P CO-EVOLUTION OF HLA CLASS I WITH KIR, LILR AND TCR IN A SUB-SAHARAN AFRICAN POPULATION. Paul J. Norman1, Neda Nemat-Gorgani1, Lisbeth A. Guethlein1, Hugo G. Hilton1, Marcelo Pando2, Kwandwo Koram3, Eleanor M. Riley4, Laurent Abi-Rached1, Jill A. Hollenbach5, Peter Parham1. 1Department of Structural Biology, Stanford University School of Medicine, Stanford, USA; 2Department of Pathology, Stanford University School of Medicine, Stanford, USA; 3Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana; 4Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom; 5Center for Genetics, Children’s Hospital Oakland Research Institute, Oakland, USA. 150-P POLYMORPHISM OF MICA IN HELICOBACTER PYLORI-POSITIVE MEXICAN PATIENTS WITH GASTRODUODENAL LESIONS. Oswaldo Partida-Rodriguez1, Javier Torres2, Miriam E. Nieves-Ramirez1, Lourdes Flores3, Margarita Camorlinga2, Eduardo Lazcano3, Martha E. Perez-Rodriguez1. 1HLA Laboratory, Medical Research Unit in Immunology, Mexican Institute of Social Security, Mexico City, Mexico; 2Medical Research Unit in Infectious and Parasitic Diseases, Mexican Institute of Social Security, Mexico City, Mexico; 3National Institute of Public Health, Health Ministry, Cuernavaca, Morelos, Mexico.

151-P SUSCEPTIBILITY OF GENETIC POLYMORPHISM IN TOLL-LIKE RECEPTORS 2, 4 AND 9 TO AMOEBIC LIVER ABSCESS IN MEXICAN POPULATION. Oswaldo Partida-Rodriguez1, Eric G. Hernandez1, Carmen Maldonado2, Olivia Valenzuela3, Ulises J.C. Magaña3, Edgar Rascón3, Miriam E. Nieves-Ramirez1, Alicia Valadez1, Valeria Zermeño1, Rene Cerritos1, Tobias Portillo1, Liliana Rojas1, Enrique Gonzalez1, Patricia Moran1, Cecilia Ximenez1. 1Department of Experimental Medicine, National Autonomous University of Mexico, Mexico City, Mexico; 2Laboratory of Hematology, Children’s Hospital of Mexico Federico Gomez, Mexico City, Mexico; 3Department of Chemistry and Biological Sciences, University of Sonora, Hermosillo, Sonora, Mexico.

Final Program 79 Abstracts 152-P TYPING AMBIGUITY SCORE – A STANDARDIZED MEASURE FOR EVALUATING AMBIGUITY IN HLA TYPING. Vanja Paunic, Loren Gragert, Joel Schneider, Chaitanya Ambadipudi, Martin Maiers. Bioinformatics Research, National Marrow Donor Program, Minneapolis, MN, USA.

153-P HIGH-RESOLUTION TYPING BY NEXT-GENERATION SEQUENCING IN A CLINICAL HLA LABORATORY. J. Ryan A. Pena1, Attila Berces2, Heather Kent1, Endre Major2, Tim Hague2, Susan L. Saidman1. 1Pathology, Massachusetts General Hospital, Boston, MA, USA; 2Omixon, Omixon Biocomputing Kft, Budapest, Hungary. Berces: Omixon: Employee; Stockholder. Major: Omixon: Employee. Hague: Omixon: Employee. 154-P ASSOCIATION OF HLA CLASS I AND II WITH HEPATITIS C VIRUS INFECTION IN HIGH- RISK HEMODIALYSIS PATIENTS AWAITING KIDNEY TRANSPLANTATION. Vincenzo Grimaldi1, Antonietta Picascia1, Linda Sommese1, Amalia Casamassimi2, Francesco Cacciatore3, Maria Lourdes Montesano1, Chiara Sabia1, Carmela Fiorito1, Gustavo De Iorio1, Claudio Napoli1,2. 1U.O.C. Division of Immunohematology, Transfusion Medicine and Transplant Immunology (SIMT), Regional Reference Laboratory of Transplant Immunology (LIT), 1st School of Medicine, Second University of Naples, Naples, Italy; 2Department of General Pathology, Division of Clinical Pathology and Excellence Research Centre on Cardiovascular Disease, Second University of Naples, Naples; 3Cardiovascular Rehabilitation, Salvatore Maugeri Foundation, IRCCS, Telese Terme, Italy.

155-P EXTENDED B*73 HAPLOTYPES CONFIRMED BY FAMILY STUDIES. Lois E. Regen1, Reena Patel1, Debra Cordell1, Shalini E. Pereira1,2,3. 1Clinical Immunogenetics Laboratory, Seattle Cancer Care Alliance, Seattle, WA, USA; 2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 3Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.

156-P POPULATION STUDY OF HÉMA-QUÉBEC STEM CELL DONOR REGISTRY. Lucie Richard1, Stéphane Buhler2, José M. Nunes2, Alicia Sanchez-Mazas2. 1Reference and Stem Cell Laboratory, Héma-Québec, Saint-Laurent, QC, Canada; 2Department of Genetics and Evolution - Anthropology Unit, University of Geneva, Geneva, Switzerland.

157-P NGSengine: THE ULTIMATE TOOL FOR NGS HLA TYPING. Raul Kooter, Frans Paul Ruzius, Maarten T. Penning, Wietse Mulder, Erik H. Rozemuller. R&D, GenDx, Utrecht, Netherlands. Kooter: GenDx: Employee. Ruzius: GenDx: Employee. Penning: GenDx: Employee. Mulder: GenDx: Employee; Stockholder. Rozemuller: GenDx: Employee; Stockholder.

80 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 158-P NGSengine EARLY ACCESS PROGRAM: FINDINGS IN A MULTICENTER EVALUATION. Maarten T. Penning, Raul Kooter, Frans Paul Ruzius, Wietse Mulder, Erik H. Rozemuller. R&D, GenDx, Utrecht, Netherlands. Penning: GenDx: Employee. Kooter: GenDx: Employee. Ruzius: GenDx: Employee. Mulder: GenDx: Employee; Stockholder. Rozemuller: GenDx: Employee; Stockholder.

159-P LABFLOW LITE: A DIGITAL LAB ASSISTANT FOR AN EFFICIENT SBT LABORATORY WORKFLOW. Elize de Jager1, Maureen Flink2, Maarten T. Penning1, Wietse Mulder1, Erik H. Rozemuller1. 1R&D, GenDx, Utrecht, Netherlands; 2Immunogenetics and Transplantation Immunology, Leiden University Medical Center, Leiden, Netherlands. de Jager: GenDx: Employee. Penning: GenDx: Employee. Mulder: GenDx: Employee; Stockholder. Rozemuller: GenDx: Employee; Stockholder.

160-P neXtype: A SAFE CAR ON THE NGS ROLLER COASTER. Jürgen Sauter1, Jan A. Hofmann1, Vinzenz Lange2, Irina Böhme2, Kathrin Lang2, Daniel M. Baier1, Bianca Schöne2, Ulf Ehninger3, Alexander H. Schmidt1, Gerhard Ehninger4, Julia Pingel1. 1Science, DKMS German Bone Marrow Donor Center, Tübingen, Germany; 2Research and Development, DKMS Life Science Lab, Dresden, Germany; 3Software Development, Molpe Software Development, Kirchentellinsfurt, Germany; 4Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany. 161-P NEXT GENERATION HLA TYPING SOFTWARE AS TORRENT SERVER PLUG-IN ON ION PGM. Joel Shi, Dave Dinauer, Marie Radick, Mike Hunsicker, Inta Veldre, Mike Lelivelt, Scott Conradson. R&D, Life Technologies, Brown Deer, WI, USA. Shi: Life Technologies: Employee. Dinauer: Life Technologies: Employee. Radick: Life Technologies: Employee. Hunsicker: Life Technologies: Employee. Veldre: Life Technologies: Employee. Lelivelt: Life Technologies: Employee. Conradson: Life Technologies: Employee. 162-P ASSOCIATION OF CYTOKINES (SNPs) BETWEEN DUST MITES SENSITIVE AND NON- SENSITIVE INDIVIDUALS IN A POPULATION OF PARANA STATE, BRAZIL. Marcela C.C.L. Caniatti1, Ariella A. Marchioro1, Ana Lúcia F. Guilherme1, Gustavo F. Guilherme2, Luiza T. Tsuneto1. 1Immunogenetics Laboratory, State University of Maringa (UEM), Maringá, Parana, Brazil; 2Medicine, Evangelical University of Paraná (Fepar), Curitiba, Parana, Brazil.

Final Program 81 Abstracts 163-P STUDY OF THE ASSOCIATION BETWEEN HLA-DRB1*04 AND FYa ALLOIMMUNIZATION IN POLYTRANSFUSED PATIENTS FROM SOUTHERN BRAZIL. Camila Rodrigues1, Ana Maria Sell1, Lilian Castilho2, Emilia A. Sippert2, Gláucia G. Guelsin2, Adriana V. Bruder1, Josiane B. Alencar1, Luciana C. Macedo1, Mari E. Ferreira3, Jeane E.L. Visentainer1. 1Ciências Básicas da Saúde, Universidade Estadual de Maringá, Maringá, Paraná, Brazil; 2Centro de Hematologia e Hemoterapia, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil; 3Instituto de Hemoterapia Maringá, Hospital do Câncer, Maringá, Paraná, Brazil.

164-P HLA DQB1 06:09 SIGNIFICANTLY INCREASES THE RISK OF MULTIPLE SCLEROSIS AMONGST PARSIS (ZOROASTRIANS) OF INDIA. Noshir Hormusji Wadia1, Jitesh Marar1, P.P. Nimkar2, P.M. Marathe2, Vrinda Satyendra Trikannad2. 1Neurology, Jaslok Hospital & Research Centre, Mumbai, Maharashtra, India; 2Immunology, Jaslok Hospital & Research Centre, Mumbai, Maharashtra, India.

165-P NEW PCR AND SEQUENCING REAGENTS FOR SEQUENCE BASED TYPING OF HLA-DRB1 EXON 2 AND EXON 3. Jana Kobrle, Birgit Drews, Persis P. Wadia, Sharon S. Jiang, Christopher L. Sigua, Douglas A. Bost. Product Development, Celera / Quest Diagnostics, Alameda, CA, USA. Wadia: Celera / Quest Diagnostics: Employee; Stockholder. Drews: Celera / Quest Diagnostics: Employee. Sigua: Celera / Quest Diagnostics: Employee. Jiang: Celera / Quest Diagnostics: Employee. Bost: Celera / Quest Diagnostics: Employee. 166-P IDENTIFICATION OF A NEW HLA-B27 ALLELE. Jinguo Wang1, Carrera Kostur1, Jolene Anderson1, Sharon Zeeben1, Kim Larlee1, Luz Stamm1, Faisal M. Khan1,2,3, Noureddine Berka1,2. 1Tissue Typing Laboratory, Calgary Laboratory Services, Calgary, AB, Canada; 2Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada; 3Pediatrics, University of Calgary, Calgary, AB, Canada.

167-P HIGH-THROUGHPUT SHOTGUN SEQUENCING OF THE HLA-DQA1 GENE USING NEXT GENERATION SEQUENCING. Fumiko Yamamoto1, Kalyan Mallempati1, Carolyn Bialozynski2, Joel Shi2, Endre Major3, Tim Hague3, David Dinauer2, Dolly B. Tyan1, Marcelo Fernandez-Vina1, Matthew W. Anderson4. 1Histocompatibility, Immunogenetics, and Disease Profiling Laboratory, Department of Pathology, Stanford University School of Medicine, Palo Alto, CA, USA; 2Clinical Diagnostics Research & Development, Life Technologies, Brown Deer, WI, USA; 3Software Development, Omixon Biocomputing, Budapest, Hungary; 4Diagnostic Laboratories, Blood Center of Wisconsin, Milwaukee, WI, USA. Yamamoto: Life Technologies: Grant Research. Mallempati: Life Technologies: Grant Research. Bialozynski: Life Technologies: Employee. Shi: Life Technologies: Employee. Major: Life Technologies: Grant Research. Hague: Life Technologies: Grant Research. Dinauer: Life Technologies: Employee. Tyan: Life Technologies: Grant Research. Fernandez-Vina: Life Technologies: Grant Research. Anderson: Life Technologies: Grant Research.

82 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 168-P NOVEL B*51:11N ASSOCIATION WITH THE A*03:01-C*07:02-DRB1*04:02-DQB1*03:02 HAPLOTYPE IN AN AFRICAN AMERICAN FAMILY. Zeying Du1, Wuhua Sun1, Kristin Dastych1, Natasia Kowalkowski1, Bozena Labuda2, Andres Jaramillo1,2, Sujata Gaitonde1. 1Pathology, University of University Hospital and Health Sciences System, Chicago, USA; 2Histocompatibility Laboratory, Gift of Hope Organ & Tissue Donor Network, Itasca, USA.

169-P SIGNIFICANCE OF FLOW CYTOMETRIC CROSSMATCH IN THE REALM OF VIRTUAL CROSSMATCH: A CASE OF ALTERED HLA EXPRESSION ON CELL SURFACE. Manish J. Gandhi1, Theresa Jacobson1, Doris Kubat1, Mike Chen2, Jar-How Lee2, Laurie Voit1. 1Division of Transfusion Medicine, Mayo Clinic, Rochester, MN, USA; 2Transplant Diagnostics, Thermo Fisher Scientific, Canoga Park, CA, USA. Chen: Thermo Fisher Scientific: Employee. Lee: Thermo Fisher Scientific: Employee. 170-P ALTERNATIVE TO 8/8 MATCHED DONORS - A CASE STUDY. Lisa Harper, Teri Steeves. Histocompatibility Laboratory, Hamilton Healtch Sciences, Hamilton, ON, Canada.

171-P VIRTUAL CROSSMATCHING: IT’S NOT AS SIMPLE AS IT SEEMS. June Jones, Julie Houp, Alyson Morris, Annette Jackson, Mary Leffell, Andrea Zachary. Immunogenetics, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.

172-P MYSTERIOUS “SUBOPTIMAL” FUNCTION OF A DECEASED DONOR (DD) RENAL ALLOGRAFT. Michele Prod, Maria Oppermann, Ina Kurbegovic-Skaljic, Sylvia Piggott, Erin Christian, Siva Kanangat. Pathology, Rush University Medical Center, Chicago, IL, USA.

173-P A SINGLE DONOR SPECIFIC HLA-DP ANTIBODY IN A KIDNEY TRANSPLANT RECIPIENT RESULTING IN ANTIBODY MEDIATED REJECTION. Nathan A. Lemp1, James C. Cicciarelli1, Noriyuki Kasahara1, Michael N. Koss2, Robert Naraghi3,4, Tariq Shah3,4. 1Immunogenetics Laboratory, Mendez National Institute of Transplantation, Los Angeles, CA, USA; 2Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; 3Multi-Organ Transplant Center, St. Vincent Medical Center, Los Angeles, CA, USA; 4Transplant Research Institute, Los Angeles, CA, USA.

174-P VIRTUAL CROSSMATCH IN A PATIENT WITH HLA ALLELE SPECIFIC ANTIBODY. Grace Pan, Peter Masiakos, Adriana Colovai. Transplant Surgery, Montefiore Medical Center, Bronx, NY, USA.

Final Program 83 Abstracts 175-P NEGATIVE CDC AND FLOW CROSSMATCH BUT STRONG DSA DETECTED BY LUMINEX SINGLE ANTIGEN TEST AND C1q SINGLE ANTIGEN TEST. Geraldine Ong, Mehrnoush Naim, Qi Wang, Rolando Gumatay, Robin Masukawa, Maria Manalo, Lesley Cabigon, Dianne Paredes, Alfredo Santiago, Nancy L. Reinsmoen, Chih-Hung Lai. HLA Lab, Cedars-Sinai Health System, Los Angeles, CA, USA.

176-P SERIAL DILUTIONS OF SINGLE ANTIGEN BEAD ASSAYS PROVIDE ADDITIONAL INFORMATION IN TRANSPLANT-PATIENT MONITORING CASE STUDY. Elizabeth A. Portwood, Paul A. Brailey, Alin L. Girnita. Transplantation Immunology Division, University of Cincinnati Medical Center, Cincinnati, OH, USA.

177-P ONE IS NOT ENOUGH: POTENTIAL IMPACT OF DISCONNECTS BETWEEN SOLID-PHASE ASSAYS. Tiffany K. Roberts-Wilson, Gizem Tumer, Howard M. Gebel, Robert A. Bray. Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.

178-P A CASE OF AN UNUSUAL DRB1/DRB3/DRB5 RECOMBINATION. Sharon E. Zeeben1, Jinguo Wang1, Luz Stamm1, Michelle Petrosenko1, Carrera Kostur1, Kim Larlee1, Chad Dumont1, Faisal M. Khan1,2,3, Noureddine Berka1,2. 1Tissue Typing Laboratory, Calgary Laboratory Services, Calgary, AB, Canada; 2Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada; 3Pediatrics, University of Calgary, Calgary, AB, Canada.

179-P A BLIND STUDY OF HLA-A TYPING BY REFERENCE STRAND MEDIATED CONFORMATION ANALYSIS (RSCA). Rafael Arguello1, Daniel Arellano1, Ana Y. Garcia2. 1Molecular Immunobiology, Facultad de Medicina Torreon Universidad Autonoma de Coahuila, Torreon, Coahuila, Mexico; 2Molecular Biology, Instituto de Ciencia y Medicina Genomica, Torreon, Coahuila, Mexico.

180-P ANTI-HLA-CLASS-I ANTIBODIES AND PLATELET TRANSFUSION REFRACTORINESS. Pedro Cano, Hemantkumar Patel, Kai Cao. Laboratory Medicine, MD Anderson Cancer Center, Houston, TX, USA.

181-P UTILIZING THE LEAN PROCESS IN THE HLA LAB. Marilyn P. Downs, Sandra L. Smith, Amanda N. Cameron, Jerry L. Morrisey, William Koss. Pathology/ HLA, Scott & White Memorial Hospital, Temple, TX, USA.

84 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts 182-P EFFECT OF GLUCOSE AND ALTERNATIVE SWEETENERS (FRUCTOSE, ASPARTAME AND REBAUDIOSIDE A) ON ENDOTHELIAL PROGENITOR CELLS. Amelia Casamassimi1, Vincenzo Grimaldi2, Concetta Schiano3, Linda Sommese2, Francesco Cavalca2, Barbieri Michelangela4, Paolisso Giuseppe4, Claudio Napoli1,2. 1Department of General Pathology and Excellence Research Centre on Cardiovascular Disease, 1st School of Medicine, Second University of Naples, Naples, Italy; 2U.O.C. Immunohematology, Transfusion Medicine and Transplant Immunology (SIMT), Regional Reference Laboratory of Transplant Immunology (LIT), Azienda Universitaria Policlinico (AOU), 1st School of Medicine, Second University of Naples, Naples,; 3Institute of Diagnostic and Nuclear Development, SDN Foundation, Naples, Italy; 4Department of Geriatrics and Metabolic Diseases, 1st School of Medicine, Second University of Naples, Naples, Italy.

183-P PATIENT cPRA PERCENTAGE CORRELATES WITH, AND THEREBY MAY BE PREDICTED OF, DONOR PLATELET POSITIVE CROSSMATCH PERCENTAGE (%DP-XM). Soumya Pandey, Eric R. Rosenbaum, Bobbie Rhodes-Clark, Marsha L. Rood, Dawnelle C. Crowley, Catherine M. Lee, Michele H. Cottler-Fox, Terry O. Harville. Pathology and Laboratory Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

184-P KEEP REAGENT RECEIPT AND QUALITY CONTROL UNDER CONTROL. Dong Li, Olga Timofeeva, Mariam Awwad, Christina Shaw, Sandra Rosen-Bronson. Histocompatibility Laboratory, MedStar Georgetown Univeristy Hospital, NW, DC, USA.

185-P IDENTIFICATION BY RNA-Seq OF NOVEL ANCESTRAL MEDIATOR TRANSCRIPTS IN ENDOTHELIAL PROGENITORS. Monica Rienzo1, Antonietta Picascia2, Concetta Schiano3, Amelia Casamassimi1, Vincenzo Grimaldi2, Claudio Napoli1,2. 1Department of General Pathology, Division of Clinical Pathology and Excellence Research Centre on Cardiovascular Disease, Second University of Naples, Naples, Italy; 2U.O.C. Division of Immunohematology, Transfusion Medicine and Transplant Immunology (SIMT), Regional Reference Laboratory of Transplant Immunology (LIT), Second University of Naples, Naples, Italy; 3Institute of Diagnostic and Nuclear Development, SDN Foundation, Naples, Italy.

186-P COMPARISON OF DIFFERENT EXTRACTION PROTOCOLS ON DNA YEILD AND PURITY. Lucie Richard. Reference and Stem Cell Laboratory, Hema-Quebec, Saint-Laurent, QC, Canada.

Final Program 85 Abstracts 187-P ANTI HLA IMMUNIZATION REDUCES ACCESS TO VASCULARIZED COMPOSITE ALLO TRANSPLANTATION FOR EXTENSIVELY BURNED PATIENTS. Caroline Suberbielle1, Patrick Duhamel2, Philippe Grimbert3, Benoit Audry4, Christian Jacquelinet4, Maryvonnick Carmagnat1, Chantal Gautreau1, Dominique Charron1, Laurent Lantieri5, Mikael Hivelin5. 1Laboratoire Regional d’Histocompatibiblite “Jean Dausset”, Hopital Saint Louis, Paris, France; 2Service de Chirurgie Plastique, Hopital d’instruction des armees Percy, Clamart, France; 3Service de Nephrologie et Transplantation, CHU Henri Mondor, Creteil, France; 4Agence de la Biomedecine, Agence de la Biomedecine, Saint Denis, France; 5Service de Chirurgie Plastique et Reconstructrice, Hopital europeen Georges Pompidou, Paris, France.

188-P A PRELIMINARY STUDY OF NEUTROPHILS CD177 GENOTYPE AND HNA-2a EXPRESSION IN GUANGDONG POPULATION. Xin Ye, Xiuzhang Xu, Wenjie Xia, Haoqian Ding, Yangkai Chen. Guangzhou Blood Center, Institute of Clinical Blood Transfusion, Guangzhou, China.

Late Breaking Abstracts- Oral

Monday, November 18, 2013 2:00 PM – 3:30 PM Abstract Session 1: New Assays (Genomics/ Proteomics)

1034-LBO DIFFERENTIAL MICRORNA EXPRESSION PROFILING IN LUNG ALLOGRAFT RECIPIENTS WHO DEVELOP DONOR SPECIFIC ANTIBODY AND BRONCHIOLITIS OBLITERANS SYNDROME Zhongping Xu, PhD1, Sabarinathan Ramachandran, PhD1, Nayan Sarma, PhD1, Venkataswarup Tiriveedhi, PhD1, Baskaran Gautam, MD3, Aviva Aloush, RN1, Nancy Steward, MS1, Ramsey Hachem, MD3, Elbert Trulock, MD3, G. Alexander Patterson, MD1and Thalachallour Mohanakumar, PhD1,2. 1Surgery, Washington Univ Sch Med, St. Louis, United States; 2Pathology & Immunology, Washington Univ Sch Med, St. Louis, United States and 3Medicine, Washington Univ Sch Med, St. Louis, United States.

86 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts

Tuesday, November 19, 2013 2:00 PM – 3:30 PM Abstract Session 4: Basic Science Transplantation

1036-LBO BATF PLAYS A CRUCIAL ROLE IN INDUCTION OF AUTOIMMUNITY AND BOS DEVELOPMENT FOLLOWING ADMINISTRATION OF ANTIBODIES TO MHC Sabarinathan Ramachandran, Ph.D1, Nicholas Benshoff, BS1 and T Mohanakumar, Ph.D1,2. 1Surgery, Washington University School of Medicine, St Louis, MO, United States, 63110 and 2Pathology & Immunology, Washington University School of Medicine, St Louis, MO, United States, 63110.

Late Breaking Abstracts- Poster 1004-LBP HLA SEQUENCE-BASED TYPING WITH NEXT GENERATION TECHNOLOGY Chul-Woo Pyo, PhD1,2, Wyatt Nelson, PhD2, Yoon Soo Pyon, PhD1, Ruihan Wang, MS1,2, Akiko Ishitani, PhD2, Shu Shen, PhD1, Anajane Smith, MS2, Shalini Pereira, PhD2 and Daniel E Geraghty, PhD1,2. 1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States, 98109 and 2Immune Response Division, Scisco Genetic Inc., Seattle, WA, United States, 98115. 1005-LBP AUTOMATION AND COMPARATIVE VALIDATION OF MULTIPLE MACHINE LEARNING TECHNIQUES FOR THE PREDICTION OF HLA SEROLOGIC SPECIFICITIES: BEYOND THE NEURAL NETWORK Adarsh Sivasankaran, MSEE2, Abeer Madbouly, PhD1, Vladimir Cherkassky, PhD2 and Martin Maiers, BA1. 1Bioinformatics Research, National Marrow Donor Program, Minneapolis, MN, United States, 55413 and 2Biomedical Informatics and Computational Biology, University of Minnesota Rochester, Rochester, MN, United States, 55904.

1006-LBP TIDES AND BIGDAWG: AN INTEGRATED HLA AND KIR DATA MANAGEMENT AND ANALYSIS PIPELINE Steven J Mack, PhD1, Ken D Yamaguchi, PhD2, Hugh Salamon, PhD2, Anthony G Pena, BS3, Robert M Horton, PhD4, Patricia Francis-Lyon, PhD3, Martin Maiers, BA5 and Jill A Hollenbach , PhD, MPH1. 1Center for Genetics, Children’s Hospital Oakland Research Institute, Oakland, CA, United States, 94609;2Knowledge Synthesis Inc., Berkeley, CA, United States, 94710;3Department of Computer Science, University of San Francisco, San Francisco, CA, United States, 94117; 4Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, United States, 94143 and 5Division of Bioinformatics, National Marrow Donor Program, Minneapolis, MN, United States, 55413.

Final Program 87 Abstracts 1007-LBP A NOVEL MEASURE OF RECIPIENT-DONOR HLA MISMATCH PREDICTS ALLOGRAFT REJECTION AFTER HEART TRANSPLANTATION Evan P Kransdorf, MD, PhD1, Tomas Carvajal, MD2, D. Eric Steidley, MD1, Vijayan Balan, MD4, Andrew Bordner, PhD5 and Octavio E Pajaro, MD, PhD3, 5. 1Division of Cardiovascular Diseases, Mayo Clinic Arizona, Phoenix, AZ, United States, 85054;2Division of Surgery, Mayo Clinic Arizona, Phoenix, AZ, United States, 85054; 3Division of Cardiothoracic Surgery, Mayo Clinic Arizona, Phoenix, AZ, United States, 85054; 4Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Phoenix, AZ, United States, 85054 and 5Center for Regenerative Medicine, Mayo Clinic Arizona, Phoenix, AZ, United States.

1008-LBP COMPARISON OF SINGLE NUCLEOTIDE POLYMORPHISM GENOTYPING OF CYP2C19*2 AND CYP2C19*3 ALLELES BY LOOP-MEDIATED ISOTHERMAL AMPLIFICATION AND REAL- TIME PCR MELTING CURVE ANALYSIS KM Kwong, MMedSc1, CC Tam, MD2, Raymond Chan, MD2, WL Lee, MD2, Ricky Lau, PhD1, Edmund KK Tung, PhD1 and Janette Kwok, MD1. 1Division of Transplantation and Immunogenetics, Department of Pathology and Clinical Biochemistry, Queen Mary Hospital, Hong Kong, Hong Kong and 2Division of Cardiology, Queen Mary Hospital, Hong Kong, Hong Kong.

1009-LBP NON-INVASIVE MOLECULAR PROTOCOL FOR DEDUCTION OF MISMATCHED DONOR HLA FROM URINE SAMPLES OF RENAL TRANSPLANT RECIPIENTS Ricky Lau, PhD1, Gavin Chan, MD2, Leo Choi, Bsc1, MF Lam, MD3, Maggie Mok, MD3, WL Chak, MD4, Au Cheuk, MD5, KW Chan, MD6, KF Chau, MD4, Matthew Tong, MD5, TM Chan, MD3 and Janette Kwok, MD1. 1Transplantation and Immunogenetics, Queen Mary Hospital, Hong Kong, Hong Kong; 2Anatomical Pathology, Queen Mary Hospital, Hong Kong, Hong Kong; 3Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong;4Department of Medicine, Queen Elizabeth Hospital, Hong Kong, Hong Kong; 5Department of Medicine & Geriatrics, Princess Margaret Hospital, Hong Kong, Hong Kong and 6Department of Pathology, The University of Hong Kong, Hong Kong, Hong Kong.

1010-LBP SIMULATION OF POTENTIAL STEM CELL DONOR SEARCHES: AVAILABLE MATCHING DONOR IS NOT ALWAYS IDENTIFIED Jürgen Sauter, PhD1, Ute Solloch, -1, Jan Hofmann, PhD1, Julia Pingel, PhD1, Alexander H Schmidt, PhD, MD1 and Gerhard Ehninger, MD2. 1Science, DKMS German Bone Marrow Donor Center, Tübingen, Germany, 72072 and 2Internal Medicine I, University Hospital Dresden, Dresden, Germany.

88 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts

1011-LBP ILT3FC INHIBITS THE INFLAMMATORY EFFECT OF EXOSOMES FROM PRIMARY MLC Zheng Xu, MS1, Chih-Chao Chang, PhD1, Sophey Ho, -1, Zhuoru Liu, PhD1, George Vlad, PhD1, Raffaello Cortesini, MD1, Raphael A Clynes, MD, PhD1 and Nicole Suciu-Foca, PhD1. 1Pathology and Cell Biology, Columbia University, New York, NY, United States, 10032.

1012-LBP A COMPARISON OF PHYSICAL AND ENZYMATIC FRAGMENTATION METHODS IN LIBRARY PREPARATION FOR HLA SEQUENCING ON THE ILLUMINA MISEQ Tracie Profaizer, BS1, Emily M Coonrod, PhD1, Julio Delgado, MD1and Attila Kumanovics, MD1. 1ARUP Institute for Clinical and Experimental Pathology, Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, United States, 84132.

1013-LBP IDENTIFICATION OF 2127 NEW HLA ALLELES IN POTENTIAL DONORS REGISTERED WITH DKMS DONOR CENTERS IN GERMANY, THE UNITED STATES AND POLAND Camila J Hernandez-Frederick, PhD1, Anette S Giani, MSc.1, Nezih Cereb, MD2, Rolando Silva- Gonzalez, Dipl.Biol.1, Julia Pingel, PhD1, Alexander H Schmidt, PhD-MD1, Gerhard Ehninger, MD3and Soo Young Yang, PhD2. 1DKMS German Bone Marrow Donor Center, DKMS German Bone Marrow Donor Center, Tuebingen, Germany; 2HistoGenetics, Inc., HistoGenetics, Inc., Ossining, New York, Germany and 3Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.

1014-LBP POSITIVE FLOW CYTOMETRY CROSSMATCH RESULTS WITH PRONASE-TREATED T-CELLS INDUCED BY NON-HLA AUTOANTIBODIES IN HIV-INFECTED PATIENTS Katarzyna Brooks, BS1, Daniel Magas, BS1, Kristin Sieg, BS1, Justin D Carrera, BS1, Bozena Labuda, BS1, Martin D Jendrisak, MD1 and Andres Jaramillo, PhD1. 1Histocompatibility & Immunogenetics Laboratory, Gift of Hope Organ & Tissue Donor Network, Itasca, IL, United States, 60143; 2Itasca, IL, 60143 and3Itasca, IL, 60143.

1015-LBP NOVEL SOFTWARE AND REAGENTS FOR QPCR-BASED TRANSPLANT MONITORING Dick Roovers, PhD1, Jeroen Adema, BASc1, Michelle Bacelar, BASc1, Nienke Westerink, PhD1, Maarten Penning, PhD1, Wietse Mulder, PhD1,2, Erik Rozemuller, PhD1,2 and Doug Bost, BA2.1Product Development, GenDx, BV, Utrecht, Netherlands and 2Product Development, KimerDx, BV io, Utrecht, Netherlands.

Final Program 89 Abstracts

1016-LBP ROSETTESEP HLA - AN EXCEPTIONAL METHOD FOR ISOLATION OF LYMPHOCYTES FROM PERIPHERAL BLOOD Nathan A. Lemp, PhD1, James C. Cicciarelli, PhD1, Jan Chew, BS1and Suhad Musa, MS1. 1Immunogenetics Laboratory, Mendez National Institute of Transplantation, Los Angeles, California, United States, 90057.

1017-LBP EXPRESSION PROFILE OF CANDIDATE T-CELL IMMUNE RESPONSE GENES IN PATIENTS AFTER HAEMATOPOIETIC STEM CELL TRANSPLANTATION Petra Klevcova, MSc1, Frantisek Mrazek, MD, PhD1, Zdenka Navratilova, MSc, PhD1, Antonin Vitek, MD2, Michael Doubek, MD, PhD3 and Martin Petrek, MD, PhD1,4. 1Laboratory of Immunogenomics and Immunoproteomics, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic;2Institute of Hematology and Blood Transfusion, Prague, Czech Republic; 3Internal Medicine - Hematooncology, University Hospital, Brno, Czech Republic and 4Institute of Clinical and Molecular Pathology, University Hospital, Olomouc, Czech Republic.

1018-LBP COMPARATIVE STUDY OF BIOFORTUNA SSPGO HLA TYPING PRODUCT (IUO/PEO) Jean L. Heneghan, MS1, Kellie Jordan, MS1 and Ronald K. Charlton, PhD1. 1Medicine, Tulane University, New Orleans, LA, United States.

1020-LBP A SYSTEM FOR HIGH-THROUGHPUT LIBRARY PREPARATION ALLOWS HIGH- RESOLUTION HLA TYPING USING NEXT-GENERATION SEQUENCING Camila Egidio, PhD1, Kathrin Lang, PhD2, Ilona Holcomb, PhD1, Johanna Andreas, PhD2, Vinzenz Lange, PhD2, Ramesh Ramakrishnan, PhD1, Irina Boehme, PhD2, Alexander Schmidt, PhD2 and Brian Fowler, MS1. 1R&D, Fluidigm Corporation, South San Francisco, California, United States, 94080 and 2R&D, DKMS Life Science Lab, Dresden, Germany.

1021-LBP THE SIGNIFICANCE OF DONOR-SPECIFIC HLA ANTIBODIES DETECTED BY C1Q-SAB OR FLOW CYTOMETRY CROSSMATCHES IN LIVER TRANSPLANTATION Jun Zou, MD, Ph D1, Donna Phelan, BA1, Thalachallour Mohanakumar, Ph D1,2, William Chapman, MD2 and Jason Wellen, MD2. 1Dept. of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, United States, 63110 and2Dept. of Surgery, Washington University School of Medince, St. Louis, MO, United States, 63110.

90 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts

1022-LBP IDENTIFICATION OF NEW ALLELES AND THEIR IMPACT ON HEMATOPOIETIC STEM CELL TRANSPLANTAT DONOR SELECTION Taba Kheradmand, PhD1, Rebecca Upchurch, CHT1, Brenda Issangya, BS1, Walter Herczyk, CHS1 and Susana R Marino, MD, PhD1. 1Pathology, University of Chicago Medicine, Chicago, IL, United States, 60637.

1023-LBP SUCCESSFUL DESENSITIZATION OF ANTI-HLA ANTIBODIES IN A HAPLO-CORD HEMATOPOIETIC CELL TRANSPLANT Taba Kheradmand, PhD1, Walter Herczyck, MT, CHS1, Jerome Weidner, CHS1, Andrew Artz, MD1 and Marino R Susana, MD, PHD1. 1Pathology, University of Chicago Medicine, Chicago, IL, United States, 60637.

1024-LBP HLA DPA1∼DPB1 ALLELE-LEVEL AND MOTIF-LEVEL HAPLOTYPE FREQUENCIES OF FOUR US POPULATIONS Michael Halagan, BS1, Jill A. Hollenbach, Phd,MPH1,2, Abeer Madbouly, PhD,MS1, Loren Gragert, BS1, Cynthia Vierra-Green, MS3, Susan Flesch, BS3, Stephen R. Spellman, MBS3, Ann Begovich, PhD4, Harriet Noreen, PhD5, Elizabeth Trachtenberg, PhD2, Thomas M. Williams, MD6, Neng Yu, MD7, Georgia Zannelli, MS7, Marcelo Fernandez-Vina, PhD8 and Martin Maiers, BS1.1Bioinformatics Research, National Marrow Donor Program, Minneapolis, Minnesota, United States, 55413; 2Noble Lab, Children’s Hospital Oakland Research Institute, Oakland, CA, United States; 3Immunobiology & Observational Research, Center for International Blood and Marrow Transplant Research, Minneapolis, MN, United States, 55413; 4Genomics & Oncology, Roche Diagnostics, Pleasanton, CA, United States; 5Laboratory Medicine and Pathology, Fairview Hospital, Fairview, MN, United States; 6Department of Pathology, University of New Mexico, Albuquerque, NM, United States; 7Blood Services, American Red Cross, Dedham, MA, United States and 8Department of Pathology, Stanford University School of Medicine, Palo Alto, CA, United States.

1025-LBP IDENTIFYING SOURCE OF EYE CARCINOMA BIOPSY. Jennifer N Wendel, Bachelors CLS1, Brittany Johnson, Bachelors1and Paul A Brailey, Bachelors1. 1Transplantation Immunology Division, University of Cincinnati, Cincinnati, OH, United States, 45267.

1026-LBP THE INFLUENCE OF CYTOKINES POLYMORPHISMS ON TYPE 1 DIABETES DEVELOPMENT IN BRAZILIAN PATIENTS Aline Brazao, BsC1, Vivian A Pereira, BsC1, Gustavo M. Fabrício-Silva, PhD1, Danielli C.M. Oliveira, MD, PhD1 and Luis Critsóvão M.S. Porto, MD, PhD1. 1Laboratório de Histocompatibilidade e Criopreservação - Histologia e Embriologia, Universidade do Estado do Rio de Janeiro, Rio de Janeiro,

Final Program 91 Abstracts

RJ, Brazil. 1027-LBP INTERPLAY BETWEEN AUTO- AND ALLO-IMMUNITY IN THE DEVELOPMENT OF LUNG ALLOGRAFT REJECTION Ankit Bharat, MD1, Vijay Subramanian, MD2, Andy Gelman, PhD3, Daniel Kreisel, MD3 and T Mohanakumar, PhD3. 1Surgery/ Thoracic, Northwestern University, Chicago, IL, United States, 60611; 2Surgery, University of Mississippi, Jackson, MS, United States and 3Surgery/ Cardiothoracic, Washington University, St Louis, MO, United States.

1028-LBP ASSOCIATION OF MISMATCHED POLYMORPHIC AMINO ACID RESIDUES IN HLA WITH CHRONIC REJECTION OF KIDNEY TRANSPLANTS Julia B Udell, BS1,2, Javier Arsuaga, Ph.D1, Henry B Elrich, Ph.D2, Daniel R Salomon, M.D.3 and Elizabeth Trachtenberg, Ph.D2.1Department of Mathematics, San Francisco State University, San Francisco, CA, United States, 94132; 2Children’s Hospital of Oakland Research Institute, Oakland, CA, United States, 94609 and 3Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, United States, 92037.

1029-LBP IMMUNE RESPONSES TO COLLAGEN IV AND FIBRONECTIN IN RENAL TRANSPLANT RECIPIENTS WITH TRANSPLANT GLOMERULOPATHY Muthukumar Gunasekaran, Ph.D1, Angaswamy nataraju, Ph.D1, Klein Christina, Ph.D3, Tiriveedhi Venkataswarup, Ph.D1, Siddiq Anwar, Ph.D3, Phelan Donna, Ph.D4, Wellen Jason, M.D1, Shenoy Surendra, M.D1, Chapman William, M.D1 and Mohanakumar Thalachallour, Ph.D1. 1Department of Surgery, Washington University, Saint Louis, MO, United States, 63110; 2Department of Pathology & Immunology, Washington University, Saint Louis, MO, United States, 63110; 3Department of Medicine, Washington University, Saint Louis, MO, United States, 63110 and 4HLA Laboratory, Barnes-Jewish Hospital, Saint Louis, MO, United States, 63110.

1030-LBP HEPATITIS C VIRUS INDUCED CHANGES IN MICRORNA-107 AND MICRORNA-449A MODULATE THE INFLAMMATORY CHEMOKINE CCL2 BY TARGETING IL6 RECEPTOR COMPLEX IN PATIENTS WITH HEPATIC FIBROSIS Nayan Sarma, PhD1, Venkataswarup Tiriveedhi, PhD1, Jeffrey Crippin, MD3, William Chapman, MD1 and Thalachallour Mohanakumar, PhD1,2. 1Surgery, Washington Univ Sch Med, St. Louis, United States; 2Pathology & Immunology, Washington Univ Sch Med, St. Louis, United States and 3Medicine, Washington Univ Sch med, St. Louis, United States.

1031-LBP EVALUATION OF URACIL DNA GLYCOSYLASE (UDG) WITH THE LINKSĒQ™ REAL-TIME PCR HLA TYPING METHOD Miroslaw M Lizak, MHS, CHT(ABHI)1, Kathleen Gerolami, CHS(ABHI)1 and Laurine Bow, PhD, (HCLD)1. 1Histocompatibility and Immune Evaluation Laboratory, Yale University School of Medicine, New Haven, CT, United States.

92 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Abstracts

1032-LBP HLA-TYPING WITH A MICROARRAY: “THE HLA-CHIP” Gina Lopez, MS1, Melissa May, BS1, Po Lin, MD1, Rick Eggers, BS1, Kevin OBrien, PhD1 and Michael Hogan, PhD1. 1Research and Development, GMS Biotech, Tucson, AZ, United States, 85713.

1033-LBP OPTIMIZING THE VIRTAL CROSSMATCH:TRANSPLANTATION OF THE HIGHLY SENSITIZED PATIENT. Denise L Owens, BS1, Elizabeth H Field, MD1 and Christie Thomas, MD2.1Iowa Regional Histocompatibility, VA Health Care System, Iowa City, IA, United States, 52246; 2Iowa Regional Histocompatibility, VA Health Care System, Iowa City, IA, United States, 52246 and 3Center for Transplantation, The University of Iowa, Iowa City, IA, United States, 52246.

1035-LBP DEVELOPMENT OF ANTIBODIES TO HLA IN PATIENTS ON LEFT VENTRICULAR ASSISTING DEVICE (LVAD) LEADS TO INCREASED PROINFLAMMATORY CYTOKINES AND IMMUNE RESPONSES TO CARDIAC SELF-ANTIGENS, MYOSIN AND VIMENTIN Babak Banan, MD1, Venkataswarup Tiriveedhi, PhD1, Donna Phelan, BS2, Greg Ewald, MD3 and Thalachallour Mohanakumar, PhD1,4. 1Surgery, Washington Univ Sch Med, St. Louis, MO, United States; 2HLA Laboratory, Barnes-Jewish Hospital, St. Louis, MO, United States; 3Medicine, Washington Univ Sch Med, St. Louis, MO, United States and 4Pathology & Immunology, Washington Univ Sch Med, St. Louis, MO, United States.

1037-LBP LINEAGE MARKER “NEGATIVE” FRACTION RESOLVES DISCREPANCY IN LINEAGE SPECIFIC CHIMERISM. Alexandra Amador, BSMT1, Jennifer McCue, BS1, Rogelio Gonzalez, MD1, Dania Mateu, MS1, Lili Samways, BS1 and Phillip Ruiz, MD/PhD1. 1Surgery, University of Miami, Miami, Florida, United States, 33136.

1038-LBP INCOMPLETE REACTIONS OF MISMATCHED DONOR HLA ALLELE(S) IN RELAPSED AML PATIENT Gansuvd Balgansuren, MD, PhD1, Adella Clark, BS, MS1, Angelica DeOliveira, BS, MS1, Jennifer Deitz, BS1 and Dong Feng Chen, PhD1. 1Pathology, Duke University Medical Center, Durham, NC, United States, 27710.

Final Program 93 Abstracts

1039-LBP INFLUENCE OF IL28B (RS12979860) POLIMORPHISMS AND KIR GENES IN SPONTANEOUS CLEARANCE OF HEPATITIS C VIRUS IN A MULTI-ETHNIC POPULATION FROM RIO DE JANEIRO (BRAZIL) Gustavo Milson Fabricio-Silva, MsC, PhD1, Bruno Silva de Almeida, MsC2, Ronaldo Santos, MsC2, Renata Mello Perez, PhD2, Fatima Figueiredo, PhD2 and Luis Cristovão Porto, PhD1.1Histocompatibility and Criopreservation Laboratory, State of Rio de Janeiro University, Rio de Janeiro, RJ, Brazil, 20950- 000 and2Gastroenterology and Hepatology Service - Pedro Ernesto University Hospital, State of Rio de Janeiro University, Rio de Janeiro, RJ, Brazil.

1040-LBP SHORT TANDEM REPEAT (STR) ANALYSIS USED TO ASSESS BIOLOGICAL IDENTITY BETWEEN A POTENTIAL KIDNEY DONOR-RECIPIENT PAIR OF TWINS WITH THE PATIENT HAVING A HISTORY OF POLYCYSTIC KIDNEY DISEASE. Valia Bravo-Egana, PhD1 and Phillip Ruiz, MD, PhD1.1Transplantation Laboratories and Immunopathology, University of Miami, Miami, Florida, United States, 33136.

1041-LBP ESTABLISHMENT OF A CONSISTENT SINGLE ANTIGEN BEAD (SAB) IGG SUBTYPE ALLOANTIBODY ASSAY. CORRELATION WITH C1Q COMPLEMENT FIXING ALLOANTIBODY. Valia Bravo-Egana, PhD1, Alina Gutierrez, BSc1 and Phillip Ruiz, MD, PhD1. 1Transplantation Laboratories and Immunopathology, University of Miami, Miami, Florida, United States, 33136.

94 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Hotel Floor Plans SHERATON CHICAGO HOTEL & TOWERS LEVEL 1 - EXHIBIT HALL

Final Program 95 Hotel Floor Plans

96 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Hotel Floor Plans

Final Program 97 Hotel Floor Plans

98 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013 Hotel Floor Plans

Final Program 99 Future Annual Meetings 40th Annual Meeting October 20 – 24, 2014 Sheraton Denver Downtown Hotel Denver, Colorado

41st Annual Meeting September 28 – October 2, 2015 Savannah International Trade & Convention Center Savannah, Georgia

42nd Annual Meeting September 26 – 30, 2016 Hyatt Regency St. Louis at the Arch St. Louis, Missouri

43rd Annual Meeting September 11 – 15, 2017 Hilton San Francisco Union Square San Francisco, California

100 Chicago, Illinois • Sheraton Chicago Hotel and Towers • November 17 – 21, 2013